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Abstract
Adoptive transfer of T cell receptor (TCR) gene-modified T cells is a promising
field of tumour immunology. However whilst these cells can potently control
tumour growth, this occurs in only a subset of patients. In order to devise new
strategies to improve the anti-tumour response we need a clear understanding of
the mechanisms by which transferred T cells are activated to kill tumours. Whilst
dendritic cells (DC) are required to activate and control T cell function in adaptive
immune responses it is not known whether control of tumours by adoptively
transferred T cells depends on similar interactions with endogenous DC.
To address this the CD11c.DTR model was used to transiently deplete DC in
mice with established B16.F10 sub-cutaneous tumours after having been treated
with TCR-transduced T cells. Unexpectedly we found that depletion of CD11c+
cells facilitates enhanced expansion and effector-phenotype differentiation of the
transferred T cells. This appears to be mediated by depletion of a DC population
with regulatory capabilities. However depletion of DC in the closely related
CD11c.DOG model fails to promote accumulation of TCR-transduced T cells.
Indeed, in this model DC depletion leads to less T cell infiltration into tumours.
These contrasting results following depletion likely reflect the heterogeneous
CD11c+/DC compartment in the tumour, where different populations contribute
pro- or anti-inflammatory roles. Nonetheless these data suggest that
TCR-transduced T cells interact with the endogenous immune system, although
the exact nature of this interaction requires further investigation.
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Chapter 1 Introduction
1.1 Immune surveillance of cancer
The immune system has evolved as an intricately detailed cellular system to
destroy pathogens. However the concept that the immune system could control
and eradicate transformed, cancerous cells that arise throughout our lives was,
until relatively recently, widely disputed.
First postulated by Paul Ehrlich in 1909, tumour immune surveillance proposes
that tumour cells can be distinguished from healthy cells and that they will be
eliminated by the immune system before they are clinically detected (Ehrlich
1909). However lack of convincing evidence meant this theory fell from popular
thought and wasn’t rekindled until the latter half of the 20th century. Evidence
then began to emerge that the immune system was able to control tumour
growth and this was formalised as the theory of ‘cancer immune surveillance’ by
Sir MacFarlane Burnet and Lewis Thomas in 1957, who stated:
"It is by no means inconceivable that small accumulations of tumour
cells may develop and because of their possession of new antigenic
potentialities provoke an effective immunological reaction with
regression of the tumour and no clinical hint of its existence"
Burnet argued that it was an "evolutionary necessity" that there be a system in
place for dealing with mutated, cancerous cells. Central to this idea was the
concept that tumour cells would express antigens that would allow the immune
system to differentiate them from healthy cells. However at this time the field of
cellular immunology was relatively new and there was conflicting evidence over
the ability of the immune system to destroy cancerous cells. What was known
was that lymphocytes caused the rejection of transplanted tissue-graphs with
incredible precision. However the mechanism that caused this and perhaps as
importantly, the evolutionary reason for this mechanism, were not understood.
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As Thomas stated in 1982:
"Surely this intricate and powerful apparatus was not selected in
evolution in order to provide experimental surgeons and pathologists
with something to do for a living".
They believed that the reason foreign tissue-graphs were able to be rejected was
as a result of an immune system designed to recognise subtle differences in cells
and eradicate those that it deemed ‘foreign’. However despite this conviction, the
data generated in animal models largely refuted the tumour immune surveillance
hypothesis. As Thomas astutely noted:
"The greatest trouble with the idea of immunosurveillance is that it
cannot be shown to exist in experimental animals."
This changed in the 1990s when our understanding of cellular immunity improved,
partly through the availability of better animal models. It was then that evidence
of immunosurveillance began to emerge and the theory eventually became well
accepted.
1.1.1 Evidence of immune surveillance
Key to the initial misgivings was work from two labs which showed that athymic,
nude mice (which should lack mature T cells) were no more susceptible to
spontaneous or induced tumours than wild-type (WT) mice (Povlsen 1974;
Stutman 1974). However the flaws in these animal models were unknown to
researchers at the time. It was later discovered that these mice were not
completely immunocompromised as they did contain a small population of T
cells. Secondly these mice had an increased abundance in natural killer (NK)
cells (Ikehara et al. 1984; Maleckar and Sherman 1987) which themselves have
potent abilities to control tumour growth (Cerwenka and Lanier 2001).
The first conclusive evidence supporting a role for the immune system in tumour
control came through experiments in mice lacking interferon gamma (IFN-g).
These experiments showed that in mice injected with an IFN-g neutralising
19
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monoclonal antibody, transplanted sarcomas grew faster than in control mice.
Likewise fibrosarcomas which over-expressed the truncated dominant-negative
IFN-g receptor a were insensitive to IFN-g and showed more tumorigenicity and
less immunogenicity when transplanted into syngeneic mice (Dighe et al. 1994).
This IFN-g mediated control was shown not only in transplantable tumours but
also in tumours induced by the chemical carcinogen, methylcholanthrene (MCA)
(Kaplan et al. 1998). As well as IFN-g, later experiments showed that mice
lacking perforin (a key element of cellular cytotoxicity) were similarly more
susceptible to a variety of tumours than perforin-sufficient mice (Broek et al.
1996; Smyth et al. 2000; Street et al. 2001).
These data showed a clear role for the immune system, particularly
lymphocytes, in tumour control. This was built upon in subsequent work,
primarily using knockout mice, which aimed to identify that cellular component of
immune control. Experiments in mice lacking recombinase activating gene 1 or 2
(RAG-1 or RAG-2) were central to this. These are DNA repair enzymes that are
expressed solely in lymphoid cells and are essential for lymphocytes to
rearrange their antigen receptors. Mice deficient in RAG-1 or RAG-2 therefore
completely lack T cells, B cells and NKT cells (Shinkai et al. 1992). Injection of
MCA into these mice was found to induce tumour formation at a greater rate and
frequency than WT mice. RAG-2 knockout (-/-) mice also spontaneously formed
significantly more neoplastic lesions than WT mice (Shankaran et al. 2001).
Interestingly when RAG-2-/- mice were crossed with mice which can’t respond to
IFN-g (Stat-1-/-), there was no different in the formation of induced tumours
compared to RAG-2-/- or Stat-1-/- mice alone. This suggested there was a heavy
overlap between these two mechanisms of tumour control. The prospect of T
cell mediated control of tumours was given further credence by the identification
of a human melanoma-specific antigen able to be presented to cytotoxic T cells
(Bruggen et al. 1991). These works were a fundamental step in determining how
the immune system controls cancer. However this raised a pertinent question; if
the immune system is able to differentiate healthy cells from tumour cells and
control tumour growth, why do immunocompetent hosts still get tumours?
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1.1.2 Immunoediting
Whilst the theory of cancer immune surveillance postulated that a developing
tumour could be controlled by the immune response, this did not fully describe the
range of interactions a tumour had with the immune system. Instead Shankaran
and Schreiber suggested that the term ‘cancer immunoediting’ be used. This
alteration was based on the observation that cancers do develop in the presence
of an intact immune system and that these tumours are less immunogenic than
tumours which develop in immunodeficient mice. This lead them to suggest that a
developing tumour is constantly sculpted by the immune response to it, and that
those tumours that do develop will, by default, be less able to be controlled by
the immune system (Shankaran et al. 2001). This immunoediting concept can be
separated into three different processes: elimination, equilibrium and escape (Fig
1.1)
‘Elimination’ refers to what was originally described in the tumour immune
surveillance hypothesis; that the immune system will destroy nascent tumour
cells before they become clinically relevant. This has been extensively reviewed
by Dunn et al. 2002, in brief: The immune response to a tumour begins when
innate cells such as NK cells and NKT cells respond to local inflammation and
produce IFN-g. These have direct anti-proliferative and apoptotic effects on the
tumour, or can indirectly prevent angiogenesis, which both cause tumour cell
death. Tumour antigens are acquired by DC which migrate to the LN and present
antigen to T cells. At the same time the escalating immune response recruits NK
cells and macrophages which themselves can induce tumour cell death. Lastly
tumour antigen-specific T cells migrate from the LN to the tumour and mediate
tumour regression. The specific roles of T cells and DC in this anti-tumour
response are discussed in more detail later. However although effective, this
immune response is not always sufficient to prevent tumour development.
‘Equilibrium’ therefore refers to when the immune system and the tumour reach
a state of dynamic equilibrium, in which further tumour growth is controlled but
the tumour is not eliminated. Evidence for this process arose from experiments
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in which mice were injected with MCA to induce tumorigenesis. However those
mice that did not develop tumours were then injected with antibodies to deplete
CD8 or CD4 T cells or neutralise IFN-g . More than half of mice with these
compromised immune systems subsequently developed sarcomas, suggesting
that microscopic tumours were being controlled by the immune response and
were only able to grow when this control was removed (Koebel et al. 2007). Yet
whilst most cancer cells will be eliminated by the immune response in the
equilibrium phase, proliferation of the genetically unstable tumour mass will
constantly produce new tumour cell variants. During this process the immune
system is paradoxically selecting for variants which can escape selective
immune pressure. This process has been demonstrated in an MCA-induced
tumour from a RAG-2-/- mouse. This expressed a highly immunogenic antigen
which, when transplanted into WT mice, was presented by MHCI to CD8 T cells.
However subsequent tumours that grew in these mice lacked expression of this
antigen due to this immune pressure (Matsushita et al. 2012).
CD8
CD4
NK cell
CD8
CD4
NK cell
Tumour Tumour
CD8 CD4
Tumour
✗ ✗ ✗ ✗ ✗
Elimination Equilibrium Escape
✗
Figure 1.1: Cancer immunoediting.
Elimination: The immune response against the tumour is able to kill tumour cells and
reject the tumour.
Equilibrium: Incomplete elimination of the tumour leads to tumour cells being present
but controlled by the immune response.
Escape: Accumulation of mutations that prevent the tumour being recognised by the
immune system, or active mechanisms to induce immune system dysfunction allow the
tumour to evade the immune response.
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‘Escape’ therefore represents the final process of immunoediting in which new
mutations accumulated in tumour variants prevent their recognition or elimination
by cells of the immune system. This leads to uncontrolled growth of the tumour
and clinical presentation as a malignant disease. One primary mechanism by
which tumour cells can lose immunogenicity is though reduced expression of the
tumour antigen, or of the proteins involved in antigen presentation. For example
tumours have been shown to limit antigen presentation though reducing
expression either of human leukocyte antigen (HLA) directly (Algarra et al. 2000)
or of the components of the antigen processing pathways (Seliger et al. 2000).
Alternatively, immune pressure can also silence expression of tumour antigens
themselves. This is particularly prevalent in immunotherapies that focus on a
particular tumour antigen, which is often lost on relapsed/growing tumours
(Jäger et al. 1997; Maude et al. 2014; Verdegaal et al. 2016; Yee et al. 2002).
Alternatively, tumours can lessen the effect of immune recognition by acquiring
mutations that evade apoptosis. For example human tumours have been shown
to down-regulate proteins involved in apoptosis signalling such as the TRAIL
receptors or caspase proteins. Alternatively tumours can over-express proteins
that inhibit apoptosis such as the ‘inhibitor of apoptosis proteins’ (IAB), FLIP or
Bcl-2 (Fulda 2009).
An alternative and perhaps complimentary explanation for tumour immune
escape is not through reduced immunogenicity of the tumour itself, but by
promotion of immune dysfunction (Willimsky and Blankenstein 2005). Tumours
can over-express immunosuppressive cytokines such as interleukin 10 (IL-10)
and transforming growth factor beta (TGF-b) (Khong and Restifo 2002).
Alternatively tumours can also recruit immunosuppressive cells such as
regulatory T cells (Tregs) and NKT cells (Terabe and Berzofsky 2004). More
recently the importance of tumour-resident myeloid derived suppressor cells
(MDSC) (Gabrilovich and Nagaraj 2009) and dysfunctional dendritic cells (DC)
(Pinzon-Charry et al. 2005) in promoting immune suppression have been
recognised. These mechanisms all contribute to suppress T cell responses and
promote tumour escape.
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1.1.3 Evidence in humans
Despite the emergence of convincing data in pre-clinical mouse models,
evidence of immunoediting in humans was less forthcoming. However
longitudinal studies of patients who were under long-term immunosuppression,
such as after organ transplants, did begin to reveal a propensity for cancer
formation. This was most prevalent in tumours thought to be of a viral etiology,
which had been previously accepted to heavily rely on the immune system for
prevention. However tumorigenesis of a plethora of tumours not thought to be
induced by viral infection, including but not limited to melanomas and lung
cancer, were also shown to be more frequent in immunosuppressed patients.
(Vesely et al. 2011). These data therefore replicated the results seen in immune
suppressed mice which showed that a suppressed immune system allows
tumour growth, or conversely that a functional immune system can prevent
tumour growth.
These data from transplant patients suggested that the immune system could
mediate tumour elimination in humans as well as mice. Evidence of the
equilibrium phase of tumour immunoediting arose from a similar source;
numerous incidences of tumours being passed from a seemingly disease free
host to an organ transplant recipient have been recorded (MacKie et al. 2003;
Penn 1996). These suggest that a clinically undetectable tumour was being
controlled by the host which then outgrew when transferred to an
immunosuppressed recipient.
Perhaps the most convincing data for the involvement of the immune system in
controlling or shaping human tumours is from whether immune cell infiltration is
associated with improved prognosis. A wide variety of immune cells have been
shown to infiltrate tumours including myeloid cells and different T cell subsets
(Bindea et al. 2013) and the composition of immune cells in the tumour can
affect patient survival. Infiltration of CD8+ T cells is a positive prognostic factor in
colorectal cancer (Galon et al. 2006), melanoma (Zhang et al. 2003) and breast
cancer (Mahmoud et al. 2011). In contrast, in line with their predicted role in
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promoting tumour escape, infiltration of Tregs has been associated with a poor
prognosis (DeLeeuw et al. 2012; Shang et al. 2015). These data suggest that
the immune cell composition of the tumour can be an important prognostic
factor.
The importance of immune suppression in or by the tumour can also be seen in
the striking recent data from patients treated with immune checkpoint inhibitors.
Expression of the inhibitory receptor cytotoxic T lymphocyte associated antigen
4 (CTLA-4) on Tregs is a critical regulator of T cell activation (Schwartz 1992).
Likewise dysfunction of tumour-infiltrating T cells can be promoted by
over-expression of the immuno-modulatory receptor programmed death-ligand 1
(PD-L1), which is a consistent feature of malignant tumours (Chen et al. 2012).
Recent attempts to prevent this immunosuppression via monoclonal antibodies
that block CTLA-4, PD-L1 or its receptor on T cells, PD-1, have led to promising
clinical outcomes (Korman et al. 2006; Pardoll 2012). These data further show
that, as in the pre-clinical setting, human tumours subvert immune responses to
escape immune control but therapeutic measures to diminish this suppression
can enhance pre-existing anti-tumour immunity.
From a position of widespread debate, cancer immune surveillance and later
cancer immunoediting has now arisen as a fundamental aspect of tumour
growth. Indeed the strength of the data supporting these hypotheses led
Hanahan and Weinberg to include ‘avoiding immune destruction’ as one of their
updated ‘hallmarks of cancer’ in 2011 (Hanahan et al. 2011). This research has
led to great improvements in our knowledge of how the immune system
functions and how it is able to control tumour growth. However work still remains
to identify the best way to exploit these advances to provide better therapeutic
options for cancer patients.
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1.2 T cell biology
As discussed above, T cells are one of the principle components of anti-tumour
immunity. Along with B cells, T cells form the adaptive immune response that is
utilised when innate immune cells such as macrophages, NK cells and neutrophils
are insufficient to deal with a pathogen. Whereas innate immunity is characterised
by rapid responses which recognise a broad set of pathogen associated signals,
adaptive immunity is slower but cells recognise a more defined, specific signal.
For T cells this recognition is determined by the specificity of a unique T cell
receptor which defines antigen recognition by that cell.
1.2.1 The T cell receptor
T cell receptors (TCRs) are expressed on the surface of all T cells and specify
which antigens that T cell is able to respond to. The TCR is a heterodimeric,
membrane anchored protein consisting of a disulphide-linked alpha (a) and beta
(b) chain (Fig 1.2). Each chain consists of a constant region that spans the cell
membrane and a variable region that projects outward and is responsible for
antigen binding (Davis and Bjorkman 1988). This variable region recognises
short antigen fragments (peptides) when presented by major histocompatibility
complex (MHC) molecules, and antigen binding leads to T cell activation via
TCR-mediated signalling. However as the cytoplasmic domain of the TCR
constant region does not itself confer signalling properties, TCR signalling is
dependent on the association with the CD3 molecules; e, d, g and z.
Phosphorylation of the immunoreceptor tyrosine-based activation motifs (ITAMs)
on intracellular CD3 leads to the signalling cascade that activates the T cell
(Smith-Garvin et al. 2009). This activation pathway is discussed in more detail
later (section 1.2.3).
The crucial aspect of the TCR, which itself characterises the T cell, is the highly
variable regions that confer antigen specificity. This specificity is partly generated
by the assembly of the two different TCR chains, which promotes variation in
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Figure 1.2: T cell receptor structure.
antigen binding. However in humans whilst there are numerous Va and Vb genes,
this combination alone can not possibly confer the antigen specificity necessary to
respond to the myriad pathogens encountered by the immune system. Additional
variation is added to the TCR via a process known as V(D)J recombination.
As T cells mature in the thymus, they undergo a process of somatic
recombination which rearranges the variable (V), joining (J) and, in the b-chain,
diversity (D) gene segments that comprise the variable region of the TCR.
During these recombination events additional nucleotides are also inserted or
deleted at the junctions between these rearranged regions (Schatz et al. 1992).
The V(D)J genes that get recombined are found in the complementarity-
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determining regions (CDR) of the TCR chains, particularly CDR3 which is
responsible for antigen recognition. Therefore this novel CDR3 amino acid
sequence in the TCR can theoretically generate an enormous number of TCRs,
each with different antigen specificity. It was initially thought that each TCR and
therefore each individual T cell was specific for a unique antigen. However there
are >1015 potential foreign peptides that an immune system would need to be
able to respond to (Mason 1998; Sewell 2012). To put that in context there are
only 1012 T cells in the human body and in order to mount an effective immune
response, many of those cells will be clones expressing the same TCR. It has
been estimated that of the naive T cells there are only 108 unique TCRs (Arstila
et al. 1999). Therefore in order to generate immunity to the breadth of possible
foreign peptides, TCRs are thought to be degenerate: a specific TCR will
actually recognise a variety of different peptides, and conversely many TCRs will
recognise the same peptide (Mason 1998; Sewell 2012).
1.2.2 Central tolerance
Although V(D)J recombination is capable of generating a TCR repertoire that
can recognise a vast array of peptides, not all newly generated TCRs will be
functional and some may be potentially self-reactive. Therefore during T cell
maturation in the thymus, developing T cells undergo a process known as
central tolerance in which only TCRs capable of binding to pMHC complexes
without self-reactivity are maintained. There are three broad outcomes for T cell
progenitors (thymocytes) in the thymus; if the TCR has no affinity for MHC these
cells do not receive further TCR signalling and will die by neglect. TCRs with
low-medium affinity for self-peptide-MHC will proliferate and mature into
functional T cells in what is known as ‘positive selection’. This occurs in the
thymic cortex and is controlled by MHC expression on epithelial cells (cTECs).
This process also determines whether the CD4/CD8 double positive thymocytes
mature into CD4 or CD8 T cells, depending on whether they bind to MHCII or
MHCI respectively. However thymocytes also migrate to the thymic medulla
where those cells with high self-peptide-MHC affinity will be selected against.
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‘Negative selection’ depends on a population of medullary thymic epithelial cells
(mTECs) which, through the expression of the autoimmune regulator (AIRE)
protein, can present tissue specific antigens not normally found in the thymus.
Alternatively cross-presenting migratory DC can also present tissue antigens in
the thymus. Negative selection of these self-reactive T cells can occur through a
number of mechanisms, although most commonly self-reactive T cells are
deleted from the repertoire. Alternatively the TCR may be further edited to
reduce self-reactivity. Lastly to exploit TCRs with high self-reactivity without
deleting them, these T cells can be converted into regulatory T cells (Tregs)
(reviewed in Derbinski and Kyewski 2010; Hogquist et al. 2005 and Xing and
Hogquist 2012).
Theoretically the mature T cells that leave the thymus will either be naive T cells
that have the potential to recognise foreign antigen or self-reactive Tregs.
However the occurrence of autoimmunity shows that some self-reactive T cell
clones do escape central tolerance and migrate into the periphery. To prevent
these T cells from mediating damaging autoimmunity however these cells are
subject to peripheral tolerance. This includes T cell suppression through
regulatory T cells (Tregs) which produce immuno-suppressive cytokines such as
IL-10 and express inhibitory receptors such as CTLA-4. These concepts will be
discussed in the context of Treg function later. In additional DC can also mediate
peripheral tolerance by presenting antigen to self-reactive T cells and induing T
cell hypo-responsiveness. The role of DC in peripheral tolerance will be
discussed in chapter 1.3.
For the T cells not under the control of central or peripheral tolerance, in order
to assume effector functions, naive T cells need to bind to peptide as presented
by MHC. A naive T cell will then undergo a sequence of signalling reactions that
lead to T cell activation and proliferation. This process governing T cell activation
is summarised in Fig 1.3 and discussed in more detail below.
29
Chapter 1 Section 1.2
1.2.3 T cell activation
Upon binding of the TCR to a peptide-MHC complex (pMHC) a series of
phosphorylation events drives transcription factor mediated gene expression. An
important facet of this TCR-pMHC binding is the CD8 and CD4 co-receptors.
These are expressed on the cell surface of CD8 or CD4 T cells and are able to
bind to either MHCI or MHCII molecules respectively. Whilst these may act to
help stabilise the TCR-pMHC interaction, their more important function is to
bring the lymphocyte-specific protein tyrosine kinase (Lck) into contact with the
TCR complex (Artyomov et al. 2010). Lck is bound to the cytoplasmic domain of
the CD8/CD4 co-receptor and upon co-receptor binding to MHC, Lck is able to
phosphorylate ITAMs on the CD3 chains. Phosphorylation of ITAMs then recruits
the cytosolic zeta-chain-associated protein kinase of 70kDa (ZAP-70) which
itself is phosphorylated by Lck. The activated ZAP-70 can then phosphorylate
two adaptor molecules; linker of activated T cells (LAT) and SH2 domain
containing leukocyte protein of 76kDa (SLP-76). The phosphorylated form of
these molecules then form a complex which activates phospholipase C gamma
1 (PLCg1). Finally, this produces inositol trisphosphate (IP3) and diacylglycerol
(DAG). These two substrates induce T cell activation by three separate
mechanisms. IP3 causes the release of calcium from the endoplasmic reticulum
into the cytosol and activates calcineurin, which dephosphorylates and activates
a transcription factor; nuclear factor of activated T cells (NFAT). Alternatively
DAG can de-inhibit the transcription factor NFkB or activate the
mitogen-activated protein (MAP) kinase cascade and activate another
transcription factor; Activator protein 1 (AP-1). These three transcription factors
(NFAT, NFkB and AP-1) then translocate to the nucleus and induce the
transcription of a variety of genes necessary for T cell proliferation, differentiation
and cytokine production (Malissen and Bongrand 2015; Smith-Garvin et al.
2009).
Whilst the molecular mechanisms behind T cell activation are now well
understood there remains uncertainty over the initial triggering event for TCR
signalling. It was initially supposed that upon TCR-pMHC engagement,
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Figure 1.3: T cell receptor signalling.
conformational changes in the intracellular TCR regions allowed phosphorylation
of ITAMs and the signal was thusly propagated. Whereas this was true of other
transmembrane receptors such as G protein-coupled receptors, the relevance of
conformational changes to the TCR-CD3 complex has been questioned
(Malissen and Bongrand 2015). Indeed, chimeric antigen receptors (CARs) have
utilised CD3-z signalling to induce T cell activation in a setting where changes to
TCR conformation are irrelevant (Sadelain et al. 2013). An alternative
explanation is one based on the spatial arrangement of proteins at the site of
TCR-pMHC engagement. The ‘kinetic segregation model’ supposes that the
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TCR/CD3 complex is continuously being simultaneously phosphorylated by Lck
and subsequently dephosphorylated by the phosphatases CD45 and CD148.
However upon the binding of the TCR with pMHC, the surfaces of the T cell and
antigen presenting cell (APC) are brought close together and this is sufficient to
exclude proteins with large ectodomains (such as CD45 and CD148) from this
zone. This steric exclusion of the phosphatases prevents ITAM
dephosphorylation, allows recruitment of ZAP-70 and the TCR signal is
propagated as described above (Davis and Merwe 2006; Merwe et al.
2000).
However whilst it is a requirement for T cell activation, TCR signalling via TCR-
pMHC binding alone is not sufficient to fully activate T cells. Full T cell activation
and differentiation requires three signals, of which TCR signalling is one. The two
further signals are both provided by the APC which provides co-stimulation via
binding of CD80/86 to CD28 on the T cell (signal 2) (Chen and Flies 2013) and will
secrete inflammatory cytokines such as IL-12 (signal 3) (Curtsinger and Mescher
2010). TCR signalling in the absence of these additional signals generates a T
cell response unable to optimally expand, develop effector functions or generate
memory (Chen and Flies 2013; Curtsinger and Mescher 2010). The conditions
under which APC provide signals 2 and 3 are discussed in section 1.3.
1.2.4 T cell effector function
Upon activation through TCR signalling and co-stimulation, a naive T cell will
proliferate, differentiate and begin to assume effector functions. Despite TCR
promiscuity there are relatively few T cells specific for an antigen in the naive
population. However once primed, these cells have a remarkable capacity for
proliferation; for example in mice a population of naive T cells specific for a
lymphocytic choriomeningitis virus (LCMV) epitope expanded 105-fold (from
~100 to 107 cells) upon LCMV infection (Blattman 2002). The acquisition of
effector function is also tightly linked to this proliferation (Kaech and Ahmed
2001). Priming of naive T cells can therefore generate a large population of
antigen-specific, effector T cells.
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However there are differences in the proliferative response between CD4 and
CD8 T cells. CD8+ T cells will rapidly and extensively proliferate and differentiate
into cytotoxic T lymphocytes (CTLs). In comparison, CD4+ T cells begin
proliferation after a slight delay and have a relatively lesser ability to divide
(Foulds et al. 2002; Kaech et al. 2002). CD4 T cells also have a more diverse
differentiation repertoire including type 1 T helper (Th1), Th2, Th17, Treg and
follicular B helper T cells (Tfh) (Wan and Flavell 2009). Some of the differences
between CD8 and CD4 T cell functions are described below.
CD4+ T cell effector function
CD4+ T cells were initially thought to differentiate into either Th1 or Th2 cells
(Mosmann et al. 1986), however this has now been expanded to include Th17,
Tfh, Th9, Th22 and Treg cells (O’Shea and Paul 2010). These cells are all
functionally distinct and can be distinguished by the different cytokine profile that
defines each population and contributes to their effector function. As well as this
distinctive cytokine production, differentiated CD4 T cells also express a defined
transcription factor. The transcription factors and cytokines associated with the
main CD4 populations are summarised in Fig 1.4.
Th1 cells produce pro-inflammatory cytokines such as IFN-g, TNF-a and TNF-
b. These are thought primarily to stimulate cellular immunity by activating innate
cells such as macrophages, by promoting cellular cytolytic function of T cells or
by inducing IgG2a production by B cells (Wan and Flavell 2009).
Th2 cells however produce cytokines including IL-4, IL-5, IL-9, IL-10 and IL-13.
These are responsible for promoting B cell proliferation and antibody
class-switching to IgG1 and IgE antibodies (Mosmann et al. 1986).
Th17 cells are named due to their signature production of IL-17, although they
also produce IL-21 and IL-22. Th17 cells have important roles in promoting
inflammation, however whereas Th1 cells protect against intracellular pathogens,
Th17 responses are directed against extracellular pathogens/fungi, and have
also been implicated in auto-immunity (Zambrano-Zaragoza et al. 2014).
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In contrast to Th1, Th2 and Th17 cells, the ‘effector’ functions of Tregs are
broadly to suppress immune responses. Tregs can either develop from
self-reactive T cells in the thymus during central tolerance or can differentiate
from naive CD4 T cells in the periphery. Induced Tregs (iTregs) and natural Tregs
have similar although non-redundant immunosuppressive functions in vivo
(Haribhai et al. 2011). These are achieved through production of the regulatory
cytokines IL-10 and TGF-b (Stassen et al. 2004) which help Tregs maintain
self-tolerance and immune homeostasis. Treg dysfunction or depletion can lead
to a wide variety of autoimmune and inflammatory diseases (Sakaguchi et al.
1995). Along with production of these cytokines, Tregs also suppress immune
responses by expressing high levels of CTLA-4 (Schwartz 1992). This binds to
CD80/86 on APCs with a higher affinity that CD28, and so limits T cell
co-stimulation, either by out-competing CD28 or by physically removing CD80/86
from the APC surface (Krummel and Allison 1995; Qureshi et al. 2011; Sansom
2000).
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Figure 1.4: CD4 T cell differentiation.
Adapted from O’Shea and Paul 2010.
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Lastly Tfh express the chemokine receptor CXCR5 and so are found
predominantly in the LN B cell zones where they promote memory B cells and
the production of high affinity antibodies (Wan and Flavell 2009).
However whether these CD4 subtypes are truly distinct lineages has recently
been questioned as cytokine production may not be as rigidly determined by
differentiation as first thought (O’Shea and Paul 2010). Nonetheless despite
questions remaining over the plasticity of differentiated CD4 T cells, they clearly
have a diverse but important role in the immune system.
CD8+ T cell effector function
Cytotoxic T lymphocytes (CTLs) are so named as they are able to induce
cytotoxicity of target cells by inducing two separate apoptosis pathways. Firstly,
upon TCR engagement with pMHC, the CTL and target cell form a tight
‘immunological synapse’ (Stinchcombe et al. 2001). TCR signalling leads to
influx of calcium, which causes polarisation of the microtubule cytoskeleton
towards the synapse (Pores-Fernando and Zweifach 2009). This initiates
degranulation of the CTL and exocytosis of lytic granules containing perforin and
granzymes across the synapse where they contact the target cell (Jenkins and
Griffiths 2010). Perforin molecules form a pore in the target cell membrane (but
not the CTL membrane) into which the granzymes can enter (Lopez et al. 2013).
Once inside the cell, granzymes induce target cell death by cleaving the BH3
interacting-domain death agonist (BID) and activating the ‘intrinsic’ apoptosis
signalling pathway (Sutton et al. 2000).
Alternatively CTLs can also induce cytotoxicity via an calcium independent
mechanism based upon the interaction of FAS with FAS ligand (FasL). FasL is a
transmembrane protein that belongs to the tumour necrosis factor family and is
expressed on activated CTLs (Berke 1995). The target cell expresses the Fas
receptor which, upon FasL binding, trimerises to form the death-inducing
signalling complex (DISC). DISC formation then leads to target cell death by
activating the ‘extrinsic’ apoptosis signalling pathway (Kischkel et al. 1995).
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The overall purpose of CD8 and CD4 T cell effector activity is the resolution of
the infection or pathogen. As mentioned, whereas the innate immune response
is very rapid it lacks the specific antigen recognition capabilities of adaptive
immunity. The other distinguishing feature is that the adaptive immune system
can generate memory and so respond more rapidly to a repeated infection. The
mechanisms underlying this memory formation are discussed below.
1.2.5 Memory formation
A complete T cell response to a pathogen will consist of 4 phases. As discussed
above, upon antigen exposure naive T cells will proliferate and begin to develop
effector functions. During this ‘expansion’ phase CTLs traffic to the site of
infection, secrete inflammatory cytokines and kill infected cells. The number of
antigen-specific CTLs peak at around day 7 after infection and after that T cell
numbers begin to reduce as cells undergo apoptosis. During this ‘contraction’
phase around 90-95% of expanded CTLs will die. However there is a population
of antigen-specific memory cells that remain and will be stably maintained for
years in the ‘memory’ phase. Lastly, if the same pathogen was to re-infect the
host at a later date, this memory population is able to rapidly respond and
provide better protection than antigen-inexperienced T cells (Williams and Bevan
2007).
The T cell memory compartment is comprised of two main populations; central
memory (TCM) and effector memory (TEM), which can be separated by CCR7
expression. TCM are CCR7+ so will traffic to secondary lymphoid organs. TCM are
less dependent on co-stimulation than naive T cells and after TCR signalling will
mainly produce IL-2 (Sallusto et al. 2004). Whilst they display limited effector
functions, TCM have a greater potential to proliferate and differentiate into effector
cells able to produce large amounts of IFN-g or IL-4. Conversely, TEM are CCR7-
and express chemokine receptors that promote migration to inflamed tissues.
These have less proliferative capacity but are better able to rapidly produce
effector cytokines and lyse target cells (Sallusto et al. 1999; Sallusto et al.
2004).
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Naive T cell expansion to form multiple effector cells followed by contraction and
subsequent memory formation has been well established, however the
differentiation pathway that generates these memory cells is less well
understood. The expression of the transcription factors T-bet and Eomes
determines the differentiation of T cells into either central or effector memory
subsets. High expression of T-bet is associated with formation of TEM whilst
expression of Eomes is linked to maintainance of TCM (Intlekofer et al. 2005;
Joshi et al. 2007). It was initially assumed that a sub-population of effector T
cells, possibly those with the greatest effector function, go on to form memory
cells, whilst the remaining cells undergo apoptosis (Youngblood et al. 2013).
However this model (as shown in Fig 1.5A) proposes that the cytolytic effector
cells ‘de-differentiate’ into a more naive-like memory cell.
An alternative model (Fig 1.5B) suggests instead that T cells follow a more linear
differentiation pathway. In this model, memory cells do not form from effector
cells, but directly from naive cells. This would still occur in primed T cells
following TCR signalling, but these cells won’t have reached the full cytotoxic
effector stage yet. T cells progress through this pathway, losing their proliferative
capacity but gaining effector functions associated with effector T cells. In
contrast to the ‘de-differentiation’ model, here effector T cells eventually become
terminally differentiated, lose effector function and become senescent or die
(Restifo and Gattinoni 2013). Progression along this pathway is predicted to be
set by the strength of the T cell activation signal, which could include the amount
of antigen presented, the frequency of pMHC-TCR engagement, or the level of
co-stimulation. To support this it has been shown that when T cells are injected
into mice later in an infection (where they may receive a weaker activation
signals), these cells show signs of increased memory potential (D’Souza and
Hedrick 2006).
This linear differentiation model has been given further credence by recent work
utilising in vivo fate mapping of murine T cells. These have shown that increased
proliferation tends to generate short-lived effector cells, whereas reduced
proliferation favours longer-lived memory cells. Likewise, in contrast to the
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original model, this data suggested that the T cell populations that comprise the
effector response are less likely to be involved in a later re-call response
(Buchholz et al. 2013; Gerlach et al. 2013).
Memory T cells are clearly a fundamental aspect of the adaptive immune
response, however more work is required to elucidate the exact model of
differentiation that drives their formation. This may have important
consequences as the differentiation status of therapeutic T cells may play a
significant role in their functional ability. This will be discussed in more detail in
the context of tumour immunotherapy in section 1.4.
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These sections have shown that T cells are able to recognise tumour cells through
their unique TCR and expand and acquire effector functions that allow the specific
cytolysis of that tumour cell. However an important facet of this response, which
controls T cell priming, is the presentation of antigen to the T cell. The biology
of one of the key antigen presenting cells, the dendritic cell, is discussed in more
detail in the next section.
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1.3 Dendritic cell biology
Since their discovery by Ralph Steinman in the 1970s (Steinman and Cohn
1973), Dendritic cells (DC) have arisen as a crucial cell population necessary to
control and regulate the adaptive immune response. Broadly speaking the role
of DC are to act as sentinels; tissue resident DC sample their environment and
engulf any pathogens. DC then migrate to the LNs and present antigen to the T
and B cells of the adaptive immune system. As shown earlier, this antigen
presentation primes T cells and allows them to travel to the site of infection and
kill the pathogen. DC therefore are the link between the innate and adaptive
immune systems. However DC orchestrate adaptive immunity not only through
priming antigen-specific T cells but they also have roles in preserving peripheral
tolerance to self-antigens (Banchereau and Steinman 1998) and directly
controlling effector T cell responses in tissues (Bennett and Chakraverty 2012).
The various features that DC exhibit in order to efficiently carry out these
functions are described in more detail below.
1.3.1 Antigen processing and presentation
The primary role of DC in the immune system is to capture, process and present
antigens to lymphocytes in the context of MHCI and II. Whereas other cell
populations such as macrophages and B cells can express MHCII and are able
to present antigens, DC are professional antigen presenting cells (APCs) and as
such are uniquely able to activate naive T cells (Croft et al. 1992; Ronchese and
Hausmann 1993). This superior ability as APC is dependent on various
functional characteristics that DC possess. Firstly, DC were initially defined and
named due to their unusual morphology. Unlike other haematopoetic cells, DC
are stellate and have numerous processes or ‘dendrites’ that extent outwards
into their surroundings (Banchereau and Steinman 1998). This greatly increases
the DC surface area and allows contact with multiple surrounding cells.
Immature, tissue-resident DC utilise this morphology to capture antigens and are
proficient at doing so via three mechanisms. Firstly, DC are able to phagocytose
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particles and pathogens from their surroundings (Inaba et al. 1993). Alternatively
they express receptors that mediate endocytosis. These include the Fcg and Fce
receptors that endocytose immune complexes (Sallusto and Lanzavecchia 1994)
or the macrophage mannose receptor and DEC-205 which bind to
carbohydrates (Jiang et al. 1995). Lastly DC are also able to take up large
amounts of extracellular fluid into pinocytic vesicles from which antigens can be
sampled in a process called macropinocytosis (Norbury et al. 1997).
DC then have different mechanisms for processing and presenting either
exogenously acquired antigens or endogenously synthesised antigens. DC
process endogenous antigen, either from the cells own proteins or from viral
infections, and present this via MHCI molecules. As shown in Fig 1.6A,
intracellular antigens are degraded into multiple oligopeptides by the cytosolic
proteasome, a complex of multiple proteolytic and regulatory subunits (Rock and
Goldberg 1999). Peptides are then transported into the endoplasmic reticulum
(ER) by the transporter associated with antigen processing (TAP) and loaded
onto nascent MHCI molecules (Purcell 2000). pMHCI complexes are then
transported to the cell surface by the Golgi apparatus where they can present
the peptide to CD8 T cells. DC also utilise a separate mechanism to process
and present extracellular antigens. After antigen capture, internalised antigens
reside in endosomal and lysosomal compartments. These contain various
proteases known as cathepsins, that degrade endocytosed proteins (Honey and
Rudensky 2003). Peptides are then loaded onto MHCII molecules and
transported to the cell surface where they are presented to CD4 T cells.
However these two mechanisms alone would severely restrict the repertoire of
peptides able to be presented to T cells. Therefore DC can also direct
endogenous antigens to be presented via the MHCII pathway by transfer of
antigen into endosomal compartments during autophagy (Strawbridge and Blum
2007). DC can additionally use a separate mechanism that allows exogenous
antigen (usually presented on MHCII) to be presented on MHCI to CD8 T cells.
This process, known as cross-presentation, can occur by two mechanisms, the
first, which relies on the proteasome, is summarised in Fig 1.6B. Internalised
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(a) Direct presentation (b) Cross-presentation
Figure 1.6: Dendritic cell antigen presentation.
antigens are transferred from the phagosome to the cytosol, where they are able
to be degraded by the proteasome (Kovacsovics-Bankowski and Rock 1995). As
before, newly generated peptides enter the ER through TAP and bind to MHCI
molecules. Whilst proteasome inhibition prevents this cytosolic
cross-presentation, a separate proteasome-independent mechanism is also
available to DC. This process is sensitive to lysosome proteolysis inhibition
which suggests that MHCI molecules can access the phagosome and be loaded
with peptide directly (Shen et al. 2004). However cross-presentation is not yet
fully understood and the exact mechanisms used to cross-present antigens are
unclear. For example the role of the ER has recently been questioned as
ER-resident proteins that mediate MHCI loading have been found on
phagosomes (Guermonprez et al. 2003). The recruitment of these proteins to
the phagosome depends on the ER protein, Sec22b and cells deficient in this
protein are unable to cross-present antigens (Cebrian et al. 2011). Likewise
whilst TAP mediated import into the ER/phagosome was thought to be required
for peptide loading onto MHCI, this may also occur via a TAP-independent
mechanism (Lawand et al. 2016).
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The machinery that enables cross-presentation via these pathways appears to
be specific to DC as other APC such as macrophages are unable to
cross-present antigen in vivo (Jung et al. 2002). DC may be able to preserve
antigens so that they are available for cross-presentation as lysosomal
proteolysis is reduced in DC compared to macrophages (Delamarre et al. 2005).
DC that are adept at cross-presentation also express low levels of the lectin
Siglec-G, which has recently been described to inhibit cross-presentation by
increasing phagosomal hydrolysis of internalised antigens (Ding et al. 2016).
Using these mechanisms DC are therefore capable of processing and
presenting a broad range of peptides via both MHCI and II to activate CD8 and
CD4 T cells respectively.
1.3.2 DC activation
However presentation of peptide alone is insufficient to fully prime effector T
cells and can lead to T cell anergy (Steinman et al. 2003). Therefore DC require
activation, from an immature to a mature state, where they are able to provide
co-stimulation and inflammatory cytokines. DC can acquire activation signals at
the same time as they acquire antigen and these signals are usually from
pathogen associated molecular patterns (PAMPs). DC are able to recognise
PAMPs through the expression of pattern recognition receptors (PRR), of which
the most studied are toll-like receptors (TLR). Unlike receptors of the adaptive
immune response such as TCRs, TLR are germ-line encoded receptors that are
much less specific and recognise structurally similar, but widely distributed
molecules. Cell surface TLR are involved in recognition of a series of conserved
molecular patterns, specific to bacterial, fungal or protozoan pathogens while the
intracellular TLR recognise viral nucleic acids (Kanzler et al. 2007). However in a
cancer setting, DC can also promote immune responses to antigens in the
absence of pathogen associated signals. DC express PRR, including some TLR,
which can also bind to molecular structures not associated with pathogens but
which are released from cells upon tissue damage (damage associated
molecular patterns or DAMPs) (Gallo and Gallucci 2013). These have included
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intracellular proteins such as the heat shock proteins (HSP70, HSP90, and
gp96), the S100 calcium-binding protein family and HMGB1. In additon
intracellular molecules such as ATP, uric acid and dsDNA have also been shown
to induce DC maturation (Zitvogel et al. 2010). These intracellular ‘danger
signals’ are upregulated after cellular stress and can be released upon cell
apoptosis or necrosis. DAMPs can then bind to receptors on the DC surface,
principally TLR4 and induce DC maturation (Apetoh et al. 2007; Fang et al.
2014).
TLR signalling induces this shift from ‘immature’ to ‘mature’ DC which are better
able to prime T cells (Hemmi and Akira 2005). Mature DC express higher levels
of co-stimulation molecules such as CD40, CD80 and CD86 and produce
inflammatory cytokines such as IFN-a, IFN-b, TNF, IL-1 and IL-12 (Reis E Sousa
2004). These not only provide signal 2 and signal 3 to T cells, but also the
cytokines act in an autocrine fashion to promote DC maturation. Cytokine and
PRR-mediated activation appear to occur in combination though as DC
activation by inflammatory cytokines in the absence of PRR signalling is
insufficient to fully activate DC (Sporri and Reis E Sousa 2005).
A key aspect of DC maturation is the migration of DC from where they reside in
peripheral tissues to draining LN. DC migration is controlled by the expression of
chemokine receptors on the DC surface. Immature DC express chemokine
receptors involved in migration to non-lymphoid tissue, such as CC-chemokine
receptor 6 (CCR6), however as DC mature they down-regulate expression of
these receptors and up-regulate expression of CCR7, a receptor that causes DC
migration to draining LNs (Dieu et al. 1998). Therefore via these processes DC
are able to sample their environment and internalise antigen, mature in response
to pathogen associated signals, traffic to LN and present acquired antigen to
naive T cells. However whilst this outlines their broad function in priming naive T
cells in response to infection, DC have also been shown to control the effector
function of T cells in tissues.
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1.3.3 DC control of T cells in situ
Although DC prime T cell responses in the LN, these effector T cells need to
be able to adapt to a changing environment in the tissue to be able to induce
clearance of infected cells whilst minimising damage to healthy tissue. DC are
thought to have a central role in controlling T cell effector function in situ. Although
DC migrate to LN following infection, not all tissue resident DC migrate and those
that remain are further bolstered by recruitment of DC from blood precursors
(Eidsmo et al. 2009; León et al. 2007). A large proportion of these DC that migrate
to the site of infection are ‘inflammatory DC’ that differentiate from monocytes in
response to blood-borne TLR agonists (Shi et al. 2011).
These tissue-resident DC have been shown to have important roles in the control
of effector T cells. After T cell priming in the LN, depletion of lung DC results
in enhanced viral titres and mortality in influenza infected mice. This was as a
result of impaired CD8 T cell responses which were dependant on presentation
of influenza peptides by lung APC. (McGill et al. 2008). These data suggest
that the recruitment of DC into inflamed tissue may promote subsequent T cell
effector function. This inflammatory response is also noted in the intestine and
skin of patients with autoimmune diseases, which show an accumulation of DC
at these sites (Rescigno and Di Sabatino 2009; Zaba et al. 2008).
However the role of tissue-resident DC is not always to promote T cell responses.
As infections are cleared, DC are able to restrict the function of effector T cells
to prevent unwanted damage. For example whilst antigen presentation in the
skin drives production of inflammatory cytokines such as IFN-g, this also directly
promotes IL-10 production by Tregs (McLachlan et al. 2009). Effector T cells have
also been shown to interact with tissue-resident DC upon recognition of antigen.
This induces upregulation of PD-1 on the T cell, which then loses effector function
(Honda et al. 2014). The ability of DC to limit the effector function of T cells
is also shown in their ability to enforce ‘peripheral tolerance’ in the absence of
infection.
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1.3.4 DC-mediated peripheral tolerance
As mentioned previously (section 1.2.2) central tolerance is crucial to preventing
self-reactive T cells from developing, although a small amount of potentially
self-reactive T cells will escape this process. DC therefore mediate peripheral
tolerance which is crucial in preventing these self-reactive T cells from mounting
responses to healthy tissues (Xing and Hogquist 2012). In the steady-state DC
are able to promote T cell hypo-responsiveness (‘anergy’) or delete T cells to
prevent unwanted immune reactions. This is primarily achieved through
presentation of self-antigen to T cells in the absence of co-stimulation, which is
required for full T cell activation (Steinman et al. 2003). Alternatively the absence
of co-stimulation can be coupled with expression of inhibitory receptors such as
PD-L1. This can interfere with TCR signalling in a antigen-specific manner and
induce T cell anergy (Probst et al. 2005b). Although there exists a lymphocyte
counterpart in the regulatory T cell, a specific ‘regulatory DC’ that would be
required for peripheral tolerance has not been identified. Instead it has been
suggested that these functions are carried out by immature DC of different
subsets (Reis E Sousa 2006; Steinman and Nussenzweig 2002). However
although a regulatory DC subset has not been identified, DC are a heterogenous
population which do have different functions in the immune system. These DC
subsets and their roles in various immune reactions are described in more detail
below.
1.3.5 Murine DC subsets and development
DC can be broadly split into three groups, classical or conventional DC (cDC),
plasmacytoid DC (pDC) and monocyte-derived DC (moDC). Despite some early
scepticism, these DC populations have been shown to originate from a distinct
cellular precursor that doesn’t produce other lymphoid cells (Satpathy et al.
2012a). The exact expression of the various transcription factors and cytokines
that regulate DC differentiation are not yet fully understood however a summary
of DC ontology is shown in Fig 1.7.
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Common myeloid progenitors (CMP) originate in the bone marrow and gradually
differentiate into the macrophage DC progenitor (MDP) when exposed to the
growth factor fms-like tyrosine kinase 3 ligand (FLT3L) (Karsunky et al. 2003).
This population will bifurcate, of which one arm can give rise to monocytes when
exposed to macrophage colony-stimulating factor (CSF1). Generation of
monocytes was originally thought to be upstream of DC development as they are
able to differentiate into a DC population that exhibit many features associated
with what we now know as cDC (Merad et al. 2013). Differentiation of monocyte
derived DC (MoDC) occurs during inflammatory conditions (Naik et al. 2006) so
they are therefore often referred to as ‘inflammatory DC’. They have very similar
roles in antigen presentation as cDC and express similar cell surface molecules
such as CD11c, CD11b and MHCII. However due to their monocytic lineage they
also express the Fc-g receptor 1 (CD64) not found on cDC (Mildner and Jung
2014). We now know that MoDC and cDC are separate DC populations and as
mentioned earlier, it has been suggested that MoDC migrate from the blood to
inflamed tissue to boost the cDC response to infections (Hespel and Moser
2012).
However without CSF1 and in the continued presence of FLT3L, MDP lose the
potential to generate monocytes and will become common DC progenitors (CDP).
These are committed to generating either of the remaining cells of the DC lineage,
pDCs or cDCs (Merad et al. 2013). Development of pDCs is positively controlled
by expression of the E-box protein transcription factor E2-2 (Cisse et al. 2008),
although they can arise from either CDP or common lymphoid progenitors (CLP)
(Manz et al. 2001; Onai et al. 2013). pDCs are terminally differentiated in the bone
marrow and migrate to the blood. Here they exist as a specialised subset of cells
that express TLRs which bind to viral nucleic acids and are able to rapidly produce
large amounts of type I IFNs in response to viral infections (Asselin-Paturel and
Trinchieri 2005). However in addition, pDC are also able to act as APC and
present antigen to naive T cells, the hallmark of a DC response, although this is
dependent on TLR activation. (Mouriès et al. 2008; Sapoznikov et al. 2007).
However the most well-studied DC population are the cDC, which are the major
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Figure 1.7: Dendritic cell ontology.
Adapted from Merad et al. 2013, with key cytokines or transcription factors (italics) noted.
(HSC = hematopoietic stem cell; CLP = common lymphoid progenitor; CMP = common
myeloid progenitor; MDP = macrophage DC progenitor; CDP = common DC progenitor).
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antigen presenting population of DC. Expression of the DNA-binding protein
inhibitor ID-2 inhibits E2-2 transcription factor mediated pDC differentiation and
is thought to drive differentiation of CDP into pre-DCs and later cDCs (Jackson
et al. 2011). Alongside this, pre-DCs also exclusively express the transcription
factor Zbtb46, although this appears not to be strictly required for development of
pre-DC or cDC (Satpathy et al. 2012b). Pre-DCs migrate from the bone marrow
to the blood where where they populate both lymphoid and non-lymphoid
tissues. There, pre-DCs will differentiate into one of two types of cDC;
CD103/CD8+ cDC1 or CD11b+ cDC2 (Merad et al. 2013). Differentiation
between these two subsets is controlled by the expression of the transcription
factors interferon regulatory factor 8 (IRF8) and basic leucine zipper ATF-like
transcription factor 3 (Batf3) on cDC1 (Grajales-Reyes et al. 2015), or IRF4 on
cDC2 (Suzuki et al. 2004). This lineage decision is made early in pre-DC
development, when they are still in the bone marrow although it doesn’t manifest
until pre-DCs migrate to the periphery (Schlitzer et al. 2015)
The discover of CD8+ cDC1 in the lymphoid organs was one of the first
examples in DC heterogeneity (Crowley et al. 1989; Vremec et al. 1992) and
was followed by the identification of their tissue-resident counterparts, CD103+
cDC1 (Bursch et al. 2007; Rio et al. 2007). Despite these differences in marker
expression, both CD8 and CD103+ DCs belong to the same lineage and can be
collectively identified by the expression of the chemokine receptor XCR1
(lymphotactin receptor/G-protein-coupled receptor 5) (Guilliams et al. 2016).
cDC1 are the quintessential antigen presenting cells of the immune system and
are specialised in cross-presentation. Both splenic CD8+ (Haan et al. 2000) and
tissue-resident CD103+ (Bedoui et al. 2009; Broz et al. 2014) cDC have been
shown to be able to cross-present antigen in vivo. Additionally, TLR signalling on
cDC1 induces significant IL-12 production, which has important roles in
promoting T cell and DC maturation (Reis e Sousa et al. 1997).
CD11b+ cDC2 however are less well characterised than cDC1, partly because
they represent a more heterogenous population. These can be distiguished from
cDC1 as they are XCR1- and express the signal regulatory protein alpha (SIRPa
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or CD172a) (Guilliams et al. 2016). cDC2 development is controlled by the
expression of IRF4 and this appears to influence their functional role in vivo.
IRF4 expression in CD11b+ DC has been shown to induce high levels of MHCII
expression (Vander Lugt et al. 2014) and therefore these cells are adept at
presenting antigen to CD4 T cells (Dudziak et al. 2007). However this appears to
limit their ability to cross-present antigen to CD8 T cells (Mildner and Jung
2014).
Whilst these DC subsets are functionally conserved in humans, their expression
of some surface markers can vary (Satpathy et al. 2012a). However recent
attempts to identify these populations have revealed a subset phenotype that is
conserved across species. cDC1s can therefore be identified as CADM1hi
CD172alo CD11cint-hi CD26hi IRF8hi IRF4lo and cDC2s can be identified as
CADM1lo CD172ahi CD1chi CD11chi IRF4hi IRF8lo cells (Guilliams et al.
2016).
1.3.6 DC in tumour immunology
DC have numerous potential roles in tumour immunology which reflect the
heterogeneous nature of these cells and their functions. As discussed earlier, T
cell responses to tumours have been associated with improved prognoses and
patient survival (Clark et al. 1989; Clemente et al. 1996; Fridman et al. 2012;
Galon et al. 2006). The logical assumption therefore is that, as T cells require
antigen presentation to assume effector function, the DC that orchestrate this
response would have similar prognostic value. The ‘cancer-immunity cycle’ has
recently been proposed in which DC acquire tumour antigen then mature and
migrate to draining LN. Antigen presentation primes naive T cells which migrate
back to the tumour and recognise the specific p-MHC expressed on tumour
cells. Effector T cells can then induce tumour cell death, which releases further
antigen and the cycle can be repeated with increased depth and breadth of
response (Chen and Mellman 2013). Indeed infiltration of DC into tumours has
been associated with improved survival and reduced metastases (Ananiev et al.
2011; Iwamoto et al. 2003; Tsujitani et al. 1993; Zeid and Muller 1993). However
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separate studies have conversely linked tumour infiltrating DC with poorer overall
survival (Dadabayev et al. 2004; Sandel et al. 2005). This discrepancy is likely
due to differences in the localisation and maturation of DC in different tumours.
Likewise the DC that infiltrate the tumour are as phenotypically and
developmentally varied as those found in steady state tissues and lymphoid
organs (Broz et al. 2014; Salmon et al. 2016). In addition the stage of cancer
progression in which the DC are found can also have a profound impact on their
function. Scarlett et al recently showed in a inducible ovarian cancer model that
during the initial phases of tumour equilibrium, tumour infiltrating DC were
capable of stimulating T cell responses and expressed high levels of MHCII and
CD40. However the phenotype of these DC later switched as they became
immunosuppressive. Late-tumour infiltrating DC expressed lower levels of
co-stimulatory molecules, whilst up-regulating expression of PD-L1. This
phenotypic switch coincided with a phase of rapid tumour growth. In line with this
data, depletion of early-DC induced rapid tumour growth, whereas depletion of
late-DC prevented tumour escape (Scarlett et al. 2012). These data show that
DC can have various functions in the tumour that either promote or control
tumour growth.
One of the functions of DC that may have an important effect on this ability to
promote tumour escape is not the priming of effector T cells but the maintenance
of self-tolerance. This is relevant in a cancer setting as tumours clearly have
mechanisms that allow them to subvert peripheral tolerance to disrupt the
cancer-immunity cycle and evade immune responses. One mechanism that
tumours use to manipulate immunosurveillance is through preventing DC
maturation or recruiting immature DC. Tumour resident DC are known to have
low levels of CD86, MHCII and produce few pro-inflammatory cytokines (Drake
et al. 2006). Tumours are thought to directly inhibit DC maturation by
over-expressing inhibitory cytokines such as VEGF, M-CSF, IL-10 and IL-6
(Drake et al. 2006; Gabrilovich 2004). Therefore tumour-resident DC and DC
which migrate to tumour draining LN are able to acquire and present tumour
antigen to naive T cells but can only provide poor co-stimulation. In addition, DC
in tumour draining LNs have also been shown to express higher levels of PD-L1
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than those in non-draining LNs (Salmon et al. 2016). These factors contribute to
promoting anergic T cell responses that tolerise adaptive T cells to tumour
antigens and promote tumour escape.
However not all tumour resident DC are in this immature state which promote T
cell anergy. Recently CD103+ cDC1 have been described as a DC population that
infiltrate tumours and are crucial for inducing T cell immunity to tumour antigens
(Broz et al. 2014; Salmon et al. 2016). This cDC1 population acquire tumour
antigen and migrate to draining LN by expressing CCR7 (Roberts et al. 2015).
In the draining LN, CD103+ DC are essential for cross-presentation of tumour
antigen to naive T cells and the subsequent priming of T cell responses against
the tumour antigens (Broz et al. 2014; Roberts et al. 2015; Salmon et al. 2016).
However although effective, CD103+ DC are only present in small numbers and so
cannot overcome tumour immune evasion. This has been shown in experiments
with Batf3-/- mice, which lack cDC1 but in which transplanted B16 tumours grow
as quickly as WT controls (Salmon et al. 2016). In contrast, injection of FLT3L
promotes differentiation of CD103/cDC1 and results in accumulation of CD103+
DC in the tumour. This promotes greater T cell infiltration and IFN-g production
in tumours (Salmon et al. 2016). As well as priming T cell responses in the
LN, CD103+ DC are suggested to have roles in controlling T cell function in the
tumour. Depletion of CD103+ DC limits adoptively transferred, tumour specific T
cell-mediated tumour control, independent of LN priming (Broz et al. 2014). The
importance of these cells is also evident in melanoma patients where high levels
of CD103+ DC or CCR7 expression correspond to a better prognosis and survival
(Broz et al. 2014; Roberts et al. 2015). The importance of CD103+ DC in the
efficacy of various immunotherapies still needs to be fully assessed. However
pre-clinical studies have suggested that enhanced tumour control after PD-L1
checkpoint blockade requires CD103+ DC to be effective (Salmon et al. 2016).
Likewise vaccines expressing FLT3L have been shown to synergise with CTLA-
4 blockade (Curran and Allison 2009). The various approaches to developing
immune responses against tumours including use of DC vaccines are discussed
in more detail in the section 1.4.
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Combined, these data show that whilst the CD103+ subset are clearly important
in mediating T cell control of tumour growth, overall DC have mixed role in
tumour control or progression. This is reflected in the fact that they are a
heterogenous population of cells in which each subset can also exist in a
different state of maturation. Future studies will therefore need to carefully
examine the different roles of these DC subsets and the importance of their
maturation status. The next section will therefore explain the current murine
models that have allowed researchers to elucidate DC function and in particular,
the diphtheria toxin receptor depletion model.
1.3.7 Mouse models to study DC: DTR models
The availability of transgenic mice has had a dramatic impact on the study of
various aspects of immunology including DC biology. Transgenic mice in which
specific transcription factors are knocked out have been crucial in developing our
understanding of the various DC subsets and how they develop. Likewise mice
in which the Cre recombinase is expressed in DC has allowed for specific gene
deletion and the elucidation of various DC functions. However of recent
abundance and of particular importance in this study are the models of
conditional DC ablation using the diphtheria toxin receptor (DTR).
The DTR system exploits a series of advantageous aspects of cell biology to
allow specific and efficient depletion of target cells. Firstly, diphtheria toxin (DT),
the toxin produced by Corynebacterium diphtheriae, is incredibly potent and able
to efficiently block protein synthesis and induce cell apoptosis. However the
activity of DT is strictly dependent on receptor-mediated endocytosis. The DT
receptor (DTR) is a membrane-anchored form of the heparin-binding epidermal
growth factor receptor. However the murine and human/simian versions of the
DTR vary by three amino acids in the region that bind DT. This results in murine
cells being 105 times less susceptible to DT mediated killing than human cells.
These circumstances have been exploited to genetically engineer mice to
express the high-affinity, human DTR in specific cell types, making these cells
acutely susceptible to depletion upon DT injection (Saito et al. 2001).
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Figure 1.8: DT mediated toxicity.
1. DT is composed of two subunits. The B subunit binds to the human (high affinity)
DTR but not the murine (low affinity) DTR.
2. DT entry into the cell is dependant on receptor-mediated endocytosis.
3. Increased acidification in the endosome results in the separation of the A and B
subunits.
4. The A subunits enters to cytosol where it ADP-ribosylates elongation factor-2 (EF-2).
5. The inactive EF-2 prevents protein synthesis in the cell, which rapidly begins to
undergo apoptosis.
The expression of the high-affinity DTR and hence the susceptibility to depletion
can be controlled by placing DTR expression under the control of cell specific
promotors. Previously, cell ablation had been achieved by constitutively
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expressing DT-A under the control of these promotors (Saito et al. 2001).
However conditional depletion of DC offers an attractive alternative to
constitutive ablation as it has numerous advantages. Injection of a depleting
agent offers a level of temporal and possibly spatial control over cell depletion
not possible in constitutive depletion models. Likewise, conditional depletion
avoids both developmental concerns and the appearance of compensatory
mechanisms that are both associated with mice permanently depleted of cell
subsets (Sapoznikov and Jung 2008).
Previous attempts at conditional DC depletion however had been fraught with
difficulties, in part due to the heterogenous nature of these cells. Use of
depleting antibodies was limited due to the lack of unique markers on DC
(Bennett and Clausen 2007). Whilst some level of DC depletion could be
achieved using chlodronate lipsomes, these will deplete all phagocytotic cells
and are more routinely used to deplete macrophages (Rooijen and Hendrikx
2010). Therefore the DTR system was first utilised to deplete DC by Jung et al in
2002, by placing the high-affinity DTR under the control of the CD11c (Itgax)
promotor. This system avoided the downsides associated with constitutive
depletion whilst also offering improved specificity and efficiency compared to
previous conditional depletion models. High efficiency of depletion takes on a
more pronounced importance in DC depletion models due to the remarkable
ability of few DC to promote T cell responses (Bennett and Clausen 2007). The
DTR model is capable of this efficiency because of the high toxicity of DT; as
little as one DT molecule in the cytosol may be sufficient to induce cell death
(Yamaizumi et al. 1978). Lastly, the DTR model is also well suited to depletion in
an immunological context as DT-mediated killing of target cells occurs through
programmed apoptosis (Thorburn et al. 2003) which, in a similar depletion
model, did not cause inflammation (Bennett et al. 2005).
In CD11c.DTR mice a single i.p. injection of DT (4ng/g) will deplete 85-90% of
splenic DC within 24 hours and this is maintained for 3 days, after which time DC
repopulate and return to homeostatic levels (Jung et al. 2002). However cd11c is
expressed at varying levels in DC and depletion favours CD11chi DC. It may be
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that the Itgax promoter fragment is insufficient to fully control CD11c expression
in all cells. For example CD11cint pDC and NK cells transcribe their endogenous
Itgax allele and express CD11c but are not susceptible to depletion (Lucas et al.
2007; Sapoznikov et al. 2007). Whereas the Itgax promotor is also active in
some activated T cells (Jung et al. 2002) and B cell plasma blasts (Hebel et al.
2006), however these cells are susceptible to depletion. Lastly detailed
histological analysis has revealed that DT injection completely depletes marginal
zone and metallophilic macrophages from the spleen and their sinusoidal
counterparts from the lymph nodes (Probst et al. 2005a). Therefore careful
consideration must be taken when interpreting data from this model due to the
potential depletion of other CD11c+ cells. CD11c.DTR mice also suffer from an
unexpected phenotype where DTR expression causes a lack of migrating DC in
the LN, and an overall LN hypocellularity (Blijswijk et al. 2015). The reason
behind this is unclear but appears to be dependant on DTR expression on DC
subsets as it is also found in other DC depletion models that use DTR
expression.
However the biggest disadvantage of the CD11c.DTR model is the lethality in
mice that are repeatedly injected with DT. Studies are therefore limited to one DT
injection and hence DC can only be depleted for 3 days. This appears to be
caused by CD11c expression on non-haematopoetic tissue, possibly in the gut
or brain. CD11c.DTR mice reconstituted with WT bone marrow (BM) are still
killed by repeated DT injection (Zaft et al. 2005). However this does allow for BM
chimeras to be generated in which CD11c.DTR BM is used to reconstitute WT
recipients, which circumvents the toxicity of repeated DT injections. The
downside of this approach however is that radio-resistant dermal DC (Bogunovic
et al. 2006) will be maintained from host origin and therefore not susceptible to
depletion.
An alternative to the CD11c.DTR model therefore are the CD11c.DOG mice.
These mice were generated by transferring a bacterial artificial chromosome
(BAC) rather than the usual transgenesis used to created the CD11c.DTR mice.
This means that in the CD11c.DTR mice, the DTR transgene is randomly
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inserted into the genome and expression is only controlled by the minimal
CD11c promotor. Whereas a BAC allows for the transfer of a much larger
amount of genetic information, which means that in CD11c.DOG mice the
expression of the DTR transgene is controlled by the whole CD11c gene locus,
including the promotor and related gene enhancers and silencers (Hochweller
et al. 2008). Due to this tighter restriction of DTR expression, CD11c.DOG mice
are able to be injected with DT multiple times without toxicity. Moreover, the LN
hypocellularity associated with other DTR models is not evident in the
CD11c.DOG mice (Blijswijk et al. 2015).
In addition to these DTR models that broadly target CD11c+ DC, recent attempts
have been made to deplete specific DC subsets. These mouse models are shown
in Table 1.1 and include targetting depletion to cDC (Meredith et al. 2012), pDC
(Swiecki et al. 2010; Takagi et al. 2011) and CD8+ DC (Fukaya et al. 2012; Piva et
al. 2012). As with previous depletion models however, these models have various
limitations that restrict their usage.
However one last limitation with DC depletion models not mentioned in Table 1.1
is the influx of neutrophils and monocytes after DC depletion (Hochweller et al.
2008; Sivakumaran et al. 2016; Tittel et al. 2012). This has been observed in
both the CD11c.DTR and CD11c.DOG models but it is unclear whether other
DC depletion models also exhibit these phenotpyes. Monocytosis and
neutrophilia can have a confounding effect on the study of DC depletion, for
example Tittel et al showed that despite DC depletion, DT injection promoted
bacterial clearance as a result of this neutrophil recruitment. Similarly, the
depletion-induced monocytosis occurs through an expansion of a unique
population of monocytes primed to produce TNFa (Sivakumaran et al. 2016).
These studies show that caution that must be used when interpreting data
generated through the use of these DC depletion models. However despite
these caveats, the CD11c.DTR and CD11c.DOG models are still powerful tools
to use in the investigation of DC biology.
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Table 1.1: Murine DTR models of DC depletion
Mouse model Cell depletion Limitations Ref.
CD11c.DTR
(Transgenic)
CD11c+ DCs and
some macrophages
Possible depletion of other cells:
pDCs, NK cells, activated T and B
cells. Toxicity in CD11c.DTR mice.
Jung et al.
2002
CD11c.DOG
(BAC transfer)
CD11c+ DCs and
some macrophages
Similar possible depletion to
CD11c.DTR model, although less
well defined.
Hochweller
et al. 2008
zDC.DTR
(Knockin)
Zbtb46+ cDC, but also
activated monocytes
Zbtb46 expression in erythroid
progenitors and epithelial cells
leads to lethality unless BM
chimeras are made.
Meredith et
al. 2012
BDCA2.DTR
(Transgenic)
pDCs BDCA2 expression varies so off-
target DTR expression possible.
Swiecki et al.
2010
SiglecH.DTR
(BAC transfer)
pDCs Homozygous SiglecH.DTR mice
are deficient in endogenous
SiglecH expression.
Takagi et al.
2011
Clec9a.DTR
(BAC transfer)
CD8+ (and likely
CD103+) cDCs
Partial depletion of Clec9lo pDC. Piva et al.
2012
CD205.DTR
(Knockin)
CD8+ DC, dermal DC,
and LC
DT mediated lethality; requires
generation of BM chimeras
Fukaya et al.
2012
Adapted from Van Blijswijk et al. 2013
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1.4 Cancer immunotherapy
The formalisation of the theory of immunoediting (as discussed earlier) has led
to many attempts to utilise the potential of the immune system to control tumours
in patients. This is because, despite recent advances, cancer still remains a
leading cause of mortality in the developed world. Key to this anti-tumour
immune response is the response generated by the adaptive T cells, which are
able to recognise tumour antigens and induce cytotoxic effects. The added
attractiveness of cancer immunotherapies is that tumour recognition can occur
systemically in sites distal to the tumour, potentially allowing T cells to cure
tumour metastases. Likewise the addition of immunological memory might
generate long lived, persistent protection. The majority of recent cancer
immunotherapies therefore have focused on generating a population of cytotoxic
T cells that are able to destroy the tumour. There are three main approaches to
this that have been attempted:
• Vaccination against tumour antigens to promote an endogenous T cell
response
• Expansion and adoptive transfer of tumour infiltrating lymphocytes
• Generation of a new anti-tumour T cell population by gene therapy
This section will discuss the foundations, as well as recent developments of these
three approaches.
1.4.1 Vaccines for tumour immunotherapy
DC are responsible for orchestrating adaptive immunity and so are attractive
targets for controlling anti-tumour immunity. Particularly, considerable interest
has been generated in utilising DC through vaccinations. However whilst
vaccines for infectious diseases are incredibly potent at inducing durable
immune responses, this has proved to be more challenging in a tumour setting.
For use in tumour immunotherapy, vaccination refers to therapeutic use, rather
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than prophylactic. This means patients are already burdened with an established
tumour that has likely evolved to avoid recognition or elimination by the immune
system. DC in these patients are therefore often dysfunctional and unable to
generate effector T cell responses (Pinzon-Charry et al. 2005). Provision of
additional tumour antigen in this setting is therefore not sufficient to generate
CD8 T cell responses able to effectively control tumours. The challenge that
tumour vaccines face is how to overcome the myriad immunosuppressive
mechanisms that tumours use to blunt T cell immunity. To achieve this the DC
used for vaccination must not have been subverted by the tumour
microenvironment and must be able to present antigen alongside relevant
co-stimulation. The vaccination strategies that have been used to achieve this
essentially fall into two categories; either DC are generated ex vivo and therefore
outside the influence of the tumour or endogenous DC are targeted in vivo
alongside an approach to ensure DC maturation.
Vaccination with ex vivo generated DC
The majority of initial work with tumour vaccines involved use of DC ex vivo,
such as pulsing DC with a tumour-specific peptide in vitro before transferring
them back into the patient. Whilst this technique has been shown to induce
antigen-specific T cell responses, its effect on tumour regression, particularly
when used therapeutically has been limited (Celluzzi et al. 1996; Inaba et al.
1990; Zitvogel et al. 1996). A number of different factors could be limiting the
potency of T cell responses to antigen-loaded DC. Several studies have
suggested that presentation of antigen via MHCI by peptide-loaded DC is fairly
short-lived (Amoscato et al. 1998; Kukutsch et al. 2000; Zehn et al. 2004).
Likewise radiolabelled DC injected intra-dermally into patients did not migrate
away from the injection site, which could limit their ability to present antigen to T
cells in the LN (Lesterhuis et al. 2011). Most importantly however, the
importance of providing adequate co-stimulation and inflammatory cytokines
alongside antigen presentation were not fully realised. However the generation
of DC ex vivo offer some approaches to improve this, namely that the maturation
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of the DC population can be directly controlled.
Subsequent attempts to generate DC cultures were done so with the addition of
various cytokines such as IL-1b, TNF-a , IFN-a and IL-6, or with the addition of
TLR agonists. Generation of DC in these conditions produced mature DC that
expressed higher levels of co-stimulatory molecules and cytokines such as
IL-12. These advancements in pre-clinical work (as reviewed in Kalinski et al.
2013) led to numerous clinical trials utilising ex vivo generated DC. Of particular
note is the treatment of prostate cancer patients with sipuleucel-T, a product
derived from blood APC loaded with a prostate cancer antigen. This led to
improved patient survival and as a result was one of the first cellular
immunotherapies licensed for use by the FDA (Higano et al. 2009). However ex
vivo generation and manipulation of DC is time-consuming and costly, so other
methods to generate DC-mediated T cell responses have been designed which
directly target DC in vivo.
Vaccinations targeting DC in vivo
One such technique to target in vivo DC is through the use of an relevant
antigen, fused to a monoclonal antibody that recognises a DC-specific receptor.
In a series of papers, Ralph Steinman and colleagues demonstrated the
feasibility of this approach and showed it could be used to efficiently generate
effector CD8 and CD4 T cell responses against tumour antigens (Bonifaz et al.
2002; Bonifaz et al. 2004; Hawiger et al. 2001). These studies also highlighted
the importance of co-transfer of an agent to induce DC maturation, and ensure
antigen presentation does not result in T cell tolerance. Targeting of antigen to
specific DC subsets has also allowed the examination of the different roles these
DC have in regulating immunity. For example by targeting CD8+ or CD8- DC,
Dudziak et al. 2007 showed the different ability of these cells to process and
present antigen via MHCI and II.
However a separate technique to target endogenous DC is to transduce them
directly in vivo using a viral vector that expresses a tumour-specific antigen.
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Transduced DC would then present this stable, endogenously synthesised
protein antigen through MHCI and II pathways and induce potent and sustained
T cell responses. This was shown to be a viable approach as, after injection of a
GFP-containing lentivirus (LV), transduced DC can be detected in the skin
draining LN (Arce et al. 2009). Antigen expression can be targeted specifically to
DC though use of DC specific promotors (Lopes et al. 2008), or through the use
of pseudotyped vectors which bind to specific targets (Yang et al. 2008). This is
an attractive approach as DC are required to prime the response to antigen
encoded by LV in vivo (Goold et al. 2011). However although they are necessary
to induce T cell immunity, DC do not necessarily require direct LV transduction
as they can acquire antigen from other transduced cells and cross-present this
to naive T cells in vivo (Hotblack et al. 2017). However the benefit of direct DC
transduction is that the DC can be further genetically engineered to improve the
immune response. For example DC transduced by LV that encode constitutively
active components of DC maturation signalling pathways prime enhanced T cell
responses (Escors et al. 2008).
Although vaccination via these various strategies can be effective at inducing
CTL responses in vivo, translation of this work into clinical trials has been largely
disappointing (Rosenberg et al. 2004). However recent improvements to these
techniques may be used to improve the T cell response and provide better
clinical efficacy. For example vaccination in combination with checkpoint
inhibitors (antibodies that block negative immune receptors), may be able to
boost T cell responses induced by vaccination (Kleponis et al. 2015). This was
shown in a recent clinical trial utilising a NY-ESO antigen fused to a DEC-205
antibody to target DC in vivo. 6 of the 8 patients treated with this vaccine in
combination with checkpoint blockade showed objective tumour regressions
(Dhodapkar et al. 2014). Likewise the choice of antigen used to vaccinate is
important in generating a functional immune response. Vaccinations with ‘cancer
neoantigens’ (tumour specific antigens generated by mutations in the tumour)
have recently been described and could potentially be used enhance T cell
reactivity (Schumacher and Schreiber 2015). Neoantigen-specific tumour
vaccines have been shown to induce pronounced immune responses and
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tumour regression comparable to checkpoint blockade (Gubin et al. 2014). The
choice of tumour antigen to use is also important in other tumour
immunotherapies and will be discussed in more detail in the context of
adoptively transferred T cells.
1.4.2 Adoptive T cell therapy
Rather than priming an endogenous T cell response to a vaccine, an alternative
approach to generating tumour specific T cells is to isolate autologous tumour
infiltrating lymphocytes (TILs). These are then expanded ex vivo using tumour
specific peptides and re-infused back into the patient where they can assume
effector functions and mediate tumour control (Fig 1.9). Pre-clinical models of
murine tumours, mainly melanoma, treated using adoptive cell therapy (ACT)
solidified the idea of cellular immunotherapy as a viable treatment for cancer. Of
note, these models formed many of the tenets of ACT that are required for
effective T cell responses.
The initial studies of ACT in murine models showed that adoptive transfer of ex
vivo cultured T cells caused regression of established tumours (Eberlein et al.
1982), which can be improved by the co-administration of exogenous IL-2
(Donohue et al. 1984). Soon after, tumour specific T cells isolated directly from
surgically removed tumours (TILs) were also shown to be effective, although
only when given in combination with lymphodepletive chemotherapy (Rosenberg
et al. 1986). It was initially thought that this aided transferred T cells as the
removal of the endogenous pool of T cells and NK cells allowed for transferred T
cells to homeostatically expand in vivo (Dummer et al. 2002). However it has
since been shown that whilst the removal of ‘cytokine sinks’ does favour
expansion of transferred T cells, the presence of excess IL-7 and IL-15 also
directly improved their anti-tumour function. (Gattinoni et al. 2005). In addition,
the removal of endogenous Tregs through host pre-conditioning is important in
reducing Treg-mediated immune suppression of transferred T cells (Antony et al.
2005). These promising pre-clinical results led to the design of clinical trials to
treat patients with metastatic melanoma. In these landmark studies, adoptive
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transfer of autologous TILs, in combination with host lymphodepletion and
exogenous IL-2, resulted in objective response rates in 50-70% of patients with
refractory, metastatic melanoma (Dudley et al. 2002; Dudley et al. 2008; Morgan
et al. 2006).
Tumour infiltrating 
lymphocytes are isolated 
from a patients tumour
Expansion of tumour specific T 
cells ex vivo, generates a large 
population of anti-tumour T cells
T cells are reinfused back into 
the patient in combination with 
pre-conditioning and IL-2
Figure 1.9: Adoptive cell therapy.
One of the benefits to producing tumour-specific T cells by isolating TILs is that
the population of T cells that is generated are polyclonal and contain T cells with
reactivity to a range of tumour antigens (Kvistborg et al. 2012; Lu et al. 2014).
However whilst successful, isolating TILs isn’t always viable for all patients. TIL
extraction may not be possible in patients with tumours in locations that make
surgical resection difficult or in patients with non-solid tumours. Likewise isolating
sufficient numbers of TILs from less immunogenic tumours may be difficult. Lastly,
exposure to immunosuppression in the tumour microenvironment, coupled with
lengthy ex vivo culture may limit the efficacy of TILs once re-infused back into
the patient (Restifo et al. 2012). Therefore alternative ways of generating tumour-
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specific T cells, particularly ones that allow for a broader range of tumours to
be treated, have been developed. Principal amongst these is the re-direction of
polyclonal T cells to tumour-specificity through retroviral gene transfer.
1.4.3 TCR gene therapy
The antigen specificity of a T cell is defined solely by the TCR it expresses.
Therefore tumour-specific T cells can be generated by introducing anti-tumour
TCRs into peripheral blood lymphocytes. The concept of using viral transduction
to introduce new TCR a and b chains into polyclonal T cells was shown by
various groups. Retrovirally transduced T cells exhibited the same
antigen-specificity as the T cell clone from which the TCR genes were isolated
and these cells were functional in vitro (Clay et al. 1999; Cooper et al. 2000;
Kessels et al. 2000; Stanislawski et al. 2001) and in vivo (Fujio et al. 2000). The
feasibility of using this approach to generate tumour-specific T cells was
subsequently demonstrated by Kessels et al. 2001. Here, T cells transduced
with TCRs that recognise a model antigen were able to reject antigen-expressing
tumours in vivo. These results paved the way for numerous further pre-clinical
studies and clinical trials using TCR gene therapy for tumour
immunotherapy.
Clinical trials of TCR gene therapy
The successful treatment of melanoma patients with ACT led investigators to
attempt a similar approach with TCR-modified T cells. TCR genes were isolated
from one of the responding T cell clones from a patient on this original ACT trial
(Dudley et al. 2002). This TCR recognises the antigen ‘melanoma antigen
recognised by T cells 1‘ (MART1). After lymphodepletion, melanoma patients
were treated with their own lymphocytes transduced with the HLA-A2 restricted
MART1 TCR. Unfortunately only 13% of patients treated with these cells showed
signs of a clinical response (Morgan et al. 2006). However this trial was shortly
followed-up by another trial using a higher avidity MART1 TCR which led to an
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improved clinical response rate of 30% (Johnson et al. 2009). This trial also
tested a different TCR that recognises another melanoma antigen ‘gp100’, and
reported clinical response rates of 19%. A similar trial using a TCR which
recognises ‘NY-ESO-1’, a cancer/testis antigen expressed on some melanomas
was also conducted. This resulted in clinical responses in 5 out of 11 patients
tested (45%), including 2 complete responses (Robbins et al. 2011).
Subsequent clinical trials have also been undertaken which have targeted p53,
CEA (carcinoembryonic antigen) and MAGE A-3 (melanoma associated antigen
3), (reviewed in Duong et al. 2015). Results from these trials have suggested
that TCR transduced T cells can induce clinical responses and control tumour
growth, but only in a subset of patients. Therefore work is still needed, both
pre-clinically and in clinical trials, to improve the reach of transduced T cells to
non-responsive patients and improve overall efficacy.
Polyclonal T cells are 
transduced with 
retroviruses encoding 
tumour-specific TCRs
T cells are reinfused back into 
the patient in combination with 
pre-conditioning and IL-2
PBMCs are harvested 
from the patients blood
Tumour reactive, TCR-transduced 
T cells are expanded
Figure 1.10: TCR gene therapy.
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B16 melanoma models
One of the most well studied pre-clinical tumour models is the B16 melanoma.
This is a spontaneous melanoma derived from a C57BL/6 mouse which has
been used extensively for immunotherapy studies. T cells transduced with TCRs
which recognise an antigen expressed on B16 cells were shown to be able to
delay tumour growth in mice with already established B16 tumours (Abad et al.
2008). The TCR genes used in this study were designated ‘Pmel-1’ as they
recognised the protein antigen Pmel-17, the mouse homologue of the human
gp100 protein. These proteins, like MART1, are melanocyte differentiation
antigens that are expressed in melanocytes but also in B16 melanoma and the
majority of human melanomas (Kawakami et al. 1992; Overwijk et al. 2003).
Subsequent identification of further self/melanoma antigens that are commonly
shared between melanomas led to further pre-clinical models with TCRs
targeting these antigens. TCR gene therapy with TCRs that recognise
tyrosinase-related protein 1 (TRP1) (Kerkar et al. 2011) and TRP2 (Chinnasamy
et al. 2013) have also been shown to control B16 progression in vivo. However
in the majority of these studies, anti-melanoma TCR expressing T cells were
only able to induce transient tumour control. Generating a durable T cell
response that can mediate complete tumour elimination remains a challenge in
the field.
One of the factors that could be limiting these T cells is that the introduced TCRs
recognise self antigens. The benefits of this approach is that these self antigens
are often broadly applicable to many patients, as is the case with melanoma
antigens such as MART1 and gp100. However the downside is that the T cell
response to a self antigen is often limited. The choice between using self- or
foreign-reactive TCRs is discussed in more detail below.
Choice of antigen for TCR gene therapy
The choice of a suitable antigen to target is an important issue for both TCR
gene therapy and tumour vaccines. Tumour antigens can be split into two
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groups; tumour associated antigens (TAAs) or tumour specific antigens (TSAs).
TAAs are non-mutated self antigens that are usually only expressed on certain
cell types or in specific tissues. These include the cancer testis antigens (such
as NY-ESO-1), which are antigens usually only expressed on male germline
cells, but are also often expressed in cancers. The second class of TAA are
tissue differentiation antigens. These are usually only expressed in specific
tissues but will often be upregulated in tumours arising from those tissues.
These include the melanocyte differentiation antigens, MART1, TRP2 and gp100
which are expressed in melanocytes and melanomas. Lastly, other TAAs can
derive from ubiquitously expressed proteins that are overexpressed in tumours,
including Her-2/Neu and PRAME antigens (Heemskerk et al. 2012). The benefit
of TAAs is that many are shared between tumours and patients (Kawakami et al.
1992), which increases the practicality of targeting these antigens with TCR
gene therapy. However TAA-specific T cells that are generated in patients have
been regulated by central and peripheral tolerance mechanisms designed to
prevent autoimmunity and the TCRs generated are often of a low avidity to
TAAs. For example thymic expression of gp100 and TRP1 limits the generation
of T cells reactive to those self antigens (Träger et al. 2012; Zhu et al. 2013).
The induction of peripheral tolerance to these antigens may also limit the
efficacy of adoptively transferred T cells. For example adoptively transfered,
gp100 specific T cells were functionally tolerant to a B16 tumour unless mice
were also given an antigen-specific vaccination (Overwijk et al. 2003). Likewise,
CD8 T cells transduced with a TCR for the TAA ‘MDM2’ became tolerant in vivo
unless provided with antigen specific helper CD4 T cells (Ghorashian et al.
2014). In addition, whilst targeting TAAs can be effective, this can be coupled
with ‘off-tumour, on-target’ effects where the T cells attack healthy tissue which
expresses the target antigen. This has been shown in clinical trials where gp100
and MART1 specific T cells caused adverse effects due to TAA expression in the
skin, inner ear and retina (Johnson et al. 2009).
Therefore as an alternative, tumour specific antigens (TSAs) are an attractive
target for TCR gene therapy. TSAs or ‘neoantigens’ are formed through DNA
mutations that gather in the tumour genome and produce novel protein
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sequences. Alternatively tumours that arise as a result of oncogenic viruses can
also express TSAs from the viral open reading frames. Theoretically TSAs make
ideal targets for immunotherapy as expression of neoantigens are entirely
absent from normal tissues and TCRs with neoantigen specificity are devoid of
control by central tolerance (Schumacher and Schreiber 2015).
Neoantigen-specific T cells are therefore expected to be more tumour reactive
than TAA-specific T cells (Heemskerk et al. 2012). Indeed tumour-responding T
cells from a melanoma patients blood were predominantly reactive against
patient specific neoantigens rather than the shared TAAs (Lennerz et al. 2005).
Therefore generation of neoantigen specific T cells by providing patients with a
vaccine containing neoantigen peptides has been proposed (Vonderheide and
Nathanson 2013). Alternatively the feasibility of producing neoantigen-specific
TCR transduced T cells has been described. TCRs specific for a patients
melanoma neoantigens have been identified and isolated from the blood of
healthy controls and T cells transduced with these TCRs were able to recognise
patient tumour samples in vitro (Stronen et al. 2016). A potential downside to
these neoantigen specific responses however is that the infiltration of
neoantigen-specific T cells into the tumour has been associated with the
subsequent loss of that neoantigen expression from the tumour (Verdegaal et al.
2016). This shows that neoantigen specific responses are prone to
immunoediting by the tumour. However identification of so called ‘trunk’
mutations that are universally expressed in the heterogenous tumour population
may help prevent immune escape (Gerlinger et al. 2012; Mcgranahan et al.
2016). However the major downsides to targeting neoantigens is that the vast
majority are patient specific (Heemskerk et al. 2012). As a result, the current
TCR gene therapy strategies for patients all focus on TAA and the feasibility of
targeting neoantigens in a patient specific manner will need to be addressed if
therapies targeting these antigens are to realise their potential.
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Chimeric antigen receptors
An alternative to transducing T cells with tumour reactive TCRs, is to use a novel
class of engineered receptor called the chimeric antigen receptor (CAR). The
basic structure of a CAR is an extracellular antigen binding domain that is linked
by a transmembrane domain to intracellular signalling provided by CD3-z chain
(Fig 1.11). Antigen specificity is typically provided by a single-chain antibody
variable fragment (scFv), although other receptor-ligand interactions can also be
used such as cytokine receptors (Kahlon et al. 2004; Kong et al. 2012). Initially
CAR-expressing T cells would proliferate poorly as antigen presentation and
CD3-z signalling alone was insufficient to fully activate the T cell (Brocker and
Karjalainen 1995). However subsequent generations of CARs had
co-stimulatory domains such as CD28, 4-1BB and OX-40 added to their
signalling domains, which has improved T cell activation (Finney et al. 2004).
One of the major benefits to using CAR gene therapy is, unlike TCR gene
therapy, recognition of antigen is not dependant on presentation by MHC. This
scFV
Spacer
Transmembrane domain
Co-stimulatory domain
(e.g. CD28/4-1BB)
CD3-ζ chain
Antigen recognition
Signaling
	
CAR	
Figure 1.11: Chimeric antigen receptor.
70
Chapter 1 Section 1.4
vastly improves the scope of treatments using CARs as the transduced cells are
not restricted by HLA type. A recent clinical trial using T cells transduced with a
CD19-specific CAR to treat patients with relapsed acute lymphoblastic
leukaemia has shown the efficacy of CAR therapy. Complete remissions were
achieved in 27 out of 30 patients treated with these cells (90%) (Maude et al.
2014). However the disadvantage with CAR therapy is that the range of antigens
able to be targeted is less than for TCR modified T cells. For example while
TCRs can recognise intracellular antigens including TAAs and TSAs, CARs are
restricted to antigens expressed on the cell surface.
Maximising introduced TCR avidity
Although TAA specific TCRs are often of low affinity, responses from T cells
transduced with these TCRs can be improved by enhancing the TCR avidity.
One of the primary mechanisms to achieve this is by enhancing TCR expression
on the cell surface. The TCR is formed when the TCR a and b chain
heterodimer complexes with the CD3 molecules, so these components need to
be optimally expressed in TCR transduced T cells to enhance expression. One
potential problem associated with TCR gene therapy is that the introduced a and
b chains can pair, not with each other, but with the endogenous a and b chains.
This not only reduces the availability of CD3 for the introduced TCR but these
‘mispaired’ TCRs can also generate unknown and potentially autoreactive
specificities (Bendle et al. 2010). To help promote specific pairing of the
introduced TCRs, additional cysteine residues have been added to the TCR
constant regions (Cohen et al. 2007; Kuball et al. 2007). This promotes
formation of an additional disulphide bond between the introduced a and b
chains and was shown to reduce mispairing-associated toxicity (Bendle et al.
2010). Similar approaches have altered the configuration of the constant regions
of introduced a chains to favour binding of the reciprocally altered b chain (Voss
et al. 2007). Alternatively the constant regions of human TCRs have been
replaced with murine constant regions, which preferentially pair with themselves,
rather than the fully human endogenous TCR chains. This has been shown to
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increase introduced TCR cell surface expression and improved T cell function
(Cohen et al. 2006; Thomas et al. 2007).
Mispairing can also be reduced by ensuring that there are equal amounts of
introduced TCR a and b chains available. Use of a viral self-cleaving 2A peptide
sequence to separate the a and b chains in the viral vector results in the
co-translational cleavage of one mRNA strand containing both TCR chains. This
has been proposed to improve specific pairing as both chains are expressed
equally (Furler et al. 2001; Szymczak et al. 2004). This approach differs from
use of an internal ribosome entry site (IRES) which requires two transcription
events to produce the a and b chains.
Lastly, even in the absence of mispairing, to be expressed on the cell surface
introduced TCRs must compete with endogenous TCRs for CD3 (Call and
Wucherpfennig 2005; Thomas et al. 2010). Codon optimisation of the introduced
TCR sequences can improve gene expression and allow introduced TCRs to
outcompete endogenous TCRs. This has been shown to be crucial for high
levels of TCR expression on the cell surface (De Witte et al. 2008a; Kerkar et al.
2011). Alternatively as CD3 availability can be limiting, provision of additional
CD3 by co-transduction of the TCR with CD3 g, d, e and z chains can enhance
introduced TCR expression on the cell surface and improve anti-tumour function
in vivo (Ahmadi et al. 2011).
Optimising TCR gene therapy - DC interaction
The potential role of T cell - DC interactions have been shown in ACT models,
where effective responses from adoptively transferred transgenic T cells require
the provision of tumour-antigen expressing vaccines (Overwijk et al. 2003). This
effect may be as a result of tumour-vaccines being required to break tolerance to
tumour antigen in TCR transgenic mice (Schreurs et al. 2000), however in
another study whilst vaccination enhanced the proliferation of TRP2 transgenic T
cells in vivo, they still became tolerised and were unable to control B16 growth
(Singh et al. 2009). In addition, the use of vaccines to supplement in vitro
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activated, TCR transduced T cells is less clear. One study has found that
vaccination was essential for tumour control by TCR transduced T cells in a
prostate cancer model (De Witte et al. 2008b), however the immunological
mechanism behind this synergy was not investigated. Importantly, the role of
endogenous DC rather than DC in the context of a vaccine, has not been
investigated in these models, and could have an important impact on the efficacy
of TCR-transduced T cells.
The role of DC in the adoptive transfer of T cells may vary when
TCR-transduced T cells are transferred, rather than transgenic T cells. In order
to transduce T cells with retroviruses expressing TCR genes, the T cells must be
activated in vitro. This could have numerous effects on the T cell population
used to treat tumours and affect their interaction with endogenous immune cells.
For example T cell activation and transduction with retrovirus in vitro has been
shown to impair the function of adoptively transferred T cells compared to naive
T cells (Sauce et al. 2002). This could be as a result of enhanced effector
differentiation; in pre-clinical tumour models transfer of TCM cells resulted in
greater expansion and anti-tumour efficacy than transfer of TEM cells (Klebanoff
et al. 2005). In contrast to TCM populations, TEM are able to rapidly differentiate
into effector T cells but have limited proliferative potential (Sallusto et al. 1999).
Effector cells that differentiate from adoptively transferred naive populations,
rather than TCM have also been shown mediate enhanced tumour responses in
vivo (Hinrichs et al. 2009). Interestingly these data suggest that in vitro
activated, transduced T cells can interact with DC in vivo to differentiate and
acquire effector function. In line with this, the greater efficacy of tumour control
mediated by these less-differentiated T cells corresponds to enhanced trafficking
to secondary lymphoid organs (Klebanoff et al. 2005). Indeed, following adoptive
transfer, TCR transduced T cells have also been shown to accumulate in tumour
draining, but not in non-tumour draining LN (Koya et al. 2010). This suggests a
role for DC mediated antigen presentation to transferred T cells in the lymphoid
organs. However the importance of these potential interactions in mediating
tumour control by transferred T cells is not known. In addition to potentially
controlling transferred T cell responses in the lymphoid organs, DC may also
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have a role in controlling T cell effector function in the tumour. Recently,
depletion of CD103+ DC during the transfer of activated, antigen-specific T cells
was shown to limit, but not prevent tumour control. This was thought to be
dependant on tumour resident DC as the importance of priming CTLs in the LN
was avoided by blocking lymph node egress with FTY-720 (Broz et al. 2014).
Transferred T cells therefore have numerous opportunities to interact with
endogenous DC, however the extent/importance of these potential interactions
are unclear.
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1.5 Research aims and hypothesis
Considering the numerous roles of DC in promoting and controlling endogenous
T cell responses, it is likely that DC are also involved in regulating or promoting
transferred T cell responses. However DC have varied functions that can either
enhance or diminish tumour control. These appear to be dependant on a number
of factors, such as the specific DC subset, their maturation state and the phase of
immunoediting that the tumour is exposed to. A greater understanding of the roles
these DC have in the anti-tumour immune response is important for improving
tumour immunotherapies. In particular, the context in which DC interact with TCR-
transduced T cells will effect their ability to control tumour growth.
This project therefore was designed to investigate the interactions between
endogenous DC and TCR-transduced T cells. We hypothesised that
endogenous DC were required for the effective clearance of tumours by TCR
transduced T cells. To address this we chose to use the CD11c.DTR and
CD11c.DOG depletion models. This would allow us to interrogate numerous
aspects of transferred T cells efficacy, including in vivo expansion and tumour
control, in the absence of DC.
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2.1 Cloning of TCRs into pMP71 vector
2.1.1 PCR reactions
DNA for the TRP2 and Pmel-1 TCRs were a kind gift from Prof Ton Schumacher
(Netherlands Cancer Institute). These were originally in the pMX plasmid, but
were cloned into the pMP71 IRES CD19 vector. To clone the TRP2 TCR
sequence into the pMP71 vector, primers were designed to be flanked by the
restriction sites Not1 and Sal1 (highlighted in bold). These were designed using
the DNA analysis program SnapGene and ordered from Invitrogen:
Not1 TRP2 b fw:
5’- ATTTGCGGCCGCATGGCCCCGCGGCTGCTGTG -3’
TRP2 a Sal1 rv:
5’- CGCGGTCGACTCAGCTGCTCCACAGCCTCAGGGT -3’
A polymerase chain reaction (PCR) was carried out with 1µg DNA from the pMX
plasmid containing the TRP2 TCR. This was added to 10µl 2xPhusion PCR
master mix (Invitrogen), 10mM forward primer, 10mM reverse primer and made
up to 20µl with nuclease free water. The PCR reaction was then carried out as
follows: 3min initial denaturation at 94°C, then 30 cycles of: 30s denaturation at
94°C, 1min annealing at 58°C and 1min elongation at 72°C, lastly there was a
final 10min elongation at 72°C.
To clone the Pmel-1 TCR and replace the IRES sequence with a 2A sequence
an overlap extension PCR was performed using the pMX Pmel-1 DNA. The first
PCR amplified the a chain and a separate PCR reaction amplified the b chain.
These products omitted the IRES sequence which was replaced with overlapping
sections containing the 2A sequence (underlined):
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Not1 Pmel-1 a fw:
5’- ATTTGCGGCCGCATGAAGAGCCTGAGCGTGAGCCTGGTGGTGCTG -3’
Pmel-1 a P2A rv:
5’-CCGGCCTGCTTCAGCAGGCTGAAGTTGGTGGCGCCGCTGCCGCTGCTG
CTCCACAGCCTCAGGGTCATCA -3’
This PCR was done alongside another PCR to amplify the b chain:
P2A Pmel-1 b fw:
5’- CACCAACTTCAGCCTGCTGAAGCAGGCCGGCGACGTGGAGGAAAACCC
TGGCCATGGCCACAACCATGGCCCC -3’
Pmel-1 b Sal1 rv:
5’- GACGTCGACTCAGCTGTTCTTCTTCTTCACCATGGCCATC -3’
These two PCR reactions were carried out as described above for the TRP2
TCR, although the annealing temperature was reduced from 58 to 55°C. Finally
the fusion PCR was performed using the products from these two PCR reactions
(0.5µg each) and the primers that bind either side of the whole sequence (Not1
Pmel-1 a fw and Pmel-1 b Sal1 rv). This produced a final PCR product that
contained the Pmel-1 a and b chains, separated by the 2A sequence and flanked
by Not1 and Sal1.
PCR products were extracted by gel electrophoresis (2% Agarose, 0.5x TBE +
0.5x water, Ethidium Bromide 1:1000) after addition of Gel Loading Solution
(Sigma G2526) in a 1:5 dilution with 5µl of Hyper Ladder 1 (Bioline 33025) to
determine the fragment size. Gels were analysed using Ultrospec 1100 pro
(Amersham Biosciences) and the specific band cut and purified with QIA Quick
Gel extraction kit (Qiagen 28704).
2.1.2 TRP1 TCR sequence design and synthesis
The TRP1 TCR sequence (Kerkar et al. 2011; Muranski et al. 2008) was
synthesised by GeneArt (Invitrogen) with Not1 and Sal1 sites flanking the TCR,
so a PCR reaction was not required. In addition the TCR was codon-optimised
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and an extra cysteine was added by amino acid substitution in both chains:
a-T179C and b-S186C.
2.1.3 Plasmid digestion and ligation
The TRP2, Pmel-1 and TRP1 TCRs were cloned into the pMP71 IRES CD19
vector backbone by excision of the F5 TCR and replacing it with the relevant
TCR. The PCR products (TRP2 and Pmel-1 TCRs), 1µg of the pMX TRP1 vector
(from GeneArt) and 1µg of the pMP71 F5 CD19 vector (from laboratory stocks,
see appendix for details) were separately digested with 1µl of Not1 (NEB R0189L)
and 1µl of Sal1 (NEB R0138L) restriction enzymes, with 2µl of 10x buffer 3 (NEB
B7003S) and made up to 20µl with nuclease free water. Digestion reactions took
place at 37°C for 1 hour. After which, the digested pMX TRP1 and pMP71 F5
CD19 vectors were analysed by gel electrophoresis as described above. The
TRP1 TCR (1800bp) and the pMP71 CD19 backbone (6301bp) from which the F5
TCR had been excised were extracted with QIAquick Gel Extraction Kit and eluted
in 50µl of nuclease free water. The digested PCR products containing the TRP2
(1801bp) or Pmel-1 (1813bp) TCRs were purified with QIA Quick PCR purification
kit (Qiagen 28106) and DNA was eluted in 30µl of nuclease free water.
A ligation reaction was carried out to ligate the TRP2, Pmel-1 or TRP1 TCRs
into the empty pMP71 CD19 vector. This was performed in an Eppendorf tube at
room temperature for 10 minutes containing the following reagents: 10µl 2x Quick
Ligase Buffer (NEB B2200S), 1.5µl of the digested vector backbone, 3µl digested
TCR inserts, 1µl Quick T4 DNA Ligase (NEB M2200L) and 4.5µl nuclease free
water.
2µl of the ligation product was added to 25µl of Max Efficiency DH5a bacteria
(NEB C2987H) in a 1.5ml eppendorf and tubes left on ice for 30min. Tubes were
heat-shocked at 42°C for 45s followed by a 2min incubation on ice. Transformed
bacteria were plated onto LB agar plates (0.1 mg/ml, Sigma-Aldrich) containing
Ampicillin and left in the incubator overnight at 37°C. Colonies were inoculated
into 5ml of Ampicillin containing LB Broth medium (0.1 mg/ml, Sigma-Aldrich)
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and incubated overnight. DNA was extracted using QIAPrep Spin Miniprep kit
(Qiagen 27106) according to manufacturers instructions and sent to Eurofins
MWG Operon for sequencing. For larger DNA preparations, correctly
transformed colonies were inoculated into 100ml of LB broth overnight and DNA
extracted using the Qiagen Plasmid Midi Kit (Qiagen 12143).
2.1.4 Final TCR retroviral constructs
The plasmid maps and DNA sequences for these TCRs can be found in the
appendix. The retroviral vector pMP71 was used for all TCR constructs with a
2A sequence separating the a and b chains, followed by an IRES CD19
sequence. The F5 TCR recognises the influenza A virus nucleoprotein
(NP366-379) in the context of H-2Db. The Pmel-1 TCR recognises the gp100
peptide (gp10025-33) in the context of H-2Db. The TRP2 TCR recognises
Tyrosinase related protein 2 (TRP2181-188) in the context of H-2Kb. The TRP1
TCR recognises Tyrosinase related protein 1 (TRP1113-127) on MHCII. All TCRs
were codon optimised and the F5, TRP1 and TRP2 also contain an extra
cysteine residue in the constant chain.
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2.2 Cell culture
2.2.1 Tissue culture and cell counting
Tissue culture work was performed in Biohit Biological Safety Cabinet Class 2
hoods. Cells were counted on a haemocytometer (Abcam). 10µl of cells were
mixed with 10µl Trypan Blue (Life Technologies, 15250-061) and live cells were
counted under a light microscope as cells that had not taken up the dye.
For counting cells from FACS samples, CountBright Absolute Counting Beads
(Life Technologies, C36950) were used. A set volume (10µl) of beads were
added per sample, which relates to a certain amount of beads. From this the
total number of cells per sample can be calculated.
2.2.2 Phoenix eco and ampho cells
The human 293T cell line (a human embryonic kidney line transformed with
adenovirus E1a) had been stably transfected with DNA encoding for the gag-pol
proteins as well as the ecotropic or amphotropic virus envelope (Nolan
laboratories). These packaging cells are easily transfected with DNA for the
production of retroviruses. Cells were grown in tissue culture flasks 75 qcm (TPP
90076) with Isocove’s Modified Dulbecco medium (IMDM) (Lonza BE12722F),
supplemented with 10% Fetal Calf Serum (FCS) (Biosera), 1% L-glutamine
200mM (GIBCO 25030) (2 mM) and 1% Penicillin/Streptomycin (GIBCO 15070)
(100 U/ml). Cells were detached by treating them with 3ml of 0.05%
Trypsin-EDTA (GIBCO 25300) for 1 minute before neutralisation with normal
medium. Cells were split 1/8 every 2 days as the cells became over 90%
confluent.
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2.2.3 B16.F10
B16.F10 is a murine melanoma cell line derived from a C57BL/6 mouse. Cells
were cultured in tissue culture flasks 75 qcm (TPP 90076) in RPMI 1640
medium (Lonza BE12-167F), supplemented with 10% FCS (Biosera), 1% L-
glutamine (2 mM) and 1% Penicillin/Streptomycin (100 U/ml). Cells were
detached by treating them with 3ml of 0.05% Trypsin-EDTA (GIBCO 25300) for 3
mins in a 37°C incubator, before neutralisation with normal medium. Cells were
split 1/10 every 2 days as the cells became over 90% confluent.
2.2.4 EL4-NP
EL4 and EL4-NP are murine lymphoma cell lines derived from a C57BL/6
mouse. EL4-NP was made to stably express the influenza A virus nucleoprotein
(NP), and will express this peptide in the context of H-2Db. These were a kind
gift from Prof B. Stockinger (Francis Crick Institute, London). EL4-NP cells were
maintained in RPMI 1640 medium (Lonza BE12-167F), supplemented with 10%
FCS (Biosera), 1% L-Glutamine (2mM) and 1% Penicillin/Streptomycin (100
U/ml). Cells were split 1/10 every 2 days. Transfected EL4-NP cells are also
resistant to the antibiotic Geneticin (Sigma G418 disulfate salt solution, A1720).
1mg/ml of Geneticin was added to culture media once a week to select for
transfected cells.
2.2.5 Murine T cell culture
C57BL/6 splenocytes were mashed through a 40µM cell strainer (BD Falcon
352340) into a 50ml Falcon centrifuge tube (TPP) and washed with PBS. Red
blood cells were lysed by resuspending the cell pellet in 2ml
ammonium-chloride-potassium (ACK) lysing buffer (Lonza 10-548E) for 2mins.
Cells were then washed with 20ml PBS. Cells were MACS sorted (see below) or
not, and cultured in RPMI 1640 medium (Lonza BE12-167F), supplemented with
10% Fetal Calf Serum (FCS) (Biosera), 1% L-glutamine (2 mM), 1%
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Penicillin/Streptomycin (100 U/ml) and 2-Beta-Mercaptoethanol (50µM).
2.2.6 T cell selection: MACS sorting
Miltenyi CD8a (Ly-2) MicroBeads (130-049-401) or CD4 (L3T4) MicroBeads
(130-049-201) were used to sort CD8 or CD4 T cells respectively. Splenocytes
were prepared as described above and resuspended in 630µl MACS buffer
(0.5% bovine serum albumin (BSA) and 2mM Ethylendiamintetraacetat (EDTA))
per spleen. 70µl of microbeads were added per spleen and incubated on ice for
20min. LS magnetic separation columns (Miltenyi 130-042-401) were rinsed with
3ml of MACS buffer. Cells were washed with 30ml of MACS buffer and
resuspended in 500µl MACS buffer per 108 cells/per spleen. Cells were loaded
into columns through a pre-separation filter (Miltenyi, 130-101-812) and washed
3 times with 3ml MACS buffer. Cells were eluted twice with 4ml MACS buffer into
a 15ml Falcon tube.
2.2.7 RMA/S cells
RMA-S cells are a TAP deficient derivative of the RMA cell line, which can
efficiently present exogenously loaded peptide (De Bruijn et al. 1991). RMA/S
cells were cultured in RPMI 1640 medium (Lonza BE12-167F), supplemented
with 10% FCS (Biosera), 1% L-Glutamine (2mM) and 1% Penicillin/Streptomycin
(100 U/ml). Cells were split 1/10 every 2 days.
2.2.8 Generation of BM-DC
Bone marrow derived DC (BM-DC) were generated by flushing the tibia and
femur of C57BL/6 mice. Bone marrow was flushed with 5ml RPMI using a 2ml
syringe (BD, 300185) and 27G needle (BD, 300635). Cells were pipetted to
generate a single cell suspension and passed through a 40µM cell strainer (BD
Falcon 352340) into a 50ml Falcon centrifuge tubes (TPP). Red blood cells were
lysed by resuspending the cell pellet in 2ml ACK lysing buffer (Lonza 10-548E)
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for 2mins. Cells were then washed with 20ml PBS, then again in complete RPMI
media (10% FCS (Biosera), 1% L- glutamine (2 mM), 1% Penicillin/Streptomycin
(100 U/ml) and 2-Beta-Mercaptoethanol (50µM)). Cells were counted and
resuspended at 2x106/ml. 1ml of cells were plated in a 24 well plate (TPP) with
40ng/ml recombinant murine granulocyte-macrophage colony-stimulating factor
(GM-CSF) (Peprotech, 315-03). 48 hours laters, non-adherent cells were
washed off by rinsing around the well with 1ml RPMI media which was discarded
and replaced with fresh media and GM-CSF. Media was replaced every 2-3
days, and BM-DC were mature by day 7.
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2.3 Retroviral production and transduction
2.3.1 Virus production
1.5-2.0x106 Phoenix eco packaging cells were plated on a 60.1 qcm tissue
culture dish (TPP 93100) in 8ml of complete IMDM medium. The next day
medium was replaced with 5ml of fresh IMDM medium. The transfection mix was
set up as follows; 10µl Fugene HD Transfection Reagent (Roche 04709713001)
was added to 75 µl OPTIMEM media (GIBCO 31985) in a 1.5ml Eppendorf tube.
The DNA mix was prepared separately; 2.6µg of vector DNA and 1.5µg pCl-Eco
DNA were added to a total volume of 50µl water. DNA mix was carefully added
to the Fugene mix and incubated at room temperature for 15-20 minutes before
dripping it onto the Phoenix eco plates. The next morning, medium was replaced
with 5ml complete T cell medium and cells were incubated during the day and
overnight. On day 4, virus supernatant was collected from Phoenix eco plates
and spun down to remove cell debris. Virus supernatant could either be used for
transduction or stored at -80°C.
2.3.2 T cell transduction
Bulk or CD4/CD8 sorted splenocytes were resuspended at 1.5x106 cells/ml and
activated with Concanavalin A (ConA) (Sigma, L7647) (2 µg/ml) and IL-7 (R&D
Systems, 207-IL) (1ng/ml) for 24 hours before transduction. The next day cells
were counted and 4-6x106 T cells were resuspended in 1.5ml of viral
supernatant. Non-tissue culture plates were prepared by coating with 2ml
RetroNectin (Takara T100B) for 3 hours at room temperature, then blocked with
filter sterilised 2% BSA/PBS for 30 minutes and washed twice with PBS. Cells
were added to these prepared plates and spun at 2,000 rpm for 90 minutes at
32°C. 2.5ml of T cell media containing IL-2 (Roche, 11011456001) (total volume
of 100 U/ml) was added and cells were cultured in a 37°C incubator. Fresh
media and IL-2 was added every 2-3 days.
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2.3.3 B16.F10 transduction
Retroviral supernatant was generated as above, although Phoenix ampho cells
and pCl-Ampho DNA were used. pMP71 NP IRES GFP had previously been
generated by a PhD student in the laboratory, Bernado Alvares. 1x105 B16.F10
cells were plated onto a 6 well plate (TPP) and 1.5ml of viral supernatant was
added overnight. The next day, cells were detached with 500µl 0.05%
Trypsin-EDTA (GIBCO 25300) for 3 mins in a 37°C incubator, before
neutralisation with normal medium. Cells were transferred to a T75 tissue culture
flask (TPP 90076) for continued culture. Transduction was measured by GFP
expression by FACS. Transduced cells were FACS sorted by gating on GFP+
cells on a BD FACSAria.
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2.4 Flow cytometry
2.4.1 Surface staining
<2x106 cells (typically 0.5-1x106 cells) were routinely stained for FACS analysis.
Cells were washed once with PBS and resuspended in 50µl of FACS buffer (1%
FCS/PBS) containing the monoclonal antibodies of interest and Fc block in the
appropriate dilutions (see table 2.1 for details). Cells were incubated on ice in
the dark for 20-30 minutes before being washed in FACS buffer and analysed on
the FACS machines. FACS data was acquired on a BD Fortessa or LSR 2 FACS
machine.
2.4.2 Intracellular staining
BD cytofix/cytoperm kit (BD Biosciences 554714) was used for intracellular
cytokine staining. Cells were firstly stained for surface molecules as above, and
fixed with 100µl of 2% paraformaldehyde for 10mins on ice. Cells were washed
with 200µl FACS buffer and left in the fridge overnight. The next day cells were
fixed with 50µl of the fixation solution and incubated on ice for 15 mins. Cells
were washed with 150µl of perm/wash solution, and incubated for 30mins with
the intracellular antibodies (IFN-g APC) diluted in perm/wash buffer. Cells were
finally washed once in perm/wash and again in FACS buffer before the cells
were analysed.
Ki67 staining was performed using the FoxP3 staining kit (eBioscience, 00-5523-
00). Cells were surface stained as above and fixed with 100µl of FoxP3 Fix/Perm
solution for 20-30mins on ice. Cells were then washed in Perm wash and stained
with Ki67 eFluor660 diluted in Perm wash for 30mins. Cells were finally washed
in Perm wash, and again in FACS buffer before being analysed.
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Table 2.1: FACS antibodies
Specificity Fluorochrome Manufacturer Dilution
CD3 FITC BD (553062) 1/100
CD4 APC-H7 BD (580181) 1/400
CD4 FITC BD (553047) 1/400
CD8 APC BD (5530350) 1/400
CD8 v450 BD (560469) 1/400
CD11b v450 eBioscience (48-0112-82) 1/400
CD11c APC BD (550261) 1/200
CD11c FITC BD (553801) 1/200
CD19 PerCP-Cy5.5 eBioscience (45-0193) 1/200
CD24 BV711 BD (563450) 1/1000
CD45.2 v500 BD (562129) 1/200
CD62L PE BD (55315) 1/400
CD62L Alexa700 BD (560517) 1/400
CD64 PE Biologend (139303) 1/200
CD103 Biotin BD (557493) 1/100
CD127 eFluor660 eBioscience (50-1271-80) 1/100
F4/80 APC-eFluor780 eBioscience (47-4801-82) 1/400
H2-Kb FITC BD (553569) 1/100
I-Ab PE BD (553552) 1/800
IFN-g APC BD (554413) 1/200
Ki-67 eFluor660 eBioscience (50-5698) 1/200
Ly6C PeCy7 BD (560593) 1/400
NK1.1 APC-eFluor780 eBioscience (47-5941-80) 1/200
PD-L1 APC BD (564715) 1/400
Streptavadin PerCP-Cy5.5 BD (551419) 1/100
Thy1.1 PeCy7 eBioscience (25-0900-82) 1/10,000
Vb3 PE BD (553209) 1/400
Vb11 PE BD (553198) 1/200
Vb13 PE BD (561541) 1/800
Vb14 FITC BD (553258) 1/400
Fc-block (CD16/CD32) N/A BD (14-0161-86) 1/100
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2.5 Functional assays
2.5.1 T cell co-culture with peptide-loaded cells
T cells transduced with TCRs were left for 5 days post-transduction then
stimulated with peptide loaded cells. 1x106 RMA/S cells were cultured overnight
at 20°C to stabilise empty MHC molecules. The next day RMA/S cells were
loaded with 10µM - 100pM of relevant or irrelevant peptide. Alternatively, on day
7 of BM-DC culture, cells were loaded with peptide as above. Peptides used
were TRP2181-188: VYDFFVWL
gp10025-33: EGSRNQDWL
TRP1113-127: CRPGWRGAACNQKI
Cells were incubated with peptide in an 37°C incubator for 2-3 hours. RMA/S
cells were then irradiated with 80Gy. Cells were then washed in complete RPMI
and 1x105 RMA/S cells or 1x104 BM-DC were plated in a 96-well plate. To this,
1x105 mock or TCR transduced T cells were added, and cells were co-cultured
overnight (at ratios of 1:1 or 10:1 respectively). The next morning, cells were
spun and 100-150µl of supernatant was harvested for ELISA, if necessary. Cells
were resuspended in media to which 5µg/µl brefeldin A had been added.
Brefeldin A blocks the transport of proteins in the Golgi apparatus, so prevents
secretion of cytokines to allow intracellular staining. After 4 hours, cells were
washed in FACS buffer and stained for intracellular IFN-g as described
above.
2.5.2 Upregulation of MHC on B16.F10
MHCI is upregulated by B16.F10 in the presence of IFN-g (Seliger et al. 2001).
To generate media containing murine IFN-g, splenocytes were activated with
ConA and IL-7 as described previously. After 24 hours, cells were centrifuged
and supernatant was collected and frozen at -20°C. B16.F10 were cultured
overnight in this defrosted ConA activated splenocyte media (CASM) to
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upregulate expression of MHC. Cells were trypsinised the next day and stained
with H-2Kb, I-Ab and PD-L1 antibodies.
2.5.3 T cell co-culture with tumour cells
CASM was added to B16.F10 cells overnight and the next day, B16.F10 were
washed with complete RPMI. B16.F10 and EL4-NP cells were then irradiated
with 80Gy and 1x105 tumour cells were washed and plated in 96-well plates.
1x105 mock or TCR transduced T cells were then added overnight. Alternatively
for shorter incubations, tumour cells weren’t irradiated and were cultured with T
cells for 4 hours. The next morning (or 4 hours later) cells were spun and
100-150µl of supernatant was harvested for ELISA, if necessary. Cells were
resuspended in media to which 5µg/µl brefeldin A had been added. After 4
hours, cells were washed in FACS buffer and stained for intracellular IFN-g as
described above.
2.5.4 ELISA
Cytokine-containing supernatants were generated as above and IFN-g was
measured using the BD OptEIA kit (555138), according to manufacturers
instructions. Supernatants were diluted 1/4 in RPMI media before use in the
assay.
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2.6 in vivo experiments
2.6.1 Mice
Animal protocols were approved by local institutional research committees and
in accordance with U.K. Home Office guidelines. C57BL/6 mice aged between 8
and 15 weeks were obtained from the in-house animal facility at the Royal Free
Hospital. Similarly aged Thy1.1 C57BL/6 mice from the animal facility were also
used as donors in multiple experiments. Homozygous CD11c.DTR/GFP
(B6.FVB-Tg(Itgax-DTR/ EGFP)57Lan/J) mice were bred in-house and used
experimentally as heterozygotes. Homozygous CD11c.DOG mice
(Tg(Itgax-DTR/OVA/EGFP)1Garbi) were a kind gift from Prof Andrew
MacDonald (University of Manchester) and breeders were established at the
Royal Free Hospital. Heterozygous mice were used for experiments. RAG-1(-/-)
mice (B6.129S7-Rag1tm1Mom/J) were ordered from Charles River and bred
with CD11c.DTR mice in-house to generate CD11c.DTRxRAG-1(-/-) mice. All
experiments were carried out under a home office license (project license
number 70/7475).
2.6.2 Generation of bone marrow chimeras
C57BL/6 were irradiated with a total of 11Gy split over 2 days. On the second day
donor bone marrow was harvested by flushing tibia and femur with 5ml RMPI.
Cells were washed, counted and resuspended at 25x106/ml in PBS. Irradiated
mice were reconstituted with 200µl (5x106) bone marrow cells by tail vein injection
and were allowed to reconstitute for a minimum of 8 weeks before mice were used
for experiments.
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2.6.3 Genotyping
CD11c.DTR mice were genotyped by PCR with primers that bind to the
DTR/GFP transgene, to give a 630bp band:
DTR fw primer: 5’-GCCACCATGAAGCTGCTGCCG-3’
DTR rv primer: 5’-TCAGTGGGAATTAGTCATGCC-3’
CD11c.DOG mice were genotyped by a PCR with primers that bind to the
ovalbumin sequence in the DTR/OVA/GFP transgene, to give a 500bp band:
DOG fw primer: 5’-AACCTGTGCAGATGATGTACCA-3’
DOG rv primer: 5’-GCGATGTGCTTGATACAGAAGA-3’.
PCR reactions were carried out as follows; 4min at 95°C, then 35 cycles of;
30sec at 94°C, 30sec at 58°C and 30sec at 72°C. Followed by a final extension
phase of 30mins at 72°C.
CD11c.DTRxRAG-1(-/-) mice were genotyped as above to check expression of the
DTR transgene. RAG-1(-/-) was assessed by phenotype, mice were tail bled and
red blood cells were lysed from 100µl of blood by transferring into 9ml water for
30secs. 1ml of 10xHBSS was then added to prevent further lysis. Cells were then
stained for expression of CD11b, CD8, CD4 and CD19.
2.6.4 Tumour protection experiments
B16.F10 or B16 NP GFP cells were trypsinised when ~50% confluent after
between 5 and 10 days of culture. Cells were washed twice in PBS and
resuspended in fresh PBS at 5x106/ml. Mice were shaved on the flank and
injected sub-cutaneously with 100µl (5x105) tumour cells. For B16 NP GFP
injections, mice were sub-lethally irradiated with 4Gy before tumour inoculation
to enhance tumour engraftment. Tumours became established and visible 7-10
days after injection. Without treatment tumours would continue growing and
mice would have to be sacrificed by day ~20 if tumours grew to >15mm in any
direction, as per home office regulations. Tumour size was measured using
callipers every 2-3 days. Width (w) and length (l) of the tumours were measured
and the tumour size was calculated according to the following formula:
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w ⇥ l ⇥ ⇡/4. Mice were also sacrificed if they lost more than 20% of their body
weight, although this was rare.
For treatment with TCR transduced T cells, CD8 or CD4 sorted splenocytes
were transduced as described above. On day 1-3 after transduction, cells were
counted, washed and resuspended in PBS. 200µl of T cells were injected into
mice by tail vein injection. For B16.F10 experiments, on day 10 mice were
irradiated with 4Gy in the morning then injected with T cells >4 hours later. For
B16 NP GFP mice were treated with T cells on day 7.
2.6.5 DC depletion
DC were depleted in CD11c.DTR mice/bone marrow chimeras by injecting 100ng
of DT (Sigma, D0564) in 200ul PBS intra-peritoneally (i.p.). This corresponds to
~5ng/g body weight. CD11c.DOG mice were similarly injected i.p. with DT that
ranged from 100ng to 1.2µg (5 to 64 ng/g). CD11c+ cells were depleted for up
to 3 days and depletion was measured in the spleen and tumour as appropriate.
Non-depleted mice were injected i.p. with 200µl PBS as a control.
2.6.6 T cell expansion after DC depletion
Mice were injected with B16.F10 or B16 NP GFP tumours as described above.
As described for each experiment, DC were depleted by i.p. injection of DT or
PBS, typically on day 6, 9 and 12. Transduced T cells were injected on day 7
(1 day post-transduction) into mice and tumour size was measured as described
above.
2.6.7 Lymphocyte isolation from tumours
Tumours were harvested from tumour-bearing mice and weighed in Bijoux tubes.
Tumour samples were mechanically digested using dissection scissors before
culturing in 1ml of RMPI containing 320µg of Liberase TL (Roche, 05401020001)
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and 200µg of DNase 1 grade 2 (Roche 10104159001). These were incubated at
37°C in a shaking incubator for 30mins. Liberase contains a mixture of
collagenase I and II which break down the extracellular matrix and release the
cells. DNase degrades DNA released from dying cells to decrease the viscosity
of the sample and improve cell yield. Tumours were then transferred to ice and
mashed through a 70µM cell strainer (BD Falcon, 352350) with 5mM EDTA/PBS.
Cells were spun and resuspended in 3ml complete RPMI at 37°C in a 15ml
Falcon tube. Cells were underlaid with 3ml of Histopaque-1077 (Sigma-aldrich,
10771). Cells were then centrifuged at room temperature for 10mins at 700g.
The upper layer containing live cells were then carefully removed and transferred
to a new 15ml Falcon tube and centrifuged again with 10ml fresh complete RPMI
for 10mins at 1500rpm to remove any remaining histopaque. Cells were then
resuspended in FACS buffer for staining.
2.6.8 ex vivo isolated tumours
Tumours were harvested and mechanically digested with dissection scissors and
washed/mashed through 70µM cell strainer (BD Falcon, 352350) with 5mM
EDTA/PBS. Live tumour cells were isolated by centrifugation with
Histopaque-1077 as above. 1x106 tumour cells were plated in a T75 flask (TPP)
and incubated for 3-7 days. Cells were trypsinised and split 1/10 when
necessary to establish an stable ex vivo tumour line.
2.6.9 MACS sorting CD11c+ cells from the tumour
Lymphocytes were isolated from the tumour as described above. CD11c+ cells
were then isolated using murine CD11c MicroBeads (Miltenyi, 130-097-059).
Cells were resuspended in 400µl MACS buffer (0.5% bovine serum albumin
(BSA) and 2mM Ethylendiamintetraacetat (EDTA)). 10µl of microbeads were
added per sample with 5µl Fc block and incubated at 4°C for 20 minutes. MS
magnetic separation columns (Miltenyi 130- 042-201) were rinsed with 500µl
MACS buffer. Cells were washed with 30ml of MACS buffer and resuspended in
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500µl MACS buffer. Cells were loaded into columns through a pre-separation
filter (Miltenyi, 130-101-812) and washed 3 times with 500µl MACS buffer. Cells
were eluted twice with 500µl MACS buffer into a 15ml Falcon tube, then passed
through another MS column to increase purity. Cells were washed twice and
eluted again with 500µl MACS buffer.
CD11c+ cells were peptide loaded with 1µM relevant peptide for 2 hours, then
washed and plated in a 96-well plate. As before 1x104 CD11c+ cells were co-
cultured overnight with 1x105 transduced T cells. The next morning cells were
incubated with brefeldin A and stained for intracellular IFN-g.
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2.7 Analysis and statistical tests
FCS flow cytometry files were analysed using FlowJo v10 software. Data was
further analysed in GraphPad Prism 6, which was also used to generate graphs
including means, medians, standard deviations and to perform statistical analysis.
Paired and unpaired students t-tests were calculated for data sets, Kaplan-Meier
survival curves and Log Rank tests were performed for survival data. Differences
were considered statistically significant when p values were <0.05 (significance
was represented by *: <0.05, **: <0.01, ***: <0.001, ****: <0.0001).
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anti-B16 TCR transduced T cells in vitro
To examine the role of DC in the context of tumour immunotherapy by adoptively
transferred, TCR-modified T cells, we established a clinically relevant murine
model in which T cells transduced with self-reactive TCRs controlled tumour
growth. The B16.F10 melanoma model was chosen because a variety of TCRs
have been identified that confer specificity for melanocyte differentiation
antigens, such as tyrosinase, MART-1, gp100, tyrosinase-related protein 1
(TRP1) and TRP2 (Rosenberg et al. 1999). These antigens are expressed on
normal melanocytes but also often over-expressed in melanomas. T cells
specific for these antigens have been identified from tumour infiltrating
lymphocytes (Boon and Bruggen 1996) and T cells transduced with TCRs which
recognise these antigens provide tumour regression in vivo. However this control
is only temporary and insufficient to clear the tumour burden as tumours
eventually evade the immune response and regrow (Abad et al. 2008;
Chinnasamy et al. 2013; Kerkar et al. 2011). We reasoned that use of a model in
which T cells only mediated partial control of tumour growth would allow us to
dissect the role of DC in the absence of an over-whelming T cell response.
Alongside the standard B16.F10 melanoma model we also established a model
in which the TCR-transduced T cells recognise a tumour specific antigen (TSA).
However despite the T cell response to melanoma in patients being
pre-dominated by T cells responding to neo-antigens (Lennerz et al. 2005), there
are no suitable TCRs for TSAs in the pre-clinical B16.F10 model. However our
group and others have previously used the F5 TCR to control tumours
expressing the influenza nucleoprotein (NP). This foreign antigen can be used in
lieu of a TSA generated by a mutation in the tumour. EL4 thymoma tumour cells
that have been engineered to stably express NP are recognised by the F5 TCR
which potently controls tumour growth (Ahmadi et al. 2011; Morris et al. 2005).
We chose to use a similar approach in the B16.F10 model, by transducing
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B16.F10 melanocytes with an retrovirus encoding the NP protein. This would
allow us to compare immune responses that had been tolerised or not to tumour
antigen when expressed on the same tumour cells.
Whether T cells are transduced with TCRs which recognise tumour
associated/self antigens or tumour specific/foreign antigens may have an
important bearing on their functional ability. As discussed in chapter 1.2.2, the
TCR affinity for self, but not foreign antigens is limited by central tolerance.
Self-reactive TCRs are therefore typified by reduced TCR affinity compared to
foreign antigen specific TCRs (Stone et al. 2015). Lower TCR avidity also
translates into lower cytotoxic ability in CTLs (Alexander-Miller et al. 1996).
Although T cell responses to tumour associated antigens in the B16.F10
melanoma model have been well studied by others, the response to tumour
specific antigens is less clear. In addition, neither model had been used by our
group previously. Therefore the aims of the following experiments were to:
1. Clone melanoma specific TCRs into retroviral expression vectors
2. Show that TCR transduced T cells recognise tumour associated antigen as
expressed on peptide loaded target cells or directly on B16.F10 tumour cells
3. Generate a NP-expressing B16.F10 cell line and show it is recognised by
F5-TCR transduced T cells
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3.1 Cloning of anti-B16.F10 TCRs into retroviral
expression vectors
To generate retrovirus that encoded the genes for melanoma specific TCRs we
were kindly provided with two MHC class I restricted TCRs by Ton Schumacher
(Netherlands Cancer Institute). These recognise melanocyte differentiation
antigens expressed by the B16.F10 melanoma (Fig 3.1A). The TRP2 TCR
recognises tyrosinase related protein 2 (TRP2181-188 on H-2Kb) and the Pmel-1
TCR recognises gp10025-33 on H-2Db. The a and b chains of the TRP2 TCR are
separated by a 2A sequence which induces a co-translational cleavage of the
polypeptide chain (Holst et al. 2006). This differs from the IRES separating the
Pmel-1 a and b chains because it uses a single mRNA strand to produce two
equimolar proteins. This stoichiometric expression is particularly important in
reducing the chance of mispairing of the introduced a/b chains with endogenous
a/b chains which can create TCRs of unknown specificity/toxicity (Bendle et al.
2010). To replace the Pmel-1 IRES sequence with a 2A sequence an
overlapping/fusion PCR was performed as demonstrated in Fig 3.1A. As well as
the 2A sequence the TRP2 TCR also had extra modifications to improve
expression not found in the Pmel-1 TCR. The DNA sequences of both TCRs had
been codon optimised however an additional cysteine residue had been added
to the TRP2 constant chains, to promote pairing between the two introduced
chains (Cohen et al. 2007; Kuball et al. 2007).
Alongside these class I restricted TCRs, the sequence for an MHC class II
restricted TCR, which recognises TRP1113-127 (Muranski et al. 2008; Quezada
et al. 2010) was synthesised by GeneArt (Life Technologies) (Fig 3.1B). As in the
TRP2 TCR, to improve TCR expression we codon optimised the TRP1 TCR and
added the extra cysteine residues by substituting one amino acid in both chains
(a-T179C and b-S186C). To further improve expression the DNA for all three
TCRs was cloned into pMP71, a retroviral expression vector optimised for
expression in lymphocytes (Fig 3.1C). This plasmid contains a truncated CD19
epitope to allow easy staining by FACS as a marker of transduction (Tey et al.
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2007). In the same vector backbone we also already had the F5 TCR, a class I
restricted TCR which recognises the influenza nucleoprotein (NP366-379) as
presented by H-2Db (Townsend et al. 1985).
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pMX
TRP2 Vβ3 2A  Vα12.1
pMX
Pmel-1 Vα1 IRES  Vβ13
pMX
TRP1 Vα3.2 2A  Vβ14
5’ LTR 3’ LTRΔCD19IRES2AVα1 Vβ13
pMP71 Pmel-1 IRES CD19:
pMP71 TRP2 IRES CD19:
5’ LTR 3’ LTRΔCD19IRES2AVβ3  Vα12.1
S S
pMP71 TRP1 IRES CD19:
5’ LTR 3’ LTRΔCD19IRESVα3.2 2A Vβ14
S S
pMP71 F5 IRES CD19:
5’ LTR 3’ LTRΔCD19IRESVα4 2A Vβ11
S S
A
C
B
Figure 3.1: Schematic representation of the retroviral expression vectors.
(A) Retroviral vectors in a pMX backbone were donated by Ton Schumacher (Netherlands
cancer institute). PCR reactions were performed to replace the IRES sequence in the
Pmel-1 vector with a 2A sequence.
(B) TRP1 TCR as ordered from GeneArt.
(C) TRP2, Pmel-1 and TRP1 TCRs were cloned into the pMP71 vector. This includes a
truncated CD19 epitope as a transduction marker, alongside the TCR.
The 2A sequence is from the porcine teschovirus-1 and allows co-translational cleavage
of the two proteins. IRES denotes an internal ribosome entry site. —S-S— denotes the
presence of an extra cysteine in the a and b chains.
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3.2 TCR transduced T cells recognise cognate
antigen
To test whether the melanoma-specific TCRs were functional in transduced T
cells, C57BL/6 splenocytes were transduced with retroviral vectors encoding the
TRP2, Pmel-1, TRP1 and F5 TCRs or mock transduced without retrovirus.
Expression of both the specific variable b chain and the CD19 marker were
detectable by FACS 3 days after transduction (Fig 3.2A). Summary data for
these transductions (Fig 3.2B) show broadly similar transduction efficiencies
between the different TCR constructs (TRP2 mean 60±14%, Pmel-1 mean
59±12%, TRP1 mean 63±14% and F5 mean 59±15%).
To ensure that T cells transduced with the Pmel-1 and TRP2 TCRs could
recognise their cognate antigen, RMA/S cells were loaded with relevant or
irrelevant peptide and co-cultured with TRP2 and Pmel-1 transduced T cells at
decreasing concentrations. After 24 hours of co-culture the CD19+ transduced
CD8 cells were stained for intracellular IFN-g production (Fig 3.3A and B). Whilst
both transduced populations produced minimal IFN-g when cultured with RMA/S
cells loaded with irrelevant peptide, the relevant peptide induced a clear IFN-g
response in both TRP2 and Pmel-1 transduced cells, comparable to PMA and
ionomycin activated T cells. At high peptide concentrations of 10µM - 100nM
there is a trend for higher IFN-g responses in TRP2 than Pmel-1 transduced
cells, although this is not significant. However as the T cell response starts to
decrease with lower peptide concentrations (10nM - 100pM) this difference is
lost.
Whilst RMA/S are suitable to present class I restricted peptides they lack MHCII
expression so will not present the class II restricted TRP1 peptide. To test the
antigen specificity of TRP1 transduced T cells we generated bone marrow
derived DC (BM-DC) which express high levels of MHCI and II. These were
loaded with relevant or irrelevant peptide and co-cultured with transduced T cells
as in Fig 3.3A. Both TRP2 and Pmel-1 transduced cells produced a similar level
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of IFN-g when cultured with peptide loaded BM-DC as compared to peptide
loaded RMA/S cells. However with peptide loaded BM-DC they appear to
maintain IFN-g production at lower peptide concentrations (Fig 3.3C). At the
highest peptide concentration (10µM), TRP1 transduced cells produced IFN-g at
the same level as TRP2 and Pmel-1 cells. However this rapidly decreased with
lower peptide concentrations. IFN-g production became undetectable at 100-fold
lower concentration in TRP2 or Pmel-1 transduced cells than TRP1. The likely
explanation for this is that the IFN-g production in this experiment has been
measured in the transduced CD8+ population. Whilst gene transfer of the same
TCR has been shown to confer antigen specificity to both CD8 and CD4 cells
(Morris et al. 2005; Roszkowski et al. 2005), it is reasonable to suggest that in
this case the T cell response following TRP1 TCR-pMHCII engagement is
inferior in the absence of the CD4 co-receptor. Whilst this is not limiting at
saturating peptide concentrations, when the peptide concentration decreases
the lack of the CD4 co-receptor in CD8+ TRP1 transduced cells limits their
activation. Surprisingly there was no IFN-g detectable after 24 hours in the CD4+
TRP1 transduced cells. This may be a fault in the experiment design as IL-2 may
be a preferable read-out for CD4+ T cell activation. Likewise the cytokine
production kinetics may differ between CD4 and CD8 T cells. Checking for
cytokine production in the supernatants by ELISA rather than intracellular
cytokine staining may offer a more sensitive approach. However this was not
pursued as these experiments had succeeded in their aim of showing that the
recently constructed TCR retroviral vectors conferred antigen specificity for the
relevant B16.F10-associated peptides.
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Figure 3.2: T cell receptor transduction of murine splenocytes.
(A) C57BL/6 splenocytes were transduced with retroviruses encoding TRP2, Pmel-1,
TRP1 or F5 TCRs or without retrovirus (mock transduced). After 3 days, cells were
stained for CD4, CD8, CD19 and the Vb chain specific for that TCR. (TRP2 = Vb3, Pmel-
1 = Vb13, TRP1 = Vb14 and F5 = Vb11). Cells are pre-gated on live lymphocytes (FSC v
SSC) then CD8 (for mock, TRP2, Pmel-1 or F5) or CD4 for TRP1. Representative FACS
plots are taken from different experiments.
(B) Summary transduction efficiencies across multiple experiments are plotted as the
mean frequency of CD19+ Vb+ in CD8+ (TRP2, Pmel-1, F5) or CD4+ (TRP1) live
splenocytes (±SD).
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Figure 3.3: TCR transduced T cells recognise cognate antigen in vitro.
Bulk splenocytes were transduced with anti-TRP2, Pmel-1 or TRP1 TCRs and 5 days
later were co-cultured overnight with RMA/S cells (A,B) or BM-DC (C). These were loaded
with decreasing concentration of specific peptide, irrelevant peptide or unloaded. Cells
were stained for intracellular IFN-g in CD8+, CD19+ lymphocytes.
(A) Gating strategy shown in representative FACS plots.
(B) Mean IFN-g+ transduced T cells from 3 independent experiments ±SD.
(C) Mean IFN-g+ transduced T cells from 1 experiment for TRP2 and Pmel-1, or 2
experiments for TRP1 ±SD.
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3.3 Transduced T cells recognise antigen
expressed on tumour cells in vitro
As well as recognising peptide-loaded cells, TCR transduced T cells must be
capable of recognising peptide when processed and presented directly by
tumour cells. However B16.F10 melanoma is a poorly immunogenic tumour and
has an almost complete lack of MHCI expression in vitro. Previous studies have
shown that B16.F10 upregulates MHCI expression in response to IFN-g (Seliger
et al. 2001) so we generated media containing murine IFN-g by harvesting the
supernatant from ConA activated splenocytes. This ConA activated splenocyte
media (CASM) contained 8.5ng of IFN-g/ml, as quantified by ELISA (Fig 3.4A).
B16.F10 cells cultured for 24 hours in CASM upregulated their expression of
MHCI to a similar level as the highly immunogenic EL4-NP thymoma line (Fig
3.4B). Interestingly, incubation with CASM also upregulated MHCII on B16.F10
cells, although this depreciated more rapidly with decreasing IFN-g concentration
than MHCI expression. Based on these experiments CASM was diluted 1/2
(4.2ng/ml) for use in subsequent assays. However IFN-g has been shown to
upregulate PD-L1 expression on ovarian tumours (Abiko et al. 2015) and
incubation with CASM upregulated expression of PD-L1 on B16.F10 melanoma
cells (Fig 3.4C).
To test whether CASM-mediated, MHC upregulation renders B16.F10 capable of
presenting the relevant peptides to transduced T cells, B16.F10 cells were
incubated overnight in CASM or normal media, washed, then co-cultured in
fresh media with mock or TRP2 transduced T cells (Fig 3.5A). Supernatant was
collected after 4 hours and tested for T cell production of IFN-g by ELISA. As
expected, without prior activation of tumour cells with CASM, neither mock nor
TRP2 transduced cells produced IFN-g. However after activation of B16.F10 with
CASM, TRP2 but not mock transduced cells produced high levels of IFN-g. In
this setting, CASM-mediated upregulation of PD-L1 on tumour cells was
therefore insufficient to prevent IFN-g production by TRP2 transduced T
cells.
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To examine the tumour specific response of TCR transduced T cells further,
overnight co-culture experiments were set up with TRP2, Pmel-1 or TRP1
transduced cells (Fig 3.5B and C). Production of IFN-g was measured by FACS
staining of transduced cells for intracellular IFN-g. The frequency of IFN-g+ TRP2
transduced cells was significantly higher when cultured with the antigen positive
B16.F10 melanoma compared to the antigen negative EL4 thymoma. However
in overnight cultures, unlike after 4 hours, there was no difference between the
response to B16.F10 that had been pre-activated with CASM or not. This
suggests that the minimal IFN-g produced by resting T cells overnight is
sufficient to induce MHC upregulation, which then enables antigen presentation
to the TRP2 transduced T cells. Indeed, in Fig 3.4 we saw MHCI upregulation in
~50% of B16.F10 cells after culture with CASM diluted 1/100. This relates to an
IFN-g concentration of 80pg/ml which is broadly equivalent to the background
level of IFN-g produced after 4 hours by transduced cells in Fig 3.5A.
Although in Fig 3.3 both TRP2 and Pmel-1 transduced cells responded to
peptide-loaded cells to a similar extent, Pmel-1 transduced cells responded
more poorly when cultured with tumour cells. The frequency of IFN-g+ Pmel-1
cells was only detectable above background after pre-incubation with CASM, but
this was still substantially lower (10%) than with TRP2 transduced cells (56%).
Whilst the frequency of IFN-g+ TRP1 cells (41%) was higher than Pmel-1 cells
this too was dependent on activation of the tumour with CASM. As shown in Fig
3.4, MHCII upregulation (and therefore presentation to TRP1 cells) requires
higher IFN-g concentrations than for MHCI upregulation. In this setting therefore
it appears that background IFN-g is not enough to induce sufficient MHCII
upregulation to fully present to TRP1 cells.
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Figure 3.4: Upregulation of MHC class I and II on B16.F10 melanoma in vitro.
(A) Concentration of IFN-g in cell-free ConA activated splenocyte media (CASM) as
measured by ELISA.
(B) MHCI and II upregulation on B16.F10 after incubation wit CASM. CASM was added to
B16.F10 melanoma at various dilutions, after 24 hours cells were harvested and stained
for MHC class I (H-2Kb) and MHC class II (I-Ab).
(C) PD-L1 expression on B16.F10 after addition of CASM (diluted 1/2) for 24 hours.
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Figure 3.5: Transduced T cells recognise antigen expressed on B16.F10 in vitro.
(A) IFN-g production by mock or TRP2 transduced splenocytes after co-culture with
B16.F10 that had been activated with CASM or left unactivated for 24 hours previously.
Supernatants were harvested after 4 hours and IFN-g concentration was measured by
ELISA.
(B,C) B16.F10 tumours were irradiated and co-cultured with transduced splenocytes
overnight. Cells were then stained for intracellular IFN-g in CD8+, CD19+ lymphocytes.
Gating strategy shown in representative FACS plots (B). Results in (C) are from 4
independent experiments and show mean frequency of IFN-g+ cells in the CD8+ CD19+
population ±SD. Statistical test: unpaired T test. ns: non significant, **: p0.01, ***:
p0.001, ****: p0.0001
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3.4 Recognition of B16 NP GFP by F5 TCR
transduced T cells
As a comparison to these TCRs which recognise self-antigens presented by the
B16.F10 tumour we established the F5 TCR model in which the tumour cells
present the foreign NP peptide to TCR transduced T cells. To ensure stable,
long-term expression of NP we transduced B16.F10 with a retrovirus that
encoded the NP protein (Fig 3.6A). This vector also contained GFP as a
transduction marker and had been generated by a previous PhD student,
Bernado Alvares. Although transduction with this vector gave a high transduction
efficiency (93% GFP+) to prevent potential outgrowth of an NP-negative
population we attempted to FACS sort a 100% GFP+ population. However
although this increased the purity of the transduced population there remained a
small GFP- population (Fig 3.6B). Therefore an alternative approach was
attempted where single cells of the transduced B16 NP GFP population were
plated in 96 well plates. Two clones were isolated by this approach that were
100% GFP+, with either medium or high GFP expression (Fig 3.6C).
To ensure that these GFP+ cells expressed and presented NP, the B16 NP GFP
cell lines were activated with CASM and co-cultured overnight with F5 or TRP2
transduced T cells. The frequency of IFN-g+ F5 transduced cells was comparable
when cultured with either B16 NP GFP or EL4-NP cells. This was specifically in
response to tumours expressing NP as the standard EL4 tumour only induced
backround IFN-g (Fig 3.6D). As with the TRP2 transduced cells in Fig 3.5C, there
was no difference when F5 transduced T cells were cultured with tumours that
had been pre-activated with CASM or not. There was also no notable difference
in the frequency of IFN-g+ F5 transduced cells when cultured with GFP medium
or GFP high cell lines, suggesting expression of the NP protein is not a limiting
factor. Nonetheless the high GFP expressing clone (B16 NP GFP clone 2) was
selected for future experiments. Interestingly, despite the F5 TCR recognising a
foreign antigen, the frequency of IFN-g+ F5 transduced cells was comparable to
TRP2 transduced cells.
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Figure 3.6: Expression of NP in B16.F10 and recognition by F5 TCR transduced T cells.
(A) The retroviral expression vector used to transduce B16.F10 with a construct
expressing the influenza nucleoprotein (NP) and GFP.
(B) FACS profile of transduced B16.F10 cells and after FACS sorting.
(C) FACS profile and median GFP intensity of single cell clones of the B16 NP GFP.
(D) As in Fig 3.5C, tumours were irradiated and co-cultured overnight with TRP2 or
F5 transduced T cells. Graph shows frequency of IFN-g+ cells in the CD8+, CD19+
population. Results are from 2 independent experiments ±SD.
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3.5 Summary and conclusion
The genes encoding the a and b chains of TCRs specific for the melanocyte
differentiation antigens TRP2, Pmel-1 or TRP1 were cloned into the pMP71
retroviral expression vector. These were used to transduce splenocytes and
these TCR engineered T cells were able to recognise their cognate antigens
when loaded onto target cells or presented directly on the B16.F10 melanoma
cell line in vitro. A number of approaches had been utilised in these introduced
TCRs to ensure that transduced T cells were capable of responding to their
cognate antigen. These modifications included codon optimisation, separation of
a and b chains with 2A sequences (Holst et al. 2006) and the addition of extra
cysteine residues to promote TCR expression on the cell surface (Cohen et al.
2007; Kuball et al. 2007). TCR expression can be further enhanced by providing
transduced cells with surplus CD3 molecules, either by co-transduction with
extra CD3 (Ahmadi et al. 2011) or by down-regulation of endogenous TCR
chains (Berdien et al. 2014; Ochi et al. 2011; Okamoto et al. 2009; Provasi et al.
2012). However as transduced T cells exhibited good effector function in vitro
these other modifications were not pursued.
TRP2 and Pmel-1 transduced cells displayed similar IFN-g production in response
to peptide-loaded target cells, suggesting the ability of each TCR to recognise
their cognate antigen is similar. However Pmel-1 transduced cells were only able
to induce a low level of IFN-g in response to the tumour cells directly, relative
to TRP2 transduced cells. It is possible this could be explained by the Pmel-
1 TCR lacking the extra cysteine modification found in TRP2 TCR. However as
both transduced T cells respond equally to peptide-loaded cells this is unlikely.
Instead this difference in IFN-g production may be due to differences in expression
of the relevant protein in the B16.F10 cell line. Melanomas including the B16.F10
melanoma are known to be relatively ‘unstable’ tumours and although analysis
of protein levels were not performed here they have been found to vary between
different laboratories and samples (Overwijk and Restifo 2001; Riker et al. 2000).
Therefore although Pmel-1 transduced T cells can recognise peptide loaded cells,
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B16.F10 cells themselves may limit recognition by presenting low levels of the
Pmel-1 peptide.
As well as these class I restricted TCRs, a class II restricted TCR (TRP1) was
also generated. As previously discussed, although T cells transduced with this
TCR responded to peptide loaded cells this was sub-optimal, possibly due to
the experimental design being optimised for CD8 not CD4 T cells. Nonetheless
these cells were able to respond to peptide presented directly by the tumour cell.
However this was largely dependent on B16.F10 upregulation of MHCII.
The F5 TCR model, which recognises the foreign NP peptide, was also
established to allow comparison to these self-reactive anti-tumour TCRs.
B16.F10 cells were engineered to express NP and presented antigen to F5 TCR
transduced T cells. This resulted in the induction of a IFN-g response
comparable to that of the well established EL4-NP cell line. Surprisingly the
IFN-g response from F5 transduced T cells was the same as from TRP2
transduced T cells. This suggests that either these TCRs have similar affinities,
that the higher affinity of the F5 TCR does not correlate with an improved
effector function, or that the detection of the effector response by this in vitro
assay is saturated. Indeed higher TCR affinities do not necessarily relate to
better effector function and have been shown not to improve T cell responses
above a certain threshold (Zhong et al. 2013). However the control of tumour
growth in vivo would be a more physiological assessment of the ability of these
TCR transduced T cells to respond to tumour antigens, compared to in vitro
assays.
Together the data in this chapter demonstrate that although the exact production
of IFN-g by T cells transduced with these TCRs varied, all four TCR constructs
showed they were capable of redirecting the antigen specificity of a polyclonal T
cell population towards a tumour associated antigen in vitro. The next chapter will
therefore focus on the ability of these TCR transduced T cells to control tumour
growth in vivo.
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growth by TCR transduced T cells in
vivo
The previous chapter showed that T cells transduced with the anti-melanoma or
anti-NP TCRs were capable of recognising their cognate antigen and producing
IFN-g in vitro. Here we tested the in vivo efficacy of T cells transduced with
these TCRs. Previous studies have shown that TRP2 or Pmel-1 transduced CD8
T cells induce a transient delay in B16.F10 tumour growth for approximately 10
days after T cell transfer (Abad et al. 2008; Chinnasamy et al. 2013; Kerkar et al.
2011). However this is insufficient to completely control the tumour, which then
quickly regrows. As discussed earlier it is possible that T cells transduced with
these TCRs may only be able to induce partial tumour control as the TCRs only
recognise tumour associated antigens with low affinity.
We would therefore predict that foreign-antigen specific and therefore high affinity
TCRs would mediate enhanced tumour clearance. However T cells transduced
with the ovalbumin (OVA) specific TCR, OT-1, induced significant but not complete
tumour regression of a B16-OVA tumour (De Witte et al. 2006). We and others
have also shown that T cells transduced with the foreign-antigen specific F5 TCR
can completely eliminate the EL4-NP thymoma (Ahmadi et al. 2011; Morris et al.
2005). However the EL4 thymoma is thought to be a more immunogenic tumour
than B16.F10, so the efficacy of elimination of a B16 NP tumour by F5 transduced
T cells is not yet know.
However despite expressing a ‘self-reactive’ TCR, CD4 T cells transduced with
the TRP1 TCR have been shown to mediate potent tumour control in vivo
(Kerkar et al. 2011). These cells, unlike the class I restricted TCRs, were able to
eliminate B16.F10 tumours without subsequent regrowth. Comparison between
these models however is complicated as different cell types are used for the
response, either CD8 or CD4 T cells. It may be that intrinsic differences between
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these cell types, rather than differences in their TCR affinity is responsible for
these different efficacies.
As mentioned earlier, above a certain threshold, increasing TCR affinity does not
increase T cell effector function (Zhong et al. 2013). However enhancing TCR
avidity, rather than affinity, of transduced T cells is an attractive strategy to
improve T cell responses. The structural modifications to the TCR that promote
TCR expression on the cell surface have been discussed earlier (chapter 1.4). In
addition to these structural modifications to the introduced TCRs, other
approaches to enhance the therapeutic effect of T cells consist of maximising
the ability of transferred T cells to expand in vivo.
Proliferation of transferred T cells can be induced either through vaccination or
through host pre-conditioning. However T cell proliferation through homeostatic
expansion after lymphodepletive pre-conditioing, rather than vaccine-induced
expansion has recently been preferred. Nonmyeloablative chemotherapy or
irradiation has been shown to promote better expansion of introduced T cells
than vaccination alone (De Witte et al. 2008a). Host pre-conditioning is thought
to provide improved T cell expansion through a number of mechanisms; firstly
expansion is driven by depletion of endogenous NK and T cells, which results in
surplus IL-7 and IL-15. Unlike vaccination, these cytokines promote proliferation
independent of antigen-recognition. This promotes long-term survival of
expanded cells rather than the rapid expansion and contraction phases
mediated by antigen-driven proliferation (De Witte et al. 2008a). Moreover
depletion of endogenous lymphocytes has the additional benefit of depleting
endogenous Tregs, which reduces potential immune suppression of the
transferred T cells. Lastly the conditioning regimen itself can induce tumour cell
destruction directly. This can also aid latter T cell expansion by release of
tumour antigen (Zitvogel et al. 2008).
However whilst essential for optimal T cell responses, pre-conditioning irradiation
also has downsides. Primarily we have noticed that mice often do not tolerate
high levels (5 Gy) of irradiation well which can induce substantial weigh loss,
requiring mice to be sacrificed regardless of tumour burden. Therefore we chose
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to irradiate mice with a slightly lower 4 Gy of irradiation and test:
1. the control of B16.F10 by:
• TRP2 or Pmel-1 transduced CD8+ T cells
• TRP1 transduced CD4+ T cells
2. the control of B16 NP GFP by F5 transduced CD8+ T cells
The purpose of these experiments was to establish a B16.F10 tumour model in
which we could achieve partial tumour control by transferred T cells. This would
allow later experiments to address the interactions these cells have with DC.
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4.1 Control of B16.F10 by TRP2 or Pmel-1
transduced T cells in vivo
To test whether T cells transduced with anti-melanoma TCRs would control the
growth of B16.F10, tumour-bearing mice were sub-lethally irradiated with 4 Gy
before receiving TRP2, Pmel-1 or mock transduced T cells (Fig 4.1A). As both
TCRs are class I restricted, CD8+ cells were sorted prior to activation and
transduction. By day 3 post-transduction the cells to be injected were >97%
CD8+ with transduction efficiencies of 61% TRP2+ and 45% Pmel-1+ (Fig 4.1B).
Mice received 2x106 transduced T cells, but as the Pmel-1 transduced cells were
less well transduced, these mice received a slightly higher total number of T
cells as the population contained more untransduced cells. This number of total
T cells was matched in mice treated with mock transduced T cells. Following T
cell injection the size of the subcutaneous B16.F10 tumour was monitored and
mice were sacrificed when tumours exceeded 15mm in any direction, as per
home office regulations.
Both TRP2 and Pmel-1 transduced T cells showed a modest delay in tumour
growth as compared to mice treated with mock transduced T cells (Fig 4.1C). For
⇠10 days after transfer of TRP2 or Pmel-1 transduced T cells the tumour growth
plateaued. However as in previous studies this control was transient and tumours
then began to regrow. This eventual failure to control tumour growth suggests
either the tumour stopped presenting the relevant antigen, that the transduced T
cells became anergised/exhausted or that they failed to persist for longer than 10
days. However although the tumour control mediated by the transduced T cells
was only partial it did result in a significant improvement in overall survival (Fig
4.1D), as mice developed tumours large enough to necessitate sacrifice at later
time points. Interestingly despite Pmel-1 transduced T cells responding poorly to
B16.F10 cells in vitro (Fig 3.5C), they were able to control tumour growth in vivo
to a similar degree as TRP2 transduced T cells.
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Figure 4.1: Transient control of B16.F10 growth by TCR transduced CD8+ T cells in vivo.
(A) Experiment outline. 5x105 B16.F10 cells were injected sub-cutaneously into the flank
of C57/BL6 mice. On day 10 post-injection mice were irradiated with a sub-lethal dose of
irradiation (4 Gy) and injected i.v. with 2x106 CD8+ splenocytes that had been transduced
with the TRP2 or Pmel-1 TCR or mock transduced.
(B) FACS profile of transduced T cells on day 3 post-transduction. Transduced cells are
identified as CD19+ and specific Vb+ lymphocytes. TRP2 = Vb3, Pmel-1 = Vb13.
(C) Tumour protection by transduced T cells was assessed by measuring tumour size.
Results are the mean from 8 mice per group from 2 independent experiments ±SEM.
(D) Kaplan Meier survival graph. Significance measured by Log Rank test. **: p0.01.
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4.2 Control of B16.F10 by TRP1 transduced T cells
in vivo
To test the ability of TRP1 transduced T cells to control growth of B16.F10, the
experiment as described in Fig 4.1 was repeated with TRP1 transduced T cells
(Fig 4.2A). As the TRP1 TCR is class II restricted we sorted CD4+ cells before
transduction and by day 3 post-transduction the cells were 95% CD4+ and 59%
TRP1+ (Fig 4.2B). As before, following T cell injection tumour size was monitored
and mice were sacrificed when necessary.
In contrast to the transient control mediated by TRP2 and Pmel-1 transduced T
cells, TRP1 transduced cells mediated profound tumour control. All mice treated
with TRP1 TCR transduced T cells completely cleared the tumour and remained
tumour-free until day 43 when the experiment was ended (Fig 4.2C). As no mice
treated with TRP1 cells had to be sacrificed due to tumour size and cleared the
tumour without any toxicity, 100% of mice survived until day 43 (Fig 4.2D).
To test whether the tumour control offered by TRP1 transduced T cells would
lessen when fewer transduced T cells were transferred, we repeated the
experiment in Fig 4.2 but transferred 1x105, 2x105, 1x106 or 2x106 TRP1 T cells
(Fig 4.3A). As in Fig 4.2, 2x106 TRP1 T cells mediated marked tumour control,
however in this experiment only 1/3 mice completely cleared the tumour. The
other 2 mice appeared to be clearing the tumour until ⇠day 45 when the tumour
rapidly regrew and the mice had to be sacrificed. A similar pattern of tumour
regression before eventual rapid outgrowth at ⇠day 40 was also observed in
mice treated with 1x106 and 2x105 TRP1 T cells. Surprisingly, despite tumour
control appearing to be the most effective at a dose of 2x106, mice treated with
10-fold fewer cells still controlled the tumour to a broadly similar extent. However
at a dose 1x105, TRP1 T cells conferred suboptimal tumour control as tumour
growth only plateaued for ⇠15 days before outgrowth, similar to the control seen
by TRP2 or Pmel-1 transduced T cells.
However in addition to this lasting tumour control and elimination, TRP1
118
Chapter 4 Section 4.2
transduced T cells also mediated off-tumour, on-target destruction of
endogenous TRP1 expressing melanocytes. Mice treated with 2x106 and 1x106
but not 2x105 TRP1 transduced T cells showed visible signs of vitiligo (skin
depigmentation) (Fig 4.4). Whilst this was most prominent and systemic at
2x106, mice treated with 1x106 TRP1 cells still showed some signs of vitiligo,
albeit limited to the skin at the tumour site. This is not unsuspected as extensive
vitiligo has been reported in mice treated with TRP1 transgenic T cells (Quezada
et al. 2010) and has been reported in some patients receiving adoptive cell
therapy for melanoma (Dudley and Rosenberg 2003).
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Figure 4.2: Control of B16.F10 growth by TRP1 transduced CD4+ T cells in vivo.
(A) Experiment outline. 5x105 B16.F10 cells were injected sub-cutaneously into the flank
of C57/BL6 mice. On day 10 post-injection mice were irradiated with a sub-lethal dose of
irradiation (4 Gy) and injected i.v. with 2x106 CD4+ splenocytes that had been transduced
with the TRP1 TCR or mock transduced.
(B) FACS profile of transduced T cells on day 3 post-transduction. Transduced CD4 T
cells are identified as CD19+ and Vb14+ lymphocytes.
(C) Tumour protection by transduced T cells was assessed by measuring tumour size.
(D) Kaplan Meier survival graph. Significance measured by Log Rank test. **: p0.01.
Results are from 5 mice per group from 1 experiment
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Figure 4.3: Control of B16.F10 growth by TRP1 T cells depends on cell dose.
(A) Tumour control by TRP1 transduced T cells. As before 5x105 B16.F10 cells were
injected sub-cutaneously into the flank of C57/BL6 mice. On day 10 post-injection mice
were irradiated 4 Gy and injected i.v. with 1x105, 2x105, 1x106 or 2x106 CD4+ TRP1 TCR
transduced T cells. Tumour protection by transduced T cells was assessed by measuring
tumour size. Results are from 3 mice per group from 1 experiment.
(B) Kaplan Meier survival graph. Significance measured by Log Rank test. *: p0.05.
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Figure 4.4: Self-reactive TRP1 transduced T cells mediate autoimmune vitiligo.
Vitiligo in mice bearing B16.F10 tumours after treatment with high numbers of TRP1
transduced T cells. Photographs show mice upon sacrifice (day 49-56) in groups treated
with 2x105, 1x106 or 2x106 CD4+ TRP1 TCR transduced T cells.
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4.3 Control of B16 NP GFP by F5 transduced T cells
in vivo
To test whether F5 TCR transduced T cells were able to control the growth of B16
NP GFP in vivo, the B16.F10 model as described previously had to be adapted.
Mice were irradiated with 4 Gy on the day of tumour injection, rather than T cell
transfer as done previously. This was done to remove endogenous NP-specific
T cells that would not be tolerised to the foreign antigen. By day 7, tumours
were well established so mice were then treated with 2x106 F5 CD19 or mock
transduced T cells (Fig 4.5A). One group of mice also received 1x106 F5 TCR
transgenic T cells as a positive control.
As for the previous experiments purified CD8 T cells were transduced, however
in these experiments transduced T cells were injected 1 day, rather than 3 days,
after transduction. This reduces the length of time cells are cultured for and
improves their survival in vitro. However it makes an accurate calculation of their
transduction efficiency more difficult. Whilst F5 TCR transduced T cells
expressed the CD19 transduction marker after 1 day, TCR expression was not
yet visible (Fig 4.5B). This may be because to be expressed on the cell surface,
the TCR a and b chains must dimerise, then form a complex with the CD3 g , d ,
e and z chains. This is inherently more complicated than expression of the
smaller, truncated CD19 protein and so takes longer to be expressed on the cell
surface. For this reason a small number of cells were cultured until day 4 to
check transduction efficiency. As expected, by day 4 the CD19+ transduced cells
had become Vb11+.
The ability of F5 TCR transduced or transgenic T cells to mediate tumour control
was monitored by measuring tumour size over the course of the experiment. Fig
4.6A demonstrates that F5 CD19 transduced T cells controlled tumour growth in
half the mice tested. Of the 7 mice treated, 3 showed pronounced tumour
regression until day ⇠35 when tumour control was lost and tumours rapidly
outgrew. 1 further mouse showed mild tumour control, but the remaining 3
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showed no evidence of tumour control. The reason why only half of the F5 CD19
treated mice responded to treatment is unclear. The mice that controlled the
tumour were spread between the two experiments so is not due to a fault in one
experiment. In contrast 5 out of 6 mice treated with F5 transgenic T cells
controlled tumour growth until day 30-35 when control was lost. 1 mouse in this
group completely cleared and remained tumour free until day 50 when the
experiment was ended. As in the B16.F10 model, treatment with mock
transduced T cells had no effect on the growth of the B16 NP GFP tumour.
Tumour control by F5 CD19 transduced or F5 transgenic T cells caused a
significant improvement in survival, although this was more significant in F5
transgenic treated mice (Fig 4.6B).
Although mice treated with either F5 TCR T cell population were able to control
tumours, the majority eventually lost this tumour control. To investigate whether
this loss of control was due to the B16 NP GFP tumours losing NP expression in
vivo, tumours from mice treated with F5 or mock transduced T cells were cultured
ex vivo. As the B16 NP GFP tumour line is 100% GFP+ (Fig 3.6C), outgrowth
of a untransduced, NP negative tumour is unlikely. Fig 4.7A shows that tumours
treated with either F5 CD19 or mock transduced T cells remain 100% GFP+.
However as GFP expression is controlled by an IRES sequence and not linked to
NP expression by a 2A sequence, it is possible that GFP+ cells have lost or down-
regulated NP expression. To test this, ex vivo tumours were co-cultured with F5,
TRP2 or mock transduced splenocytes in vitro. IFN-g expression was measured
by FACS in live, CD8+, CD19+ F5 or TRP2 transduced T cells or live, CD8+ mock
transduced T cells (Fig 4.7B). Regardless of whether tumours had been partially
controlled by F5 transduced T cells or not, ex vivo B16 NP GFP tumours were
capable of presenting NP to F5 transduced T cells to the same extent as the in
vitro cell line (Fig 4.7C). The frequency of IFN-g+ cells was also similar between
F5 and TRP2 TCR transduced T cells. This suggests that the loss of tumour
control exhibited by F5 CD19 in vivo is not due to loss of NP expression on the
tumour. Moreover ex vivo tumours taken from F5 treated mice completely failed
to control the tumour were still able to present NP in vitro.
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Figure 4.5: Establishing the B16 NP GFP in vivo model.
(A) Experiment outline. C57/BL6 mice were irradiated with 4 Gy and injected sub-
cutaneously in the flank with 5x105 B16 NP GFP cells. On day 7 mice were injected
with 2x106 CD8+ splenocytes that had been transduced with the F5 TCR or mock
transduced. A separate group was injected with 1x106 unactivated CD8+ splenocytes
from a transgenic F5 TCR mouse.
(B) FACS profile of transduced and transgenic T cells on day 1 and day 4 post-
transduction. Transduced cells are identified as CD19+ and Vb11+ lymphocytes.
F5 CD19 denotes transduced T cells, F5 tg denotes transgenic T cells.
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Figure 4.6: F5 TCR transduced T cells control B16 NP GFP in vivo.
(A) Tumour protection by transduced T cells was assessed by measuring tumour size in
mice treated with CD8+ mock or F5 CD19 transduced, or F5 transgenic (tg) T cells.
(B) Kaplan Meier survival graph. Significance measured by Log Rank test based on
survival after T cell transfer. *: p0.05, **: p0.01. Results are from 6-7 mice per group
from 2 independent experiments
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Figure 4.7: ex vivo B16 NP GFP tumours still present NP to F5 transduced T cells.
(A) GFP expression in in vitro B16 NP GFP or ex vivo B16 NP GFP tumours after
treatment with F5 CD19 or mock transduced T cells. Overlaid histograms show F5 CD19
controlled tumours, or all T cell treated tumours.
(B) Representative FACS plots for in vitro IFN-g production by F5 CD19 transduced T
cells. Cells were gated on live, CD8+, CD19+ T cells.
(C) Summary data for co-cultures of ex vivo B16 NP GFP tumours with mock, F5 CD19
or TRP2 CD19 transduced T cells. ‘F5 treated (controlled)’ indicates mice that were
sacrificed on day 33-35, ‘F5 treated (no control)’ and mock treated were tumours from
mice sacrificed on day 15-20.
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4.4 Summary and conclusion
Together, the data in chapters 3 and 4 show that TCR transduced T cells are
stimulated by tumour cells in vitro, and control tumour growth in vivo. In line with
previous reports using these TCRs (Abad et al. 2008; Chinnasamy et al. 2013;
Kerkar et al. 2011), the TRP2 and Pmel-1 TCRs were only able to induce transient
tumour control. The TRP1 TCR however was more effective and was able in
some cases to completely clear the tumour burden. This, again, is in line with
previous studies, which have reported the efficacy of CD4 T cells transduced with
this TCR (Kerkar et al. 2011). Interestingly these transduced CD4 cells are able
to induce tumour regression in the absence of CD8 T cells. The same result has
been shown in transgenic TRP1 CD4 T cells, which are able to acquire effector
functions and directly lyse B16 tumour cells in vivo (Quezada et al. 2010). In
addition CD4 T cells expressing a different transgenic TCR have been shown to
indirectly kill B16 tumours by expressing IFN-g, TNF-a and IL-2 (Shklovskaya et
al. 2016).
Whilst the enhanced control of B16 by TRP1 TCR transduced cells could be
explained by the potential differences in CD4 vs CD8 mediated control, there is
an alternative explanation. Unlike the TRP2 and Pmel-1 TCRs, the TRP1 TCR
was originally generated in mice lacking TRP1 gene expression (Muranski et al.
2008). Therefore the TRP1 TCR, although it recognises a self-antigen, has not
been through central tolerance in the same way as the TRP2 and Pmel-1 TCRs
have. TPR1 has more in common with a foreign-reactive TCR, which are able to
generate high-avidities without being deleted in the thymus. This separation
between high avidity ‘foreign’ TCRs and low avidity ‘self’ TCRs could neatly
explain the differences seen in tumour control.
In line this, T cells transduced with the foreign-antigen specific F5 TCR also
efficiently controlled growth of the B16 NP GFP tumour. This could be as a result
of NP expression in these cells being driven by a constitutive viral promotor,
resulting in a greater amount of NP being presented than TRP2. However these
data together suggest that the efficacy of the F5 TCR is mediated by a
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potentially enhanced affinity for antigen. These models are also beneficial for
future experiments as it will allow us to compare the difference in responses
when T cells have the potential to be tolerised to a self antigen or not. This may
have important consequences for the role of DC as, unlike NP, the antigens for
the TRP2, Pmel-1 and TRP1 TCRs will be chronically expressed in host tissue.
The context in which DC present antigen is crucial in the subsequent T cell
response, so restricting antigen expression to the tumour (as is the case with
NP) may affect induction of T cell anergy, effector function or memory
formation.
Lastly F5 transduced T cells can also be compared to transgenic T cells
expressing the F5 TCR. In these tumour control experiments, F5 transgenic T
cells were more effective at controlling tumour growth than F5 transduced T
cells. One potential explanation is that whereas 100% of transgenic T cells
express the F5 TCR, in the transduced population there is an untransduced,
polyclonal fraction. Co-transfer of these untransduced cells with antigen-specific
T cells has been shown to reduce expansion and tumour control by the
anti-tumour TCR expressing T cells (Abad et al. 2008; De Witte et al. 2008a). In
addition these transgenic T cells also differ from transduced cells in that they
were not pre-activated in vitro. The differentiation status of transferred T cells
affects their function in vivo. Adoptively transferred, cells that are less
differentiated/more naive proliferate more and have improved anti-tumour
immunity (Hinrichs et al. 2009; Klebanoff et al. 2005). In addition transgenic T
cells may differ in that we would also predict that they would be dependent on
antigen presentation in vivo. However whether this is required for activated,
transduced T cells is unclear.
Overall these data show that in these B16.F10 and B16 NP GFP models, T cells
transduced with anti-tumour TCRs are able to induce some level of tumour
control. It is possible that T cell expansion could be enhanced by vaccination
with tumour antigen however this is less effective than pre-conditioning
irradiation and little synergy has been reported when vaccination is used in
combination with irradiation (De Witte et al. 2008a). This has the added benefit
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for this project in establishing a tractable model in which the role of endogenous
DC can be addressed without the complication of an additional vaccine. With
these models for partial tumour control by transferred T cells set up the next
chapter will establish a murine model in which DC can be depleted, to allow the
effect of DC depletion on transferred T cells to be assessed.
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cell depletion in tumour bearing mice
To examine the role of endogenous DC in the anti-tumour response mediated by
TCR transduced T cells we chose to use a model in which we could transiently
deplete DC. Conditional DC depletion was achieved using the well described
CD11c.DTR model (Jung et al. 2002). In this model the high-affinity diphtheria
toxin receptor (DTR) is placed under the control of the CD11c promotor. Injection
of CD11c.DTR mice with diphtheria toxin (DT) results in the specific depletion of
CD11c+ cells, primarily the DC compartment. The advantages of such a model
as opposed to a constitutive DC depletion/knockout model are threefold; it allows
for temporal control of DC depletion and it avoids both developmental concerns
or the appearance of compensatory mechanisms that are both associated with
mice permanently depleted of cell subsets (Sapoznikov and Jung 2008).
However one limitation of this model is that aberrant CD11c expression on
non-haematopoetic tissue leads to lethality after multiple DT injections (Zaft
et al. 2005). Whilst generation of CD11c.DTR bone marrow chimeras can
restrict DTR to the haematopoetic system and therefore allow multiple DT
injections, presence of radio-resistant cells can obfuscate results. An alternative
therefore is to use the closely related CD11c.DOG model (Hochweller et al.
2008). These mice express the same high-affinity DTR but under the control of
the whole CD11c locus control region, rather than just the CD11c promotor. This
results in a tighter restriction of the DTR to CD11c+ haematopoetic cells and
mice can be injected with DT multiple times without toxicity.
Whilst DC depletion with the CD11c.DTR or CD11c.DOG models are powerful
tools to study DC biology there are numerous caveats and limitations to using
these depletion models. These include the expression of CD11c on other cell
types and the appearance of monocytosis/neutrophilia following DT injection
(Sivakumaran et al. 2016; Tittel et al. 2012; Van Blijswijk et al. 2013). Therefore
in order to accurately assess the ability of transduced T cells to control tumour
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growth in the absence of DC these limitations must be acknowledged. Moreover
whilst these models have frequently been used to deplete DC in lymphoid
organs, little has been done to show the efficacy or effects of DC depletion in the
tumour. An array of different myeloid cells infiltrate the complex tumour
microenvironment, including numerous DC subsets (Broz et al. 2014; Gajewski
et al. 2013). In order to address the effect DC depletion has on the ability of
transferred T cells to control tumour growth, it is paramount that the effect of DC
depletion in the tumour is addressed. The aim of this chapter therefore is
to:
1. Establish the CD11c.DTR model and define the extent of DC depletion in
tumour bearing mice.
2. Assess the depletion of other CD11c+ cell types including:
• Neutrophils and macrophage/monocyte populations
• Activated T cells
• NK cells
3. Establish the CD11c.DOG model in tumour bearing mice
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5.1 Depletion of CD11c+ cells by DT injection in
CD11c.DTR mice
To establish the DC depletion model, we first tested the efficiency of DC depletion
from the spleen of CD11c.DTR mice. 1 day after injection of 100ng DT or PBS,
mice were sacrificed and DC depletion in the spleen was assessed by FACS.
The CD11c.DTR mice carry the high affinity DTR fused to GFP under the control
of the CD11c promotor (Fig 5.1A). CD11chigh cells are therefore both GFP and
MHCII positive, and either marker can be used alongside CD11c to identify DC
(Fig 5.1B). Following DT injection, 91±6% of GFP+ or 90±7% of MHCII+ CD11c
cells were depleted (Fig 5.1C). As DC return to homeostatic levels after 3 days
post-DT injection, DC depletion was also measured in the spleen 48 hours after
DT injection. Whilst depletion was lesser by this time-point, the majority of DC
(74±14%) were still depleted (Fig 5.1C).
In addition to DC depletion, significantly higher frequencies of neutrophils and
monocytes have also been noted in the spleens of DT injected mice
(Sivakumaran et al. 2016; Tittel et al. 2012). To examine this in our experiments,
spleens were stained for CD11b+ Ly6Chigh monocytes and CD11b+ Ly6Cint
neutrophils. As expected, 48 hours after DC depletion there were significantly
higher frequencies of neutrophils and monocytes present in the spleen. Together
these results were consistent with previously published DC depletion
experiments from our laboratory using this model (Sivakumaran et al.
2016).
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Figure 5.1: Depletion of splenic CD11c+ cells by DT injection in CD11c.DTR mice.
(A) Schematic representation of the DTR/GFP transgene.
(B) CD11c.DTR mice were injected i.p. with 100ng DT or PBS. The next day mice were
sacrificed and spleens stained for expression of CD11c, GFP and MHCII. DC were gated
on scatter and PI- cells, identifying DC as either CD11c+ GFP+ or CD11c+ MHCII+.
(C,D) Summary data from 2-3 experiments showing % depletion of GFP+ or MHCII+
CD11c cells (C) or the % depletion on day 1 and 2 post-injection (D).
(E) CD11b+ Ly6Chigh monocytes and CD11b+ Ly6Cint neutrophils were pre-gated on
scatter, PI- cells and CD45+ cells, then distinguished by Ly6C expression as shown in the
representative FACS plots. Summary data shows frequency of monocytes or neutrophils
in the spleen after DT injection. Data is from 4 mice per group from 1 experiment.
Statistical test: unpaired T test. **: p0.01, ***: p0.001.
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5.2 Frequency and phenotype of tumour-resident
DC
To assess whether DT injection efficiently depletes DC from the tumour we firstly
needed to establish a method of identifying tumour-resident DC. C57BL/6 mice
bearing B16.F10 tumours were sacrificed on day 17 (as outlined in Fig 5.2A).
Tumour infiltrating myeloid cells were identified according to a recent panel
described by Broz et al. 2014, and as shown in Fig 5.2B. Tumour cells could
largely be excluded based on size, then live singlets were selected and any
remaining tumour cells were excluded by gating on CD45+ cells. These then split
into a CD11b+ Ly6C+ monocyte/neutrophil population, and a Ly6C- population.
In contrast to the spleen, it is difficult to separate tumour infiltrating neutrophils
and monocytes based on Ly6C expression, although the tumour appears to be
dominated by Ly6Chigh monocytes. The Ly6C- cells contained a broad CD11c+
MHCII+ population, referred to here as ‘APCs’. However as this APC population
contains both DC and macrophage populations, DC were further selected by
expression of the DC specific marker CD24. These CD24+ DC themselves then
split into either CD103+ cDC1 or CD11b+ cDC2, mirroring the DC populations
present in tissues (Merad et al. 2013).
Summary data showing the infiltration of these cell types in B16.F10 tumours is
shown in Fig 5.2C, either as the frequency of the total CD45+ population or as
the corresponding absolute number. These data show that whilst the vast
majority of myeloid cells in the tumour are of monocyte origin, there is a
consistently detectable CD24+ DC population, which is primarily composed of
CD103+ DC. The low tumour infiltration of cDC1 and cDC2 compared to
monocytic cells has been confirmed in other recent studies (Broz et al. 2014;
Guilliams et al. 2016; Salmon et al. 2016). However despite their low frequency,
these CD103+ DC have been previously identified as the dominant
tumour-resident population capable of cross-presenting tumour antigen to CD8 T
cells, both in the tumour and in tumour draining LNs (Broz et al. 2014; Salmon
et al. 2016).
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To assess how these myeloid cells infiltrate the tumour over time, the same
panel was run on samples taken at different points in the development of the
tumour, as outlined in Fig 5.3A. These data suggest that from day 7 to 17
tumours become increasingly cellular as the frequency of both the
monocyte/neutrophil population and the APC/CD24+ DC population increases
(Fig 5.3B). Within the DC population this increase appears to be driven by
increased infiltration of the CD103+ population, as the amount of CD11b+ DC
remains level. When tumours become large and well established by day 21 there
appears to be less infiltration by all myeloid cells. By this time point the
tumour-infiltrating DC had also started to express PD-L1. This appeared to be
largely absent on DC at day 7 and began to increase as tumours became more
established (Fig 5.3C). However these data have been generated from relatively
few mice, so these experiments would need to be repeated to confirm this.
136
Chapter 5 Section 5.2
5.2
BL/6
5x105 
B16.F10 s.c.
0 17
Sacrifice mice
Harvest spleen 
and tumour
Cell frequencies (of total)
Mo
no
/N
eu
tro AP
C
CD
24
 D
C
CD
11
b+
CD
10
3+
0
20
40
60
80
100
PBS d17 from ACH21 26 24
%
Mo
no
/N
eu
tro AP
C
CD
24
 D
C
CD
11
b+
CD
10
3+
0
1
2
3
4
5
5
15
25
35
45
55
%
 o
f C
D
45
.2
+
copy but % of CD45.2+
n=11
Tumour
49.634.4
0 103 104 105
Ly6c
0
-10 3
103
104
105
CD
11
b
34.3
0 103 104 105
MHCII
0
103
104
105
CD
11
c
19.2
0 103 104 105
F4/80
0
-10 3
103
104
105
CD
24
24.8
70.9
0-10 3 103 104 105
CD103
0
-10 3
103
104
105
CD
11
b
5.49
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
SS
C-
A
90.8
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
FS
C-
W
61.8
0 50K 100K 150K 200K 250K
FSC-A
0
-10 3
103
104
105
PI
98.3
0 50K 100K 150K 200K 250K
SSC-A
0
-10 3
103
104
105
CD
45
.2
49.634.4
0 103 104 105
Ly6c
0
-10 3
103
104
105
CD
11
b
34.3
0 103 104 105
MHCII
0
103
104
105
CD
11
c
19.2
0 103 104 105
F4/80
0
-10 3
103
104
105
CD
24
24.8
70.9
0-10 3 103 104 105
CD103
0
-10 3
103
104
105
CD
11
b
5.49
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
SS
C-
A
90.8
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
FS
C-
W
61.8
0 50K 100K 150K 200K 250K
FSC-A
0
-10 3
103
104
105
PI
98.3
0 50K 100K 150K 200K 250K
SSC-A
0
-10 3
103
104
105
CD
45
.2
49.634.4
0 103 104 105
Ly6c
0
-10 3
103
104
105
CD
11
b
34.3
0 103 104 105
MHCII
0
103
104
105
CD
11
c
19.2
0 103 104 105
F4/80
0
-10 3
103
104
105
CD
24
24.8
70.9
0-10 3 103 104 105
CD103
0
-10 3
103
104
105
CD
11
b
5.49
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
SS
C-
A
90.8
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
FS
C-
W
61.8
0 50K 100K 150K 200K 250K
FSC-A
0
-10 3
103
104
105
PI
98.3
0 50K 100K 150K 200K 250K
SSC-A
0
-10 3
103
104
105
CD
45
.2
49.634.4
0 103 104 105
Ly6c
0
-10 3
103
104
105
CD
11
b
34.3
0 103 104 105
MHCII
0
103
104
105
CD
11
c
19.2
0 103 104 105
F4/80
0
-10 3
103
104
105
CD
24
24.8
70.9
0-10 3 103 104 105
CD103
0
-10 3
103
104
105
CD
11
b
5.49
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
SS
C-
A
90.8
0 50K 100K 150 200 250
FSC-A
0
50K
100K
150K
200K
250K
FS
C-
W
61.8
0 50K 100K 150 200 250
FSC-A
0
-10 3
103
104
105
PI
98.3
0 50K 100K 150 200 250
SSC-A
0
-10 3
103
104
105
CD
45
.2
FSC-AFSC-A FSC-A SSC-A
FS
C-
W
PI
CD
45
.2
SS
C-
A
0 103 104 105
Ly6c
0
-10 3
103
104
105
CD
11
b
0 103 104 105
MHCII
0
103
104
105
CD
11
c
0 103 104 105
F4/80
0
-10 3
1 3
104
105
CD
24
0-10 3 103 104 105
CD103
0
-10 3
1 3
104
105
CD
11
b
34.4 49.6
Monocytes/
Neutrophils
0 103 104 105
Ly6c
0
-10 3
1 3
104
105
CD
11
b
0 103 104 105
MHCII
0
103
104
105
CD
11
c
0 103 104 105
F4/80
0
-10 3
1 3
104
105
CD
24
0-10 3 1 3 104 105
CD103
0
-10 3
1 3
104
105
CD
11
b
0 103 104 105
Ly6c
0
-10 3
103
104
105
CD
11
b
0 103 104 105
MHCII
0
103
104
105
CD
11
c
0 103 104 105
F4/80
0
-10 3
103
104
105
CD
24
0-10 3 103 104 105
CD103
0
-10 3
103
104
105
CD
11
b
0 103 104 105
Ly6c
0
-10 3
103
104
105
CD
11
b
0 103 1 4 105
MHCII
0
103
104
105
CD
11
c
0 103 104 105
F4/80
0
-10 3
103
104
105
CD
24
0-10 3 1 3 104 105
CD103
0
-10 3
103
104
105
CD
11
b
34.3 19.2
24.8
70.9
APC CD24 DC
CD11b
CD103
MHCII F4/80 CD103Ly6C
CD
11
b
CD
11
c
CD
24
CD
11
b
A
B
C
Mo
no
/N
eu
tro AP
C
CD
24
 D
C
CD
11
b+
CD
10
3+
0
2×104
4×104
6×104
1×105
3×105
5×105
7×105
A
bs
ol
ut
e 
nu
m
be
r
Summary pbs numbersAbsolute numbers
n=8
M
no
/N
eu
tro AP
C
CD
24
 D
C
CD
11
b+
CD
10
3+
0
20
40
60
80
100
PBS d17 from A H21 6 24
%
Mo
no
/N
eu
tro AP
C
CD
24
 D
C
CD
11
b+
CD
10
3+
0
1
2
3
4
5
5
15
25
35
45
55
%
 o
f C
D
45
.2
+
copy but % of CD45.2+
Figure 5.2: Frequency and phenotype of DC in established B16.F10 tumours.
(A) Experiment outline. C57/BL6 mice were injected with B16.F10 and sacrificed 17 days
later once tumours were well established.
(B) Representative FACS plots showing gating strategy to identify tumour-resident DC.
Live, CD45+ cells were gated as shown to identify a monocyte/neutrophil population and
a CD103 or CD11b+, CD24+ DC population.
(C) Summary data showing either the mean frequency of cell types from the total CD45+
population or the corresponding absolute number. Frequencies are from a total of 11
mice, from 3 independent experiments ±SD. Absolute numbers are from a total of 8
mice, from 2 independent experiments ±SD.
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Figure 5.3: Frequency and phenotype of DC in developing B16.F10 tumours over time.
(A) Experiment outline. Tumour bearing mice were sacrificed on day 7, 14 and 21 and
compared to previous tumours taken from day 17.
(B) Summary data showing the mean frequency of cell types from the total CD45+
population. Data is from a total of 2-4 mice per group, from 2 independent experiments
±SD. (day 7: n=2, day 14: n=4, day 21: n=2).
(C) Expression of PD-L1 on CD24+ DC. Representative FACS plots of CD24+ DC at day
17 and day 21. Summary data shows the mean frequency of PD-L1+ DC with 2 mice per
group from 1 experiment.
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5.3 Depletion of tumour-resident DC by DT
injection
With a strategy to identify tumour-resident DC now established, the degree to
which these cells are depleted in CD11c.DTR mice following DT injection can be
assessed. As shown in Fig 5.4A, CD11c.DTR mice were injected with B16.F10
tumours. On day 15, when the tumour was well-established, mice were injected
i.p. with DT or PBS and 2 days later tumours were harvested and stained to
measure the depletion of DC. Whilst there was no overall change in the
frequency of the broad APC population, DT injection caused specific depletion of
CD24+ DC (Fig 5.4B). As summarised in Fig 5.4C, DT injection depleted on
average 56±16% of CD24+ DC. This depletion appears to be mainly due to loss
of the more abundant CD103+ DC, rather than depletion of the CD11b+ DC. This
is reflected in the ratio of CD103:CD11b DC, which is 4:1 in PBS treated mice
and falls to 1:1 after DT injection (Fig 5.4D). Interestingly, despite DC depletion
mediated neutrophilia and monocytosis in the spleen, there was no difference in
the infiltration of neutrophils/monocytes into the tumour. This suggests that
although these cells may expand in the spleen, they do not traffic to the
tumour.
To give a greater reflection of the loss of these CD24+ DC following depletion,
absolute numbers of the myeloid cell populations were also calculated (Fig
5.4E). As with the change in frequency, there were markedly fewer CD24+ DC
and CD103+ DC in the tumours of DT treated mice. However whereas the
change in frequency only affected this CD24+ DC population, there was a
significant loss in cell number in all the myeloid populations. This suggests that,
while overall fewer cells infiltrate tumours after DT injection, this primarily affects
CD24+ DC.
The preferable depletion of CD103+ rather than CD11b+ DC was surprising as
both populations would be expected to express CD11c and be depleted in this
model. To address this directly, CD11c expression on the isolated CD103 or
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CD11b DC was measured. Fig 5.4F shows the median CD11c expression, or
the separate GFP expression from the DTR/GFP transgene. In PBS treated
mice both CD103 and CD11b DC expressed similar amounts of endogenous
CD11c. However whereas CD11c expression is closely linked to GFP
expression in the CD103 DC, this is not true of CD11b DC. Surprisingly these
cells express significantly lower GFP, relative to their CD11c expression.
Likewise the CD103 and CD11b cells that persist after DT injection express
similar levels of CD11c. However as in PBS treated mice, GFP expression in
CD11b DC is significantly lower than CD11c expression. Together these data
suggest that the introduced CD11c promotor faithfully expresses the DTR/GFP
transgene in CD11c+ CD103 DC which are then susceptible to depletion.
However the CD11c+ CD11b DC are able to express CD11c without expressing
the DTR transgene. The decrease in GFP MFI in CD11b cells after depletion
however suggests that those cells that do express the DTR will be depleted, but
this is only a subset of the CD11b population. This differential DTR expression is
in line with previously published data which has suggested that the CD11b DC,
unlike CD103 DC, are a heterogenous population that may have a varied
ontology (Guilliams et al. 2016; Merad et al. 2013). To further highlight this
heterogeneity a similar result has been found in zDC.DTR mice, in which the
DTR is expressed in all Zbtb46+ DC. Although both CD103+ cDC1 and CD11b+
cDC2 derive from Zbtb46+ pre-DC, DC depletion in this model is specific to
cDC1 (Broz et al. 2014). In the CD11c.DTR context, it appears that some of the
heterogenous CD11b DC express CD11c without activating the minimal CD11c
promotor which drives DTR/GFP expression.
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Figure 5.4: DT injection depletes the tumour-resident CD24+ DC population
(A) Experiment outline. Tumour bearing CD11c.DTR mice were injected with DT or PBS
on day 15 and sacrificed 48 hours later.
(B) Summary data showing the mean frequency of myeloid cells from the total tumour-
resident CD45+ population after injection of DT or PBS.
(C) Summary data showing the depletion of CD24+ DC from the tumour.
(D) Summary data showing the ratio of CD103:CD11b DC in the tumour-resident CD24+
DC population after injection of DT or PBS.
(E) Absolute numbers of tumour-resident myeloid cell populations after injection of DT or
PBS. Data are from a total of 6-8 mice per group, from 2-3 independent experiments
(mean ±SD). (8 PBS treated mice, from 3 experiments, 6 DT treated mice from 2
experiments). Statistical test: unpaired T test. *: p0.05, **: p0.01.
(F) Median fluorescence intensity of CD11c expression (black) and GFP expression
(green) in CD103 or CD11b DC. Data is from 4 mice per group from 1 experiment.
Statistical test: paired T test. *: p0.05, **: p0.01.
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5.4 Depletion of other CD11c+ cells beside DC
Whilst CD11c.DTR mice are valuable models for depleting DC, there are some
concerns over whether other CD11c+ cells are also depleted. Although DT
injection has been shown not to deplete splenic macrophages and B cells (Jung
et al. 2002), CD11c expression on some NK cell populations (Blasius et al.
2007) and activated T cells (Beyer et al. 2005; Lin et al. 2003) has been
reported. Published data has shown that NK cells aren’t depleted in this model
(Lucas et al. 2007) however we confirmed this in our experiments. FACS
staining for these cells was also performed from the experiments as described in
Fig 5.4A. Concordant with previous studies there was no difference between the
frequency of NK1.1+ cells in the spleens of mice treated with DT or PBS (Fig
5.5A and B). However in the LN there appeared to be a trend towards a greater
frequency of NK1.1+ cells following DT injection, although this wasn’t significant.
In contrast, NK cells appeared to be at a lower frequency in the tumour following
DT injection. These tumour-resident NK cells differ from those found in the LN
and spleen in that they express higher levels of CD11c (Fig 5.5C). Interestingly,
after DT injection the NK cells present in the tumour express significantly lower
levels of CD11c than after PBS injection, suggesting that the CD11chigh NK cells
are susceptible to depletion.
Although T cells have been shown to express CD11c, this is primarily after viral
infections (Beyer et al. 2005; Lin et al. 2003), and little is known about CD11c
expression in tumour-infiltrating lymphocytes. To address this we stained for
CD11c expression on T cells in tumour bearing mice to see if these cells were
susceptible to killing by DT injection. CD11c expression on CD8 and CD4 T cells
was distinguished from CD11c+ CD8 and CD4 DC by pre-gating live, CD45+
cells on the T cell markers Thy1.2 and CD3 (Fig 5.6A). Whereas only relatively
few T cells expressed CD11c in the spleen and LN, up to 40% of T cells in the
tumour were CD11c+ (Fig 5.6B). Despite this mixed expression, following DT
injection the frequency of CD11c+ CD4 T cells was significantly lower in the
spleen, LN and tumour. CD8 T cells followed a similar pattern but only had
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significantly lower CD11c+ frequency in the tumour. This suggests that, similar to
the NK cell depletion in Fig 5.5, depletion of T cells occurs primarily in the
tumour where CD11c expression is highest. As shown in Fig 5.5C, after
depletion the expression of CD11c on the remaining CD8 or CD4 T cells is
significantly lower than compared to PBS treated mice. This is true of the T cells
found in the tumour and LN, but not spleen.
These data suggest that depletion of CD11chigh cells in the CD11c.DTR model
can result in NK cell and T cell depletion. In the steady state, CD11c expression
on these cells is low, however infiltration into the tumour is associated with
increased CD11c expression on NK and T cells. Therefore depletion of these
cells may need to be addressed when using tumour-bearing CD11c.DTR
mice.
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Figure 5.5: Effect of DT injection on NK cells.
(A) Representative FACS plots showing gating of NK cells. Cells were pre-gated on live
(FSC/SSC and PI-) and CD45+ cells. NK cells were then identified as NK1.1+ and CD3-
cells.
(B) Summary data showing the frequency of NK cells in spleen, LN and tumour following
DT or PBS injection.
(C) Summary data showing median fluorescent intensity of CD11c on NK cells.
Data is from a total of 6-7 mice per group, from 2 independent experiments. Statistical
test: unpaired T test. *: p0.05.
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Figure 5.6: Depletion of CD11c+ tumour-resident T cells.
(A) Representative FACS plots showing gating of CD11c+ T cells. Cells were pre-gated
on live (FSC/SSC and PI-) and CD45+ cells. T cells were then identified by expression of
Thy1.2 and CD3, from which CD8 and CD4 T cells were identified.
(B) Summary data showing the frequency of CD11c+ CD8 and CD4 T cells in spleen, LN
and tumour following DT or PBS injection.
(C) Summary data showing median fluorescent intensity of CD11c on CD8 or CD4 T cells.
Data is from a total of 6-7 mice per group, from 2 independent experiments. Statistical
test: unpaired T test. *: p0.05, **: p0.01, ****: p0.0001
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5.5 Effect of DT injection on B16.F10 phenotype
As the B16.F10 tumour is from C57BL/6 origin and transplanted into
CD11c.DTR mice, it will not express the high affinity DTR like the endogenous
cells of these mice. However we wanted to check whether the changes to the
tumour microenvironment described above would have an effect on the B16.F10
tumour itself. After DT injection into B16.F10 tumour bearing CD11c.DTR mice,
we stained for the expression of MHCI and II on ex vivo isolated tumour cells. As
before (Fig 3.4B) in vitro B16.F10 cells were also activated with CASM to induce
MHCI upregulation, although in this experiment MHCII expression only
marginally increased (Fig 5.7A). Expression of both MHCI and II on ex vivo
tumour cells was much higher than in vitro B16.F10, comparable to after
activation with CASM. However in mice injected with DT, MHCII expression is
significantly lower and there is a trend towards lower MHCI expression (p=0.06).
A possible explanation for this decreased MHC expression on tumours of mice
treated with DT is that activated CD11c+ T cells in the tumour will be depleted
(as shown in Fig 5.6). Therefore there are fewer cells secreting IFN-g in vivo and
therefore less upregulation of MHC.
To assess whether this reduction in MHC upregulation on B16.F10 cells in vivo
lessens their ability to present antigen to transduced T cells, isolated B16.F10
tumours were cultured overnight with TRP2 or TRP1 transduced T cells. Both
PBS and DT treated tumours induced an IFN-g response from TRP2 or TRP1
transduced T cells in vitro, comparable to the in vitro B16.F10 controls (Fig 5.7B).
In fact although not significant there appears to be a slightly better IFN-g response
to DT treated tumours than to PBS.
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Figure 5.7: Decreased MHC expression on tumours of DT treated mice.
(A) Summary data of MHCI (H-2Kb) and MHCII (I-Ab) expression on ex vivo isolated
B16.F10 tumours after injection of DT or PBS.
(B) Summary data of IFN-g+ TRP2 or TRP1 transduced T cells after overnight culture with
ex vivo B16.F10. Cells were pre-gated on CD8+ and CD19+ lymphocytes.
Data is from 4 mice per group from 1 experiment. Statistical test: unpaired T test. n.s:
non significant, *: p0.05.
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5.6 Establishment of the CD11c.DOG DC depletion
model
Although it is a very effective tool for studying DC, the CD11c.DTR model is
limited by aberrant DTR expression on non-haematopoetic tissue (Zaft et al.
2005). Therefore the CD11c.DOG model, in which mice are able to be injected
with DT multiple times without toxicity, was also established. Whereas in
CD11c.DTR mice, the DTR transgene was placed under the control of the
minimal CD11c promotor, CD11c.DOG mice were created using BAC transfer.
This allowed transfer of the whole CD11c gene, including the associated
enhancer and silencer elements, into which the DTR transgene was inserted
(Fig 5.8A). This results in DTR expression being under the control of the CD11c
locus control region and a much tighter restriction of DTR expression to CD11c+
cells. As a result CD11c.DOG can be injected repeatedly and with much higher
doses of DT without toxicity (Hochweller et al. 2008). The CD11c.DOG
transgene also contains the model ovalbumin antigen (OVA) and GFP, although
the GFP does not give a fluorescent signal in these mice.
To test whether DC were depleted in the spleen and tumours of CD11c.DOG
mice after repeated DT injections, tumour bearing CD11c.DOG mice were
injected with DT or PBS on days 6, 9 and 12 and sacrificed on day 13 (Fig 5.8B).
Mice were injected with between 5-64 ng DT/g body weight (approximately
100-1200ng). As expected in all DT doses used, substantial depletion of splenic
DC was noted (Fig 5.8C) comparable to that seen in CD11c.DTR mice. However
although the highest dose of DT effectively depleted DC it was associated with
increased weight loss in mice (Fig 5.8D). Whilst these mice did not lose enough
weight to be sacrificed according to home office regulations, this may be a
concern with longer experiments.
As well as depletion in the spleen, depletion of DC in the tumours was also
measured. DC were identified as demonstrated previously (Fig 5.2B), although
CD64 was used to identify macrophages rather than F4/80. Whereas DC
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depletion in the CD11c.DTR mice primarily affected the CD24+ DC population, in
the CD11c.DOG model we see depletion of the broader CD11c/MHCII+ APC
population. Whilst this depletion occurs with a similar efficiency in mice injected
with 16, 32 and 64 ng of DT/g, no depletion was seen with the lowest dose
(<8ng/g). Of the remaining, undepleted CD11c/MHCII+ cells, the frequency of
CD24+ DC remains broadly similar to PBS injected mice (Fig 5.9C). Therefore
CD24+ DC are not specifically targeted although they will still have a reduced
frequency in DT treated mice because of the depletion of the parental
CD11c/MHCII+ population. Moreover whilst the ratio of CD103:CD11b+ DC does
slightly decrease after depletion, this is not significant like in the CD11c.DTR
model (Fig 5.9D).
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Figure 5.9: DC depletion in the tumours of CD11c.DOG mice.
(A) Representative FACS plots for depletion of DC in B16.F10 tumours. Cells were pre-
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MHCII, then CD24 and CD64.
(B) Summary data for depletion of total CD11c/MHCII+ APCs or CD24+ DCs from the
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5.7 Summary and conclusion
We have established two models in which DC can be conditionally depleted; the
CD11c.DTR and CD11c.DOG models. In these models tumours will develop
normally in a DC replete setting, from which DC can then be transiently
depleted. This will allow the interactions these cells have with transferred T cells
to be investigated. As expected, DC were depleted in the spleens of CD11c.DTR
and CD11c.DOG mice to similar extents, however the efficacy of DC depletion
from the tumour varied. Depletion of tumour-resident DC in CD11c.DTR mice
was specific to CD24+ DC, particularly the CD103+ population. In contrast
CD11c.DOG mice show depletion of the broader CD11c/MHCII+ cells. The
reason for the difference in these depletion patterns is unclear, though it may
reflect the different regulation of DTR expression on CD11c+ cells between the
two models. For example in CD11c.DOG mice, DTR expression is more tightly
restricted to expression of the CD11c gene, due to the inclusions of the
associated enhancers and silencers. This results in less toxicity after DT
injection, which allows for a higher dose of DT to be injected. It appears however
that this better association with CD11c expression also broadens the specificity
of DTR expression. Whereas DC depletion in CD11c.DTR mice is focused on
CD11chigh cells, depletion in the CD11c.DOG model occurs in a wider range of
CD11c+ cells. Therefore this may allow depletion of tumour-resident CD11cint
cells not depleted in the CD11c.DTR model. Depletion of DC in the spleen
however is consistent across both models as splenic DC express consistently
high CD11c and so are well depleted in both settings. Likewise as shown by the
GFP expression, endogenous CD11c expression and expression of the DTR
transgene are not necessarily linked in some cells in the CD11c.DTR mice. The
tighter restriction of DTR expression to CD11c+ cells in the CD11c.DOG model
may result in a more equal expression CD11c and DTR. Unfortunately the GFP
is not functional in the CD11c.DOG mice so more detailed experiments would be
needed to accurately assess the differences in DTR expression between these
mice and how that affects depletion of tumour-resident DC.
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These data do suggest however that there is a ongoing endogenous immune
response against the tumours of these mice. NK and T cell infiltration into the
tumours was easily detectible and CD11c expression on these cells was higher
in the tumour than lymphoid organs. CD11c expression is thought be expressed
on T cells (Lin et al. 2003) and NK cells (Aranami et al. 2006) after activation in
inflammatory settings. One obvious caveat with both these depletion models
then is that DTR expression is not strictly limited to DC, and can be expressed
on other CD11c+ cells. We found that activated T cells and, to a lesser extent NK
cells, were susceptible to depletion after DT injection in CD11c.DTR mice. This
effect was primarily noticeable in the tumour, although LN and splenic CD4 T
cells were also depleted. Although depletion of DTR expressing NK and T cells
is the likely explanation for the reduced frequency of these cells in tumours, it
remains plausible that this could instead be explained by DC depletion directly.
DC have important roles in inducing activation, expansion and effector function
of NK cells (Cooper et al. 2004) and T cells (Steinman 2007). The lack of
CD11c+ NK or T cells in the tumour might therefore be attributable to the
depletion of DC, rather than the direct depletion of these cells. Either way the
reduced frequency of T cells in the tumour following depletion could complicate
experiments designed to investigate the role of DC in tumour-specific T cell
responses. Of note however is that although DT injection can deplete
endogenous T cells in CD11c.DTR mice, adoptively transferred T cells can be
used from a BL/6 origin, and so won’t express the high affinity DTR.
Like transferred T cells, the injected B16.F10 tumours did not originate from
CD11c.DTR mice so they will not be depleted by DT injection. However the
reduction in CD11c+ cells in the tumour microenvironment does appear to
reduce MHC expression on the tumour. This is likely caused by depletion of
activated T cells, thereby limiting the expression of IFN-g and reducing MHC
up-regulation. The subsequent effect this MHC loss has on the ability of the
immune response to recognise the tumour in vivo is unclear, although ex vivo
B16.F10 tumours from DT treated mice, cultured with transduced T cells were
able to present as well as, if not better than, tumours from PBS treated mice.
This could be explained by the previously demonstrated IFN-g mediated
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upregulation of PD-L1 on tumours (Fig 3.4C). In this setting, diminished PD-L1
expression (mediated by reduced IFN-g in vivo) may counteract the reduced
MHC expression.
This endogenous immune response against the tumour is also suggested by the
increase in tumour-resident DC as the tumour grows. However by day 21 when
tumours are fully established DC frequency appears to decrease, whilst the
remaining DC express more PD-L1. This may reflect the immuno-editing aspect
of tumour growth as the tumour eventually becomes adept at subverting or
avoiding the immune response. However the effect of DC depletion on this
PD-L1-expressing DC population was not fully examined in these
experiments.
Whilst the effects of DC depletion have been well examined in CD11c.DTR mice
in this study, they have not been addressed in CD11c.DOG to the same extent. As
DTR expression is more restricted in these mice, one might predict that T cells
and NK cells are not as affected as in CD11c.DTR mice. Although conversely
this allows for injection of higher-doses of DT which may enhance depletion, or
allow for depletion of CD11cint cells. Moreover if the reduced frequency of NK
and T cells is mediated more by depletion of DC themselves, then this should
be similar in both models. These experiments would need to be repeated in the
CD11c.DOG mice to determine these effects.
However these data have shown that we are capable of depleting DC from the
spleens and tumours of B16.F10 tumour bearing mice. This detailed
characterisation of the DC depletion models, together with the tumour models
established in chapters 3 and 4 will allow us to examine the role of DC after the
adoptive transfer of TCR transduced T cells.
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depletion on TCR transduced T cells in
vivo
With the CD11c.DTR and CD11c.DOG models established, we could then
investigate the ability of transduced T cells to control tumour growth with or
without DC depletion. DC play a fundamental role in orchestrating T cell
responses by priming naive T cells and by regulating effector T cell responses in
the tumour and tissues. However in order to transduce adoptively transferred T
cells with retrovirus, the T cells have to be activated in vitro. It is therefore
unclear whether the effector function of pre-activated, transduced T cells
depends on interaction with APC in the same way an endogenous T cell
response would. We hypothesised that depletion of DC would lead to an inferior
response by adoptively transferred T cells.
This chapter therefore aims to address these questions by using the CD11c.DTR
model to elucidate the effect of DC depletion on tumour-specific TCR transduced
T cells. We chose initially to use the B16.F10 model in combination with TRP2
transduced T cells as we and others have shown that TRP2 transduced T cells
are capable of inducing transient tumour control. For the DC depletion we chose
to deplete DC 1 day before T cells were injected, and this was then maintained
for a further 8 days after T cell transfer. This was designed to assess the effect
of DC depletion during the time the transferred T cells would normally mediate
tumour control. However this would require repeated DT injections every 3 days,
so CD11c.DTR BM chimeras were made to prevent the toxicity associated with
repeated injections in CD11c.DTR mice. However in this model we chose to forgo
the pre-conditioning irradiation before T cell transfer. Whilst this may limit the
ability of the transduced T cells to control tumour growth, it will exclude the role
of DC in the homeostatic expansion of transferred T cells during lymphopenia
(Zaft et al. 2005). Moreover, an additional stage of pre-conditioning irradiation
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in BM chimeras may be poorly tolerated, especially after DT injection. These
experiments were therefore primarily focused on the effect of DC depletion on the
expansion rather than tumour control, of TRP2 transduced T cells in vivo.
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6.1 Transferred T cells accumulate in CD11c.DTR
mice despite DC depletion
To address the effect of DC depletion on the ability of TRP2 transduced T cells
to expand in vivo, the experiment as outlined in Fig 6.1A was performed. Bone
marrow chimeras were made by transferring CD11c.DTR bone marrow into
C57BL/6 recipients. After mice had reconstituted they were injected with
B16.F10 tumour cells. 7 days later, mice were treated with a total of 4x106 CD8
sorted splenocytes which congenically expressed Thy1.1 to allow easy tracking
of transferred cells into Thy1.2 recipients. These cells were transduced with
TRP2 CD19 and injected into mice 1 day after transduction. Remaining cells
were cultured in vitro to assess transduction efficiency. Transduced cells were
93% CD8 and Thy1.1+, and had an initial transduction efficiency of 17%,
although this rose to 31% by day 3 post transduction (Fig 6.1B). As a total of
4x106 Thy1.1+ cells were injected, the total number of TRP2 transduced cells
injected per mouse was ~1.2x106. Mice were injected with DT or PBS on days 6,
9 and 12 to deplete DC. Therefore in this setting DC would be depleted during
the first week after T cell transfer, but then return to homeostatic levels by day
15. Control mice were routinely taken on day 13 to confirm DC depletion.
Although injection of DT into mice induced relatively modest weight loss (<10%),
this was not sufficient to necessitate their sacrifice (Fig 6.1C).
The ability of TRP2 transduced T cells to control B16.F10 growth did not appear
to be different in either PBS or DT treated mice (Fig 6.1D). However in both
settings this control was very limited and it appeared that neither group were
able to control tumour growth. However in the absence of pre-conditioning
irradiation this lack of control was not unexpected.
However as tumours grew to >15mm by days 18-25, mice were sacrificed.
Tumours were harvested, alongside spleens and tumour-draining inguinal LN,
and stained to identify the frequency of transferred T cells (Fig 6.2A). Transferred
T cells could easily be identified from within the CD8 population due to
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expression of the congenic marker Thy1.1. Despite DC depletion the frequency
of total CD8+ cells in the tumour and LN was similar between PBS and DT
treated mice, however there did appear to be fewer CD8 T cells in the spleens of
DT treated mice (Fig 6.2B), although this was not significant. However contrary
to our initial hypothesis, the frequency of transferred (Thy1.1+) T cells in this
CD8+ population was greater after DC depletion in all organs, albeit only
significantly different in the spleen. As this population of transferred Thy1.1+ T
cells contains both transduced and untransduced T cells, the frequency of the
transduced, CD19+ Thy1.1 population was also measured. Like the total Thy1.1
population, the frequency of transduced T cells showed a similar trend towards
greater accumulation after DC depletion. This suggests that this accumulation of
transferred T cells occurred in both the transduced and untransduced population
and was not dependent on whether the T cells expressed an anti-tumour TCR or
not.
A potential explanation for this increased frequency of introduced T cells is that if
endogenous T cells were being depleted from within the CD8 population, this
could skew the percentages in favour of the transferred T cells. However the
frequency of the endogenous (Thy1.1-) CD8 T cells after depletion mirrored what
was seen in the total CD8 population. There was a trend towards decreased
frequency in the spleen, but no difference in the LN and tumour (Fig 6.3B). This
may explain why the increase in transferred T cell frequency is the most
prominent in the spleen, due to a reduction in the endogenous T cells from this
population.
However to address this, the absolute numbers of transferred T cells were also
calculated (Fig 6.3B). Surprisingly, the absolute number of endogenous CD8 T
cells were lower in spleen, LN and tumour after DC depletion, although this was
not significant. Whilst this may be expected in the spleen, the frequencies of
endogenous CD8 T cells in the LN and tumour were the same after DC depletion.
This suggests than in the LN and tumour particularly, there is an overall loss of
cellularity after DC depletion. However in contrast to the endogenous CD8 T cells,
the transferred Thy1.1+ T cells appeared to accumulate in greater numbers in the
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tumour and spleen, although not in the LN. However these differences were not
significant in this experiment, so further repeats would be needed to confirm this.
It is unclear why the response from T cells in the LN differs from those in the
spleen or tumour, however in comparison very few T cells were collected from the
LN which could affect the quality of this data.
As the transferred cells seemed to be accumulating to a greater extent after DC
depletion, the differentiation status of these cells was also assessed. We
characterised differentiation based on the expression of CD62L and CD127
(naive: CD62L+ CD127+, memory: CD62L- CD127+ or effector: CD62L- CD127-,
as shown in Fig 6.2A). As expected there was a selective expansion of effector
phenotype T cells in the tumour compared to the spleen or LN, however in all
organs the differentiation status of the endogenous CD8 T cells was similar
between PBS and DT treated mice (Fig 6.4). Likewise the phenotype of
transduced T cells was similar between PBS and DT treated mice in the LN and
tumour, but not in the spleen. After DT injection, transduced T cells in the spleen
acquired a significantly less naive, more effector phenotype. It is unlikely that
this is a systemic effect following DT injection, as it occurred only in the
transferred T cell population, not in endogenous T cells. Moreover this enhanced
effector phenotype presented in the spleen, where the greatest enhancement in
the accumulation of transferred T cells was seen (Fig 6.2/6.3). This suggests
that the acquisition of an effector phenotype is linked to the greater accumulation
of transferred T cells.
Taken together, these data suggest that, whilst DC depletion limits endogenous
T cell accumulation, it does not inhibit the transferred T cells. Indeed in the
spleen and tumour, DC depletion may even enhance the accumulation of
transferred T cells. However the majority of these differences are not statistically
significant. Repeated experiments with more mice per group would generate
more convincing data. However as shown by this and previous experiments,
depletion of endogenous T cells, particularly in the tumour, may have a
confounding effect on these experiments. Although the apparent increase in
absolute numbers of transferred T cells suggests that the increase in Thy1.1
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frequency isn’t as a result of skewed CD8 frequencies following endogenous T
cell depletion, there is an alternative explanation. Expansion of transferred T
cells could be mediated by reduced competition for cytokines following
endogenous T cell depletion. To address these concerns we chose to repeat
these experiments in a DC depletion model that would remove the potential to
deplete endogenous T cells. These experiments are discussed in more detail in
the next section.
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Figure 6.1: Adoptive transfer of TCR transduced T cells in DC depleted mice.
(A) Experiment outline. CD11c.DTR bone marrow chimeras were generated and once
reconstituted, injected with B16.F10. Mice were treated with 4x106 Thy1.1+ CD8+ TRP2
transduced T cells. One day prior to T cell transfer (day 6) mice were injected with PBS
or DT to depleted DC. DC depletion was maintained for 8 days after T cell injection by a
further 2 DT injections, on days 9 and 12.
(B) FACS profile of CD8 sorted, TRP2 transduced T cells (as compared to mock
transduced) on day 1, 2 and 3 after transduction.
(C) Change in weight after DT or PBS injection.
(D) Effect of DC depletion on B16.F10 tumour size in mice treated with TRP2 transduced
T cells.
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Figure 6.2: DC depletion promotes enhanced frequency of transferred T cells.
(A) Representative FACS plots for gating of tumour-resident, transferred T cells. Cells
were gated on live, CD45+ singlets. T cells were then identified by expression of CD8
and Thy1.1. Differentiation of T cells was measured by CD62L and CD127 expression.
(B) Summary data shows frequency of CD8+ cells from the total CD45+ population, or
the frequency of Thy1.1+ or CD19+ Thy1.1+ cells from the CD8+ population in spleen, LN
and tumour. Data is from 4 mice per group, from 1 experiment. Statistical test: unpaired
T test. **: p0.01.
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6.2 Depletion of DC leads to accumulation of
transferred T cells in absence of endogenous
T cell depletion
To determine the extent to which accumulation of transferred T cells was
dependent on depletion of endogenous T cells, these experiments were
repeated in a setting designed to minimise the effect of depletion of these cells
(Fig 6.5A). To achieve this CD11c.DTR mice were crossed onto the RAG-1-/-
background in which mice lack endogenous T cell expression. CD11c.DTR x
RAG-1-/- bone marrow was used to generate bone marrow chimeras and repeat
the experiment in Fig 6.1. The only T cells present in this setting are a small
proportion of T cells that reconstitute from the BL/6 recipients and the
transferred TRP2 transduced T cells, neither of which express the high affinity
DTR. Whereas the DC compartment is reconstituted from the DTR expressing
donor bone marrow and so is able to be depleted.
As before 4x106 Thy1.1+, CD8+ T cells were injected into mice which had been
injected with either DT or PBS. Transferred T cells were 91-94% CD8 and Thy1.1+
(Fig 6.5B). Transduction efficiencies ranged from 35-56%, resulting in injection
of 1.4-2.2x106 TRP2 transduced T cells (Fig 6.5C). To ensure that DT injection
was depleting DC in these mice, control mice were sacrificed and 98-99% of
splenic DC were depleted by day 13 (Fig 6.5D). Although transferred T cells may
homeostatically expand in a T cell deplete setting, we again saw no evidence of
tumour control by TRP2 CD19 transduced T cells, in both PBS or DT treated mice
(Fig 6.5E.)
Despite an absence of T cells which were sensitive to DT in this model, the total
frequency of CD8 T cells in the spleen was reduced after DT injection (Fig 6.6A).
However the frequency of CD8 T cells in the LN and tumour remained similar. As
before, specifically gating on the endogenous (Thy1.1-) CD8 population showed
a similar effect as the total CD8 (Fig 6.7A). This suggested that DC depletion, not
depletion of endogenous T cells, was directly causing the decreased frequency
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of CD8 T cells observed in the spleens of T cell replete (Fig 6.2B) and T cell
depleted (Fig 6.6A) mice.
However although the frequency of T cells in the spleen was reduced after DC
depletion, this was not true of the transferred fraction of these CD8 T cells. The
frequency of Thy1.1+ T cells in the spleen may even have increased following DC
depletion, although this was not significant. LN resident T cells show a similarly
mild and insignificant trend towards increased frequency of transferred T cells
after depletion. Of note however was that this increase became significant in the
tumour, where the mean frequency of transferred T cells increased from 20% to
33% after DC depletion. This appeared to be driven by, but not contained to, the
transduced T cell fraction of the transferred cells. The mild (in LN and spleen) or
significant (in tumour) increase of transferred T cells was enhanced in all organs
by gating on the frequency of TRP2 expressing T cells (Vb3+ Thy1.1+), rather
than just the total transferred T cells (Thy1.1+). In accordance with this, there
were more transduced T cells in the total Thy1.1+ population after DC depletion,
although this was only significant in the spleen (Fig 6.6B).
To assess whether the changes in frequency of endogenous and transferred T
cells were reflected in changes in the numbers of these cells, absolute numbers
were recorded (Fig 6.7B). However although there was a reduced endogenous
CD8 frequency in the spleen, the was no difference in absolute numbers. This
was also true of the LN and tumour. This suggested that, as intended,
endogenous T cells were not depleted by DT injection in this model. The
reduced CD8 frequency (but not number) seen in the spleen after DC depletion
may therefore be explained by a relative increase in other cell populations.
Although this was not tested directly in these experiments, this could be as a
result of neutrophilia or monocytosis that is associated with DC depletion in the
spleen.
As before, depletion of DC in this model did not impair the accumulation of
transferred T cells in spleen, LN or tumour, which remained relatively similar in
PBS or DT treated mice. However as the frequency of Thy1.1+ cells in the
tumour were increased after DT depletion, it is surprising that this is not reflected
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in the absolute numbers. This is particularly true as the stable numbers of
endogenous T cells suggests this increase was not an effect of altered
frequencies. However the numbers of transferred T cells show much greater
variability than the frequencies, so it is possible this subtle difference is not seen
as a noticeable change in the numbers.
Lastly, the differentiation status of endogenous or transferred T cells was also
assessed after DC depletion (Fig 6.8). As in the T cell replete setting (Fig 6.4),
DC depletion did not effect differentiation of the endogenous CD8 T cells in the
spleen. However within the transferred population, the frequency of effector
phenotype cells in the spleen was significantly higher following DC depletion.
This appears to be at the expense of naive T cells which are less frequent after
depletion, whereas memory cells remained constant. Moreover, this acquisition
of an effector phenotype following DC depletion is more striking when gated on
the transferred Vb11 Thy1.1+ T cells, rather than total Thy1.1+ T cells.
Within the tumour a similar pattern emerges to the spleen. However here we do
see a difference in the endogenous T cells, which see an enhanced memory
formation after DC depletion. In the tumour the Thy1.1+ population is nearly
entirely composed of TCR transduced (Vb3+) T cells, so comparison between
untransduced and transduced transferred cells is meaningless. However, like in
the spleen, there were significantly more effector phenotype, tumour resident
transferred T cells following DC depletion, again at the expense of the naive T
cells (Fig 6.8).
These data show that although transferred T cells accumulated to a similar
extent in the LN, spleen and tumours of mice in which DC were depleted, of the
total CD8 T cells that infiltrated the tumour, a greater proportion of these were
the transferred T cells. This may also be true of transferred T cells in the spleen
and LN although this was unclear. Furthermore, in the spleen and possibly LN,
after depletion there was a selective expansion of transferred T cells which
expressed the anti-tumour TCR. This suggests that the accumulation of
transduced T cells could have be driven by exposure to antigen in vivo. These
data also suggest that the differentiation of transferred T cells was controlled by
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DC in vivo, as transferred T cells acquired a more effector, less naive phenotype
in the spleen and tumour after DC depletion. This effect was more prominent in
TRP2 TCR expressing cells, but also affects activated but untransduced,
transferred T cells. However it appears to be dependant on pre-activation in vitro
as the endogenous T cell population was largely unaffected by DC depletion.
Lastly, combined these data confirm that this accumulation of effector T cells
occurred regardless of whether the endogenous T cells were present or
not.
However the enhanced T cell accumulation shown in these experiments could
have occurred as an indirect effect of DC depletion. Although DC were depleted
for the first week after T cell transfer, this depletion was only transient. In our
model DC will have returned to homeostatic levels by day 15, and would be able
to engage with the transferred T cells for a further 5 days before mice were
sacrificed. It is therefore feasible that this DC population that reconstitutes the
depleted niche has a different phenotype from those DC that remained
undepleted in PBS treated mice. This different population of reconstituted DC
could therefore be driving the expansion of the transferred T cells.
To address whether reconstituted DC were enhancing the T cell accumulation
seen previously, the frequency of the DC populations in the tumour was
examined on day 20. Cells were gated as shown previously (Fig 5.2B), to
identify monocytes/neutrophils, APCs and CD11b or CD103+ CD24+ DC. As
expected, by this time point there was no evidence of depletion in either the
frequency or absolute number of tumour-resident DC (Fig 6.9). Interestingly the
CD24+ CD103+ DC population which was predominantly depleted in the tumour
following DT injection, repopulated the tumour to a greater degree than
non-depleted mice. Although these DC were found in a significantly higher
frequency after reconstitution, this was only mildly reflected in the absolute
numbers, which showed a similar trend but with more variability.
The CD103+ DC have previously been shown to be crucial to cross-presenting
tumour antigen and inducing T cell responses in the tumour (Broz et al. 2014;
Salmon et al. 2016). These data therefore support the hypothesis that the
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enhanced T cell accumulation in these experiments is driven by the
reconstitution of DC after depletion. The ability of these different tumour-resident
DC populations to present tumour antigen to transduced T cells was therefore
assessed in the next section.
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Figure 6.5: Adoptive transfer of transduced T cells into CD11c.DTR x RAG-1-/- mice.
(A) Experiment outline. Repeat of Fig 6.1 except irradiated BL/6 mice were reconstituted
with CD11c.DTR x RAG-1-/- bone marrow.
(B) MACS sort efficiency. Data shows percentage of CD8+, Thy1.1+ lymphocytes.
(C) Transduction efficiency of TRP2 CD19 transduced T cells on day 3-4 post-
transduction. Data shows the percentage of Vb13+, CD19+ CD8 T cells. Data is from
independent 4 experiments.
(D) Mice were sacrificed on day 13 to check depletion of DC in spleen. Data shows
percentage depletion of splenic CD11c+, GFP+ cells in DT treated mice, compared to
PBS. Data is from 3 experiments.
(E) Tumour size in mice treated with TRP2 transduced T cells and DT or PBS. Data is
from a total of 15-19 mice per group, from 4 independent experiments.
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Figure 6.6: DC depletion promotes enhanced frequency of transferred T cells in absence
of endogenous T cell depletion.
(A) Summary data shows frequency of CD8+ cells from the total CD45+ population, or
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Figure 6.7: DC depletion has limited effect on transferred T cell number in CD11c.DTR
x RAG-1-/- mice.
(A) Summary data shows frequency of Thy1.1- CD8+ cells from the total CD45+
population in spleen, LN and tumour.
(B) Summary data of absolute numbers of endogenous CD8, transferred Thy1.1 or Vb3+
Thy1.1 T cells in spleen, LN and tumour. Data is from a total of 15-19 mice per group,
from 4 independent experiments.
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Figure 6.8: T cell differentiation following DC depletion in CD11c.DTR x RAG-1-/- mice.
Naive, memory or effector phenotype was determined by expression of CD62L and
CD127 as demonstrated in Fig 6.2A. Data shows frequency of differentiated endogenous
CD8 T cells, transferred Thy1.1+ T cells or transferred Thy1.1+ transduced T cells (Vb3+)
in the spleen and tumour. Data from endogenous CD8 and total Thy1.1 groups are from a
total of 15-19 mice per group, from 4 independent experiments. Data from the transduced
Vb3+ Thy1.1+ groups are from 9-14 mice per group, from 3 independent experiments.
Statistical test: unpaired T test. ns: non significant, *: p0.05, **: p0.01, ***: p0.001.
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Figure 6.9: Frequency and number of DC upon reconstitution following depletion.
(A,B) Summary data from mice sacrificed on day 20 in Fig 6.5A. Tumour-resident myeloid
cells were identified as demonstrated in Fig 5.2B. (A) shows the mean frequency of cells
from the total CD45+ population, (B) shows the related absolute number. Data is from a
total of 15 mice, from 4 independent experiments ±SD.
Statistical test: unpaired T test. ns: non significant, *: p0.05, **: p0.01
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6.3 Reconstituted DC can cross-present tumour
antigen ex vivo
The DC that reconstitute the tumour niche after depletion may not only be
present in greater numbers but they may also have an enhanced ability to
activate T cells. Whereas tumour-resident DC are normally subverted by the
tumour and become dysfunctional, reconstituting DC could be less conditioned
by this immuno-suppressive environment and so induce T cell expansion. The
ability of these different DC populations to present antigen to transduced T cells
ex vivo was therefore assessed. CD11c+ cells from the tumours of non-depleted
(PBS), transiently depleted (DT) or continuously depleted (DT DT) mice were
MACS sorted on day 19 after tumour inoculation. The isolated CD11c+ cells
from PBS or DT treated mice were broadly similar. However the CD11c+ cells
sorted from the continuously depleted mice contained no CD24+ DC as these
had been depleted, however there was a population of CD64+ macrophages (Fig
6.10A). These cells were peptide-loaded, or left to present in vivo acquired
antigen to freshly transduced TRP2 CD19 T cells in vitro. Transduced T cells
were then stained for IFN-g to assess the ability of these isolated CD11c+ cells
to present tumour antigen (Fig 6.10B). When the CD11c+ cells were peptide
loaded, all groups were able to present to transduced T cells to similar extents.
However when cells weren’t peptide loaded differences between the groups
began to emerge. Whereas the macrophage population from DC depleted mice
(DT DT) should be able to present an in vitro loaded peptide, it is unlikely they
will be able to cross-present tumour antigen directly. Indeed the IFN-g response
to these cells was very weak. However, surprisingly the non-depleted DC, which
contain a CD103+ population able to cross-present antigen, failed to do so in this
setting. Yet the similar population of DC that reconstituted the tumour appeared
to be able to induce a slightly better IFN-g response than the other groups.
These data suggest that repopulating DC either acquire and/or cross present
tumour antigens more efficiently than the tumour-resident DC, although these
experiments would need to be repeated to confirm this.
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To investigate whether there was any phenotypic evidence for this improved
capacity to stimulate T cells we stained the isolated CD11c+ cells upon isolation
from the tumour for the expression of the inhibitory receptor, PD-L1. However
the frequency of PD-L1+ reconstituted DC was similar to non-depleted DC.
Furthermore, the frequency of PD-L1+ CD11c+ APC was also similar after PBS,
DT or prolonged DT injection (Fig 6.10C).
Together these data suggests that DC do reconstitute the tumour to a greater
extent after depletion and are better able to cross-present tumour antigen ex
vivo, although this was not significant. Although PD-L1 expression is similar
between these populations, it is possible that expression of pro-inflammatory
molecules such as CD80/CD86 may vary, although this was not investigated.
The next section attempts to address the effect of reconstituted DC directly in
vivo by investigating the accumulation of transferred T cells in mice which were
depleted of DC transiently or throughout the experiment.
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Figure 6.10: ex vivo isolation of tumour-resident DC and in vitro antigen presentation.
(A) Representative FACS plots of MACS-sorted, CD11c+ cells from B16.F10 tumours.
(B) IFN-g production by TRP2 CD19 transduced cells in vitro after culture with TRP2
peptide loaded or unloaded ex vivo isolated CD11c+ cells. Data is from 2 independent
experiments.
(C) PD-L1 expression on CD24+ DC or APC after PBS, DT or prolonged DT injection.
Data is from a total of 4-5 mice per group, from 2 independent experiments.
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6.4 Enhanced T cell accumulation is not dependent
on DC reconstitution after depletion
To test whether the skewed repopulation of DC in the tumour was driving T cell
accumulation, DT was injected every 3 days throughout the experiment to
prevent DC reconstitution. CD11c.DTR bone marrow chimeras were left
undepleted (PBS), transiently depleted as before (DT) or depleted throughout
(DT DT) (Fig 6.11A). Thy1.1+ T cells were MACS sorted and were 98% CD8 and
Thy1.1+ (Fig 6.11B). A slightly higher dose of 5x106 T cells were injected 1 day
after transduction with TRP2 CD19. By day 4 these were 67% Vb3 CD19+,
meaning ~3.3x106 TRP2 transduced cells were injected (Fig 6.11C). As before
the absence of pre-conditioning irradiation meant there was no tumour control
evident in any group (Fig 6.11D).
To check the level of DC reconstitution or depletion, spleens and tumours were
stained on day 19 for the various DC populations. As expected, continuous DC
depletion resulted in significant depletion of DC in the spleen, both in frequency
and absolute number (Fig 6.12). However there was a significantly higher
frequency and number of DC in the spleen after they reconstituted the depleted
niche. The same is true in the tumour where, as also shown in Fig 6.9, DC
reconstituted the tumour to a greater extent than non-depleted mice (Fig 6.12).
Although this was only significant in the increased frequency, the absolute
numbers showed a similar trend. However compared to either non-depleted or
reconstituted mice, the frequency and absolute number of DC in the tumour was
significantly lower after continuous depletion. Prolonged DT injection depleted
DC more efficiently than after a single dose. Whereas only 56% of CD24+ DC
were depleted in Fig 5.4, when depletion was extended, 93% of CD24+ DC were
depleted.
Based on our previous data, continued depletion of CD11c+ cells should lead to
loss of endogenous CD8 T cells in this setting. Indeed, this was evident in the
spleen but not in the LN or tumour (Fig 6.13 and 6.14A). As expected, the
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frequency of transferred T cells was greater in mice after transient depletion (DT)
than in non-depleted mice (PBS). Whilst this wasn’t significant in these
experiments, the same trend was observed in spleen, LN and tumour.
However contrary to our hypothesis, prolonged DC depletion (DT DT) also
resulted in the accumulation of transferred T cells. Indeed, this increase was
more pronounced after prolonged depletion, rather than transient
depletion/reconstitution (Fig 6.13). Due to this greater increase the trend
towards enhanced frequencies of transferred T cells became significant after
prolonged depletion in the spleen and LN. Transferred T cells also accumulated
in the tumour after DC depletion (particularly after prolonged DC depletion),
although this increase was not significant in these experiments. This trend was
carried through when gating on the transduced fraction of the transferred T cells,
which also tended to be present in greater frequencies after transient or
prolonged depletion.
In the spleen this increase in the frequency of transferred T cells could be as a
result of depleting endogenous T cells from this gate. Endogenous CD8 T cells
were found in a significantly lower frequency (6.14A) and possibly lower number
(6.14B) in the spleen after prolonged DC depletion. However the frequency and
number of endogenous CD8 T cells in the LN remained unchanged after DC
depletion and whilst there was some evidence for fewer endogenous CD8 T cells
in the tumour, this wasn’t significant. There were also significantly more
endogenous T cells in the spleens of reconstituted mice when compared to mice
with prolonged DC depletion. This pattern of increased or decreased
endogenous T cells seems to follow a similar pattern to the frequency of DC in
the spleen (Fig 6.12A). This could suggest that the T cell expansion/contraction
in the spleen is controlled by the number of DC present.
The increased frequency of transferred T cells was also partially reflected in the
absolute numbers, albeit less significantly. Whilst there were significantly more
transferred T cells in the LN after prolonged depletion, a similar trend was not
significant in the spleen. Moreover there appeared to be no difference in the
number of transferred T cells in the tumour after depletion, in contrast to the
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increased frequency. As before the number of transduced cells within the
transferred population followed a similar pattern to the total transferred T
cells.
Lastly, the differentiation status of the endogenous and transferred T cells was
assessed after transient or prolonged DC depletion (Fig 6.15). In the spleen,
depletion of DC appeared to promote a less naive, more effector phenotype in
the endogenous CD8 T cells. While there was a mild difference after transient
depletion, this was significant after prolonged depletion. A similar effect is seen
in the transferred T cells in the spleen, which also acquired a significantly less
naive phenotype, whilst possibly enhancing the memory and effector
differentiation. However unlike the previous experiment, neither the endogenous
nor transferred T cells in the tumour acquired a noticeably different phenotype
after DC depletion.
Together these data suggest that although DC do reconstitute the tumour and
spleen at higher numbers after transient depletion, DC depletion at the time of T
cell transfer, rather than this reconstitution leads to the enhanced accumulation
of transferred T cells. To gain a better understanding of how DC depletion drives
accumulation of transferred T cells, we examined the process that governs how
these T cells are able to accumulate more efficiently.
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Figure 6.11: Adoptive T cell transfer alongside prolonged DC depletion.
(A) Experiment outline. Repeat of Fig 6.1 except an extra group had further DT injections
on day 15 and 18, to ensure DC were depleted throughout the experiment.
(B) MACS sort efficiency. Data shows percentage of CD8+, Thy1.1+ lymphocytes.
(C) Transduction efficiency of TRP2 CD19 transduced T cells on day 4 post-transduction.
Data shows the percentage of Vb13+, CD19+ CD8 T cells.
(D) Mean tumour size in mice treated with TRP2 CD19 transduced T cells. DC were not
depleted (PBS), transiently depleted (DT) or continuously depleted (DT DT) . Data is from
a total of 5-6 mice per group, from 2 independent experiments.
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Figure 6.15: T cell differentiation following prolonged DC depletion.
Naive, memory or effector phenotype was determined by expression of CD62L and
CD127 as demonstrated in Fig 6.2A. Data shows frequency of differentiated endogenous
CD8 T cells or transferred Thy1.1+ T cells in the spleen, LN and tumour. DC were either
not depleted (PBS), transiently depleted (DT) or continuously depleted (DT DT). Data
is from a total of 5-6 mice per group, from 2 independent experiments. Statistical test:
unpaired T test. *: p0.05, **: p0.01.
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6.5 Investigating the effect of DC depletion on
transferred T cell proliferation
Depletion of DC at the time of T cell transfer appeared to be driving the
enhanced accumulation of transferred T cells, which suggests that these DC
normally exert a regulatory effect on transferred T cells. To investigate this
hypothesis further, the mechanism that drives this T cell accumulation was
assessed. Depletion of a regulatory DC population may be driving the
accumulation of transferred T cells by removing the constraint to their
proliferation and expansion. To address this, transferred T cells were stained for
Ki-67 to mark proliferating cells (Fig 6.16A). Ki-67+ endogenous or transferred
CD8 T cells were identified in the spleens and tumours of mice receiving PBS,
transient depletion or prolonged depletion (Fig 6.16B). In the spleen, the
frequency of Ki-67+ endogenous T cells was low (8%), as expected for
unactivated T cells. This was unaffected by DC depletion. The in vitro activated,
transferred T cells in the spleen were slightly more Ki-67+ (14%), however the
majority were still Ki-67-. There was possibly a greater frequency of Ki-67+,
transferred T cells in the spleen after depletion (either transient or prolonged)
although this was not significant due to high variability.
In the tumour the endogenous T cells had a higher Ki-67 frequency (35%) than
in the spleen, and this appeared to increase after transient depletion and further
increase after prolonged depletion. This suggests that depletion of regulatory
DC was able to promote T cell proliferation. However it is not possible to tell
whether transferred T cells in the tumour are more proliferative after DC
depletion as nearly all transferred T cells were already Ki67+ (91%). These data
suggest that whilst increased proliferation may be responsible for the enhanced
accumulation of transferred T cells, this was inconclusive.
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Figure 6.16: Ki-67 expression on endogenous and transferred T cells.
(A) Representative FACS plots showing gating of Ki-67+ CD8 T cells. Cells are pre-gated
on live, CD45+ lymphocytes.
(B) Summary data showing frequency of Ki-67+ endogenous or transferred CD8 T cells
after PBS, DT or prolonged DT injection. Data is from a total of 5-6 mice per group, from
2 independent experiments.
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6.6 Summary and conclusion
Contrary to our initial hypothesis, these data showed that DC depletion led to an
enhanced accumulation of transferred T cells. This was not true of endogenous
T cells and so appeared to be dependent on pre-activation in vitro, although
non-activated transferred T cells were not assessed. However this accumulation
appeared to be further enhanced in the population of transferred T cells that
were transduced with anti-tumour TCR. This accumulation occurred
independently of endogenous T cell depletion and favoured the acquisition of a
more effector, less naive phenotype. We hypothesised that this T cell
accumulation would either be driven by depletion of a regulatory DC population
or by DC that reconstitute the depleted niches. In line with this latter hypothesis,
we found that following DC depletion, the returning DC did reconstitute the
tumour and spleen to a greater extent than in non-depleted mice. When these
DC populations were sorted from the tumour, it appeared that reconstituted DC
were better able to cross-present tumour antigen to transduced T cells ex vivo.
However this data remains inconclusive and examination of PD-L1 expression
on these cells did not show any differences.
To investigate the role of reconstituted DC in the accumulation of transferred T
cells, the model was adapted to ensure DC were depleted throughout the
experiment. In this setting we found that transferred T cells accumulated more
readily after prolonged depletion than in non-depleted mice and possibly more
than transiently depleted mice. This strongly suggested that instead of
reconstitution of a pro-inflammatory DC population, the enhanced accumulation
of transferred T cells was mediated by depletion of a regulatory DC population.
Indeed tumour resident DC are largely thought of in a tolerogenic capacity
(Pinzon-Charry et al. 2005), so depletion of these dysfunctional DC would likely
lead to increased T cell accumulation. The ability of these regulatory DC to limit
cell proliferation was therefore tested. This seemed to show that DC depletion
promoted the proliferation of endogenous T cells in the tumour. However Ki67
staining may not be sensitive enough to discriminate differences in proliferation
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in tumour resident transferred T cells which were nearly all Ki67+. Use of a more
sensitive method of tracking cell proliferation, such as CFSE dilution may be
useful in further experiments as it can provide a variable readout rather than the
binary description of cell proliferation provided by Ki67 staining.
Of note however is that despite DC depletion, anti-tumour TCR transduced T cells
were still substantially proliferative in the tumour, much more so than transferred
T cells in the spleen, or endogenous T cells in the tumour. This suggests that
tumour-antigen presentation by a non-depleted APC population in the tumour is
capable of driving the proliferation of these transferred T cells. This may then
be further enhanced by the depletion of a regulatory DC population that would
otherwise limit T cell proliferation.
However these results are surprising as although the tumour does contain
tolerogenic DC, a large population of these cells in the tumour are pDC (Wei
et al. 2005), which should not be depleted by DT injection in this model.
Furthermore the CD103+ DC population in the tumour that are specifically
depleted in this model have been shown to effectively cross-present tumour
antigen and induce pro-inflammatory T cell responses (Broz et al. 2014; Salmon
et al. 2016). However DT injection is likely responsible for depletion of a broader
range of DC subsets than has been accounted for here. Alternatively as a
specific regulatory DC population has yet to be identified, it may be that
tolerogenic DC in the tumour instead comprise a heterogenous population of DC
that have similar regulatory functions in vivo. A better understanding of the
activation status of these tumour resident DC subsets in this study would aid the
identification of these regulatory DC. Of particular importance would be careful
examination of the combinations of costimulatory molecules and inhibitory
receptors that DC use to control the T cell response.
However a third possible explanation for this T cell accumulation also exists. In
this model C57BL/6 recipients are reconstituted with CD11c.DTR bone marrow,
to allow repeated DT injection. However radio-resistant DC populations have
been identified in the skin that are capable of self-renewal (Bogunovic et al.
2006). Therefore it is possible that after depletion of donor DC, this non-DTR
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expressing DC population of recipient origin expands and creates a
pro-inflammatory environment not seen in undepleted mice. To test whether T
cell accumulation is specific to the use of chimeric mice we exploited the
CD11c.DOG model. This model allows for repeated DT injection into
non-chimeric mice and so will allow us to test this hypothesis. The next chapter
therefore examines the effect of DC depletion on transferred T cells in
CD11c.DOG mice.
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transferred T cells in CD11c.DOG mice
Unlike in CD11c.DTR mice, the CD11c.DOG model allows multiple DT injections
without toxicity. In this model therefore we could test whether transferred T cells
accumulate after DC depletion in non-chimeric mice. Alongside this we could
also assess whether this enhanced T cell accumulation is capable of inducing
superior control of tumour growth. As mentioned previously pre-conditioning
irradiation appears to be critical for effective responses from transferred T cells.
Therefore we chose to use the B16 NP GFP model to assess the ability of F5
CD19 transduced T cells to control tumour growth after DC depletion. We have
shown previously that despite T cell injection and pre-conditioning irradiation
being separated temporally, F5 CD19 transduced T cells can mediate
pronounced tumour control in vivo (Fig 4.5,4.6). This would lessen the possible
accumulative toxicity of DT injection in direct combination with irradiation.
In addition, the F5 model also allows us to question whether transduced T cells
interact with host DC differently than non-transduced T cells. To this end we can
use transgenic T cells which express the F5 TCR and compare these unactivated
but tumour specific T cells, with the activated, F5 CD19 transduced T cells. This
chapter will therefore describe the use of the CD11c.DOG model to investigate
the effects of DC depletion on:
1. Transferred T cell accumulation in non-chimeric mice
2. Accumulation of transferred T cells recognising foreign antigens
3. Tumour control by either TCR transduced or TCR transgenic T cells
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7.1 Establishing the transferred T cell expansion
model in CD11c.DOG mice
To investigate whether transferred T cell accumulation was dependent on DC
depletion in chimeric mice, we repeated the T cell accumulation experiments in
the CD11c.DOG mice (Fig 7.1A). As before mice were injected with 5x105
B16.F10 cells s.c., however here the mice were heterozygous CD11c.DOG
mice, rather than CD11c.DTR bone marrow chimeras. As before, these mice
were injected with 4x106 Thy1.1+, CD8 T cells, which had been transduced with
the TRP2 CD19 vector. To deplete DC, mice were injected with 100ng DT or
PBS.
Surprisingly, unlike in the CD11.DTR model, transferred T cells in the
CD11c.DOG mice did not accumulate in spleen, LN or tumour after DC
depletion. The frequency of Thy1.1+ cells remained similar after DC depletion
(Fig 7.1B) and the numbers of transferred cells may even have fallen after
depletion, particularly in the tumour (Fig 7.1C).
These data could suggest that the generation of chimeras was an important
facet of the enhanced T cell accumulation seen after DC depletion. However
alternatively, it could be explained by differences between the depletion of DC in
the CD11c.DTR and CD11c.DOG models. As shown in Fig 5.8 and 5.9, whilst
splenic DC in CD11c.DOG mice were well depleted after injection of 100ng DT,
depletion of tumour-resident DC was poor. As the CD11c.DOG mice are less
susceptible to DT injection, this experiment was repeated after injection of 1µg
DT (~64ng/g), with which tumour-resident DC had been largely depleted.
However again, high-dose DT injection in CD11c.DOG mice failed to replicate
the enhanced T cell accumulation seen previously (Fig 7.2B). Again, in contrast
to the CD11c.DTR model, CD11c.DOG mice injected with high-dose DT may
even have a lower frequency of transferred T cells than non-depleted mice.
As the CD11c.DTR mice could not be used without first making bone marrow
chimeras, to compare the two models accurately either CD11c.DOG bone
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marrow or CD11c.DTR bone marrow was used to make chimeras (Fig 7.3A).
Both sets of chimeras were injected with the same dose of DT (100ng) and
treated with 4x106 TRP2 CD19 transduced, Thy1.1+ CD8+ T cells. As shown
previously, Thy1.1+ T cells transferred into CD11c.DTR chimeras accumulated to
a significantly greater extent in the LN and tumour after DC depletion (Fig 7.3B).
However, despite chimerism in both models, transferred T cells did not
accumulate after DC depletion in CD11c.DOG chimeras. Furthermore, as
expected, transferred T cells in the tumours of CD11c.DTR chimeras appeared
to acquire a more effector phenotype after DC depletion. In contrast DC
depletion in the CD11c.DOG chimeras seemed to have the opposite effect. Both
the endogenous and transferred tumour-resident T cells acquired a less effector
phenotype after depletion in CD11c.DOG chimeras, although this was only
significant for the endogenous cells (Fig 7.3C).
These data show that the generation of CD11c.DOG chimeras is insufficient to
replicate the enhanced accumulation of transferred T cells seen in CD11c.DTR
chimeras. Instead it further suggests that this enhancement is mediated by
depletion of a regulatory DC population, rather than the perseverance of a radio
resistant, non-depletable DC population of BL/6 origin. As transferred T cell
accumulation is not repeated in CD11c.DOG mice however it appears that
depletion of this regulatory population only occurs in the CD11c.DTR mice. In
contrast DC depletion in the CD11c.DOG mice may even have a negative effect
on the transferred T cells, in line with our original hypothesis. However the effect
of high-dose DT injection in CD11c.DOG chimeras has not been tested here,
which could be required to replicate the phenotype seen in CD11c.DTR mice,
although this seems unlikely. The difference in response between the
CD11c.DTR and CD11c.DOG mice is likely to be driven by the varied depletion
pattern seen between these two models. For example depletion of CD24+ DC in
the CD11c.DTR mice, rather than depletion of the broader CD11c/MHCII+
population may be driving this result, although the reason why is unclear.
Alternatively the depletion of other CD11c+ cells such as NK and T cells has not
been as well defined in the CD11c.DOG model. It is possible this could have an
unknown effect on the transferred T cell response.
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Figure 7.1: Adoptive transfer of TCR transduced T cells in CD11c.DOG mice.
(A) Experiment outline. CD11c.DOG mice were injected with B16.F10. Mice were treated
with 4x106 Thy1.1+ CD8+ TRP2 transduced T cells. One day prior and for 8 days after T
cell injection, mice were injected with PBS or 100ng DT to deplete DC.
(B,C) Transferred T cells were identified by expression of Thy1.1 on CD8+, CD45.2+
live, lymphocytes. Summary data shows the frequency of Thy1.1+ cells from the CD8
population (B) or the total number of Thy1.1 T cells (C) in the spleen, LN or tumour. Data
is from a total of 7-8 mice per group from 2 independent experiments.
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Figure 7.2: Adoptive transfer of TCR transduced T cells after injection of high-dose DT.
(A) Experiment outline. CD11c.DOG mice were injected with B16.F10. Mice were treated
with 4x106 Thy1.1+ CD8+ TRP2 transduced T cells. One day prior and for 8 days after T
cell injection, mice were injected with PBS or 1µg DT to deplete DC.
(B) Transferred T cells were identified by expression of Thy1.1 on CD8+, CD45.2+
live, lymphocytes. Summary data shows the frequency of Thy1.1+ cells from the CD8
population in the spleen, LN or tumour. Data is from a total of 4 mice per group from 1
experiment.
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Figure 7.3: Transferred T cell expansion after depletion in CD11c.DTR but not
CD11c.DOG chimeras.
(A) Experiment outline. CD11c.DTR or CD11c.DOG bone marrow chimeras were
generated and once reconstituted, injected with B16.F10. Mice were treated with 4x106
Thy1.1+ CD8+ TRP2 transduced T cells. One day prior and for 8 days after T cell injection,
mice were injected with PBS or 100ng DT to deplete DC.
(B) Transferred T cells were identified by expression of Thy1.1 on CD8+, CD45.2+
live, lymphocytes. Summary data shows the frequency of Thy1.1+ cells from the CD8
population in the LN or tumour.
(C) Differentiation status of endogenous CD8 or transferred CD8 T cells in the tumours
of CD11c.DTR or CD11c.DOG chimeras. Differentiation is assessed by expression of
CD62L and CD127.
Data is from 4 CD11c.DTR or 3 CD11c.DOG mice per group, from 1 experiment.
Statistical test: unpaired T test. ns: not significant, *: p0.05.
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7.2 Expansion of transferred T cells in irradiated
CD11c.DOG mice
As DC depletion in the CD11c.DOG model appeared to be leading to reduced
accumulation of transferred T cells, we investigated whether this would affect the
ability of these T cells to control tumour growth. As tumour control with TRP2
CD19 transduced T cells was minimal, we instead turned to the F5 CD19 model.
F5 TCR transduced T cells were capable of inducing prolonged tumour control
after transfer into minimally irradiated hosts (Fig 4.3). However this model is also
similar to the previously used TRP2 model in that it uses the same B16.F10
tumour (albeit one that expresses NP), and unlike the TRP1 TCR, it is also class
I restricted. Moreover the availability of F5 TCR transgenic mice in this model
also allowed us to question whether the effect of DC depletion on in vitro
activated, transduced T cells is the same as for unactivated, transgenic T
cells.
CD11c.DOG mice were irradiated with 4 Gy on day 0 and injected with B16 NP
GFP (Fig 7.4A). To ensure robust tumour control 9x106 CD8+ F5 CD19 or mock
transduced T cells were injected 1 day after transduction. 1.5x106 unactivated
CD8+ F5 transgenic T cells were also injected into a separate group. T cells were
kept in vitro until day 4 after transduction to assess transduction efficiency (Fig
7.4B) and 70% of F5 CD19 transduced T cells were Vb11 and CD19+, meaning
these mice received 6.3x106 tumour specific T cells. The F5 transgenic T cells
were nearly all Vb11+, although as they are not transduced, they do not express
CD19.
To ensure significant DC depletion, CD11c.DOG mice were injected with 1µg DT.
Although this would deplete all splenic DC, depletion of tumour-resident DC is
more variable so control mice were taken on day 13, 1 day after the last DT
injection to check DC depletion. As with previous depletion experiments in the
CD11c.DOG model, injection of high-dose DT substantially depleted the CD11c
MHCII+ APC population in the tumour (Fig 7.4C).
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Tumours were measured following T cell transfer to assess whether DC depletion
in this model affects tumour control by transferred T cells (Fig 7.5A). Regardless of
DC depletion, both F5 CD19 transduced and F5 transgenic T cells appeared able
to control tumour growth to a similar extent. However although mice treated with
mock transduced T cells did not control the tumour without DC depletion, those
mice injected with DT showed marked tumour control. This was unexpected as
tumour growth had been unaffected by DT injection previously. As the B16 NP
GFP tumour expresses the foreign NP peptide, it is possible that an naturally
occurring anti-NP T cell clone from within the mock transduced T cell population
has mediated tumour control. However this doesn’t explain why this only occurred
in DT injected, not PBS injected mice. Alternatively the DT itself could have been
directly controlling tumour growth, however the B16 NP GFP tumours cells do not
express the high affinity DTR, so should not be directly depleted by DT. Likewise,
direct DT mediated tumour control had not been noted in other experiments.
As well as controlling tumour growth however, from day 12 onwards, all DT
injected mice lost a significant amount of weight culminating at day 17 when
these mice had to be sacrificed as they had lost >20% of their body weight (Fig
7.5B). It is possible that this systemic toxicity caused by DT injection had
inhibited tumour growth. Either way, mice were culled at this point and infiltration
of transferred T cells into the tumours was measured.
Tumour-resident CD8+ T cells were identified as shown in Fig 7.6A. Although
transferred T cells could not be identified by expression of a congenic marker in
this experiment, NP-specific T cells (either F5 CD19 or F5 transgenic) could be
identified by expression of CD8 and Vb11. Compared to mice treated with mock
transduced T cells, mice treated with F5 CD19 or F5 tg T cells showed a
significant expansion of these cells in the tumour (Fig 7.5A,B). Despite receiving
~4-fold higher NP-specific T cells, F5 CD19 T cells were found at a lower
frequency and absolute number than F5 transgenic T cells. This may reflect the
improved proliferative potential that unactivated, naive T cells have over
pre-activated T cells. However in both F5 CD19 and F5 transgenic groups, DC
depletion led to a reduced frequency and number of transferred cells. Possible
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because of the enhanced potential of the unactivated F5 transgenic cells to
proliferate, this depletion-mediated reduction in their proliferation was more
severe, compared to F5 CD19 T cells. As these mice were irradiated before T
cell transfer there are not likely to be many endogenous CD8 T cells in the
tumour. Indeed CD8+ T cells were stained for expression of Vb11 and >93% of
CD8+ T cells in F5 CD19 or F5 transgenic treated mice were Vb11+. This
appeared to fall slightly after DC depletion, however this was not
significant.
The differentiation status of tumour-resident CD8+ T cells was also assessed
after DC depletion (Fig 7.6C). Surprisingly in mice treated with F5 transgenic T
cells, despite much less T cell expansion in DC depleted mice, there was no
difference in T cell differentiation. In contrast, both mock and F5 CD19
transduced T cells had a less effector, more memory phenotype after DC
depletion. This suggests that irrespective of antigen-specificity, cells that are
pre-activated in vitro are more likely to form memory populations in the absence
of DC. This occurred at the expense of effector differentiation. In contrast,
although unactivated T cells undergo much less proliferation after DC depletion,
this did not effect their ability to differentiate in effector cells.
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Figure 7.4: Control of B16 NP GFP growth by transduced T cells after DC depletion.
(A) Experiment outline. CD11c.DOG mice were injected with B16.F10 and treated with
9x106 CD8+ mock or F5 CD19 transduced T cells, or 1.5x106 CD8+ F5 transgenic T cells.
One day prior and for 8 days after T cell injection, mice were injected with PBS or 1µg DT
to deplete DC.
(B) TCR expression on mock, F5 CD19 transduced or F5 transgenic CD8 T cells on day
4 after transduction. Cells were pre-gated on CD8+, live lymphocytes.
(C) Depletion of Ly6C- , CD11c MHCII+ APC in the tumours of DT injected mice. Cells
were pre-gated on CD45+, live cells.
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Figure 7.5: Tumour size and weight change in mice treated with T cells after DC
depletion.
(A) Tumour size in mice treated with mock, F5 CD19 transduced or F5 transgenic T cells
after PBS or DT injection.
(B) % weight change in all mice injected with either PBS or DT. Red arrows indicate
PBS/DT injection.
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Figure 7.6: T cell infiltration into tumours of DC depleted mice.
(A) Representative FACS plots. CD8+ T cells were gated on CD45+, live lymphocytes.
(B) Summary data showing CD8 frequency, CD8 number and the Vb11 frequency of
CD8+ cells, in mock, F5 CD19 transduced or F5 transgenic T cells after PBS or DT
injection.
(C) Differentiation status based on expression of CD62L and CD127 in mock, F5 CD19
transduced or F5 transgenic CD8 T cells after PBS or DT injection. Statistical test:
unpaired T test. *: p0.05.
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7.3 Tumour control by transferred T cells after DC
depletion
In order to get a more accurate assessment of tumour control in this model, the
experiment was repeated but mice were injected with a lower dose of DT
(650ng) to reduce DT-associated toxicity (Fig 7.7A). As before, CD11c.DOG
mice bearing B16 NP GFP tumours, were treated with 9x106 CD8+ mock or F5
CD19 transduced cells, or 1.5x106 CD8+ F5 transgenic T cells. Vb11 expression
on day 4 after transduction is shown in Fig 7.7B. F5 CD19 transduced cells
again showed a high level of transduction (79%), resulting in injection of
~7.1x106 antigen specific T cells. Despite the lower dose of DT used in this
experiment, injection of 650ng DT resulted in similar depletion of
tumour-resident Ly6C-, CD11c MHCII+ APC (Fig 7.7C).
The DT-mediated tumour control in mock transduced T cell treated mice noted
previously was not evident when using this lower dose of DT (Fig 7.8A). In this
setting, both mock treated groups failed to control tumour growth, regardless of
DC depletion. As expected, F5 CD19 transduced T cells were able to offer
significant tumour protection. Despite the previous experiment suggesting that
DC depletion leads to fewer transduced T cells in the tumour, the ability to
control tumour growth remained similar in DC depleted and non-depleted mice.
However whilst some mice were able to control tumour growth until day 49, in
others tumour control was lost after ~30 days as tumours rapidly regrew. In the
PBS treated mice only 1/4 controlled the tumour, with the other 3 outgrowing.
However in DT treated mice this was complicated by the return of DT associated
toxicity in 2/4 mice treated, which had to be sacrificed by day 20 (Fig 7.7B).
However of the 2 that survived, both were able to control tumour growth, and
neither had subsequent tumour outgrowth. This suggests that although initial DC
depletion led to fewer T cells in the tumour, there were still sufficient numbers to
control tumour growth. As DC returned by day 15 however, the enhanced
differentiation of memory T cells after DC depletion (as shown in Fig 7.6C) could
aid long term tumour protection and prevent subsequent tumour outgrowth.
203
Chapter 7 Section 7.3
Surprisingly, mice treated with F5 transgenic T cells, showed relatively poor
tumour control. Whilst they did receive much fewer cells than F5 CD19 treated
mice, 1.5x106 should be sufficient for tumour control. Of the 2 mice injected with
PBS, one completely failed to control tumour growth, whilst the other showed
mild tumour control. Of the 2 mice treated with DT, one had to be culled due to
weight loss although it did appear to be controlling the tumour, whilst the other
showed good tumour control until ~day 30 when the tumour outgrew. This was
surprising as we expected unactivated cells to be dependent on DC for
activation and tumour control. It may be that although DC were depleted at day
13 (Fig 7.7C), this was at the peak of DC depletion. DC depletion in this model is
not complete so it may be that the few remaining DC were sufficient to prime F5
transgenic cells to induce tumour control. The F5 tg group in particular has only
a few mice per group, so a larger repeat would be needed to confirm these data.
However together these data suggest that although DC depletion results in less
infiltration of T cells into the tumour, this is still sufficient to induce tumour
control. Moreover in mice treated with F5 CD19 transduced cells whilst initially
detrimental to the effector response, DC depletion may prime a T cell response
typified by better memory formation and a more persistent, long-term
anti-tumour response.
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Figure 7.7: Adoptive transfer of TCR transduced T cells after lower-dose DT injection.
(A) Experiment outline. CD11c.DOG mice were injected with B16.F10 and treated with
9x106 CD8+ mock or F5 CD19 transduced T cells, or 1.5x106 CD8+ F5 transgenic T cells.
One day prior and for 8 days after T cell injection, mice were injected with PBS or 650ng
DT to deplete DC.
(B) TCR expression on mock, F5 CD19 transduced or F5 transgenic CD8 T cells on day
4 after transduction. Cells were pre-gated on CD8+, live lymphocytes.
(C) Depletion of Ly6C- , CD11c MHCII+ APC in the tumours of DT injected mice. Cells
were pre-gated on CD45+, live cells.
205
Chapter 7 Section 7.3
78
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
Mock
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
Tumour
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
F5 tg
PBS
DT
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
Mock
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
Tumour
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
F5 tg
PBS
DT
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
Mock
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
Tumour
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
F5 tg
PBS
DT
0 10 20 30 40 50
70
80
90
100
110
120
%
 o
f o
rig
in
al
 w
ei
gh
t
Weight
0 10 20 30 40 50
70
80
90
100
110
120
%
 o
f o
rig
in
al
 w
ei
gh
t
Weight
0 10 20 30 40 50
70
80
90
100
110
120
%
 o
f o
rig
in
al
 w
ei
gh
t
Weight
PBS
DT
0 10 20 30 40 50
70
80
90
100
110
120
%
 o
f o
rig
in
al
 w
ei
gh
t
Weight
0 10 20 30 40 50
70
80
90
100
110
120
%
 o
f o
rig
in
al
 w
ei
gh
t
Weight
0 10 20 30 40 50
70
80
90
100
110
120
%
 o
f o
rig
in
al
 w
ei
gh
t
Weight
PBS
DT
0 10 20 30 40 50
70
80
90
100
110
120
%
 o
f o
rig
in
al
 w
ei
gh
t
Weight
0 10 20 30 40 50
70
80
90
100
110
120
%
 o
f o
rig
in
al
 w
ei
gh
t
Weight
0 10 20 30 40 50
70
80
90
100
110
120
%
 o
f o
rig
in
al
 w
ei
gh
t
Weight
PBS
DT
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
Mock
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
Tumour
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
F5 tg
PBS
DT
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
Mock
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
Tumour
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
F5 tg
PBS
DT
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
Mock
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
Tumour
0 10 20 30 40 50
0
50
100
150
200
Day
Tu
m
ou
r s
iz
e 
(m
m
2 )
F5 tg
PBS
DT
Tum ur size eight
Mock
F5 CD19
F5 tg
A B
Figure 7.8: Adoptive transfer of TCR transduced T cells in DC depleted mice.
(A) Tumour size in mice treated with mock, F5 CD19 transduced or F5 transgenic T cells
after PBS or DT injection.
(B) % weight change in mice treated with mock, F5 CD19 transduced or F5 transgenic T
cells after PBS or DT injection.
206
Chapter 7 Section 7.4
7.4 Summary and conclusion
These data suggest that there are fundamental differences in the CD11c.DTR
and CD11c.DOG models that are not explained by whether the mice are of a
chimeric background or not. In contrast to the CD11c.DTR model, TRP2 CD19
transduced T cells do not accumulate or acquire a pronounced effector phenotype
after DC depletion in the CD11c.DOGmodel. Indeed the opposite may occur, with
transferred T cells in depleted CD11c.DOG mice being found in lower numbers
and with a less effector phenotype than non-depleted mice.
This reduced response by TRP2 transduced T cells after DC depletion in
CD11c.DOG mice was also true, and to a greater extent, in irradiated hosts
treated with F5 T cells. However as the experimental models used in TRP2 and
F5 treated mice differ, it is difficult to make direct comparisons between these
responses or between the effect of DC depletion on T cells expressing a self- or
foreign-antigen specific TCR. However taken together these data do suggest
that as the proliferative capacity of transferred T cells increased, the effect of DC
depletion on curbing T cell expansion became more pronounced. In line with this
the unactivated, F5 transgenic T cells that greatly expanded in vivo appeared to
be the most affected by DC depletion.
Of note however is that despite being pre-activated in vitro, the F5 CD19
transduced T cells still expanded less well after DC depletion. This suggests that
transduced T cells do receive further activation signals from DC in vivo. However
the details governing when and where DC interact with transduced T cells are
still not clear. In addition, the nature of this interaction is also unclear as
although DC were able to cause greater proliferation of transduced T cells, this
did not seem to improve their effector function. This was shown by the similar
tumour control mediated by F5 TCR T cells after DC depletion, despite these
cells being fewer in number. Therefore in the absence of this interaction in vivo,
activation of transduced T cells in vitro is sufficient to induce functional effector T
cells that can control tumour growth. However due to the large amount of T cells
used to control tumour growth in these experiments it may be that any
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DC-mediated fine tuning of the T cell response is not noticed. For example as
both F5 CD19 and F5 transgenic T cells were able to control tumour growth after
DC depletion, this may reflect a T cell response that is already surplus to
requirements and largely unaffected by reduced proliferation.
Lastly, F5 CD19 transduced cells may even be more effective at long-term
tumour control in DC depleted rather than non-depleted mice. A possible
explanation for this is that DC depletion appears to promote T cell acquisition of
a memory phenotype. This may boost long term responses to the tumour as
transferred central memory populations have been shown to persist long-term
and induce improved T cell responses (Berger et al. 2008; Klebanoff et al. 2005).
This hypothesis would fit with the linear model of T cell differentiation, where
naive cells move from memory to effector phenotypes with increased antigen
exposure. In this setting, antigen presentation by DC drives the proliferation and
effector differentiation of naive/memory transferred T cells. However in mice in
which DC are depleted, there is less antigen presentation in vivo and
differentiation along this pathway is diminished. Transferred T cells still acquire
effector function due to in vitro activation and antigen presentation from
non-depleted DC, which is sufficient to mediate tumour control, however reduced
exposure to antigen results in less terminally differentiated effector cells. These
memory T cells are able to maintain tumour control for longer than short lived
effectors and hence help prevent tumour outgrowth. However to confirm these
hypotheses, the experiments presented above would need to be repeated.
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Adoptive transfer of TCR transduced T cells is a promising field of tumour
immunotherapy. However to translate pre-clinical work into an effective clinical
treatment requires a greater understanding of the biology involved and how this
can be exploited to improve T cell function. It has become clear that the tumour
microenvironment is adept at subverting immune responses to avoid
immune-mediated elimination. One of the mechanisms that tumours use to
suppress anti-tumour T cell responses is to induce dysfunction of DC, which
orchestrate this T cell response. DC have numerous potential roles in controlling
T cell responses to tumours, including priming of naive T cells and regulating
effector function in situ. However transduction of adoptively transferred T cells
requires in vitro pre-activation, and little is known therefore about their
requirements for interactions with DC. This project therefore aimed to
understand the role that DC have in the context of tumour control by TCR
transduced T cells. To achieve this we utilised two mouse models that allowed
selective depletion of DC to interrogate their function after adoptive T cell
transfer.
Due to their fundamental roles in promoting T cell responses, we hypothesised
that depletion of DC would lead to an inferior T cell response in which cells
proliferated less and exhibited weaker effector functions. However these
experiments produced conflicting results. Contrary to this hypothesis, in the first
depletion model (CD11c.DTR), DC depletion led to an enhanced accumulation
of transferred T cells, which also acquired a less naive, more effector phenotype.
Whereas T cells injected into CD11c.DOG mice conversely did not accumulate
better after DC depletion and in fact were reduced in number. Interestingly
though in this model neither DC depletion, nor the subsequent reduction in
tumour infiltrating T cells affected the ability of these transferred T cells to control
tumour growth. This section will discuss the implications of these findings in the
CD11c.DTR model, then the CD11c.DOG model and finally examine possible
differences between these models that could explain this contrasting effect.
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8.1 CD11c.DTR model discussion
Contrary to our initial hypothesis we found that depletion of DC in the
CD11c.DTR model was responsible for driving the enhanced accumulation of
transferred T cells. Despite DC depletion in this model, the absolute number of T
cells that infiltrated the tumour remained equal. However of the CD8 T cells in
the tumour, a greater proportion of these were the TCR transduced, adoptively
transferred T cells. Strikingly, significantly more of these transferred T cells that
infiltrated the tumour, as well as those found in the spleen, had acquired an
effector phenotype after DC depletion. However despite this enhanced
accumulation, these cells were unable to provide tumour control. These data
generated a number of different hypotheses that could explain this enhanced T
cell response. These hypotheses included possible direct effects of DC
depletion, but also the depletion of other CD11c+ cells was addressed and both
are discussed in more detail below.
8.1.1 Depletion of endogenous T cells
One caveat with this depletion model is that a wider range of cells are depleted
than just DC. Of particular importance was the possible depletion of endogenous
T cells which can express CD11c. We found that particularly in the tumour,
endogenous T cells would upregulate CD11c expression and therefore be
susceptible to depletion. This enhanced CD11c expression on the
tumour-resident T cells corroborates with previous studies which have shown
that activated T cells upregulate CD11c expression during viral infections (Beyer
et al. 2005; Lin et al. 2003). This could therefore be important in experiments
that aim to investigate the T cell responses to DC depletion. For example
depletion of endogenous, activated T cells in a model of tumour control by
transferred T cells may have an important bearing on the results. However the
impact of the endogenous T cell response on tumour control in this setting is not
fully understood. In the clinic the adoptive transfer of TILs does not seem to
promote new T cell specificities from non-transferred T cells (Kvistborg et al.
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2012). However ‘epitope spreading’ has been shown to induce novel B cell
responses to tumours after CAR-T cell therapy (Beatty et al. 2014). In our model
the absence of tumour control by either endogenous or transferred T cell limited
the effect of endogenous T cell depletion. However this could still have
enhanced transferred T cell proliferation by removing a ‘cytokine sink’. To
address this hypothesis we therefore utilised a DC depletion model in which
endogenous T cells were not depleted. In the CD11c.DTR x RAG-1-/- BM
chimeras, the only T cells present are those that reconstitute from the WT
recipient, whereas the DC will still express the DTR. In this setting a similar
expansion of transferred T cells was seen, certainly in terms of the frequency, if
not necessarily in the absolute number. This suggested that this accumulation of
transferred T cells was not dependant on endogenous T cell depletion.
However other aspects of the CD11c.DTR model were not fully accounted for,
and these could have had an effect on T cell expansion. For example although
DT injection did not deplete NK cells in the spleen or LN, they were depleted in
the tumour. Interestingly, as with the endogenous T cells, this depletion seemed
to correlate with upregulation of CD11c on the tumour-resident NK cells.
However the effect of this NK cell depletion on the T cell response was not
addressed in this study. NK cells are traditionally thought of as being part of the
innate immune response that mediate tumour immunesurveillance (Waldhauer
and Steinle 2008), however NK cells have also been shown to have a diverse
range of functions, including the direct lysis of activated T cells (Pallmer and
Oxenius 2016). It is therefore possible that the DT-mediated depletion of NK
cells in the tumour prevented lysis of transferred T cells. As the NK cell depletion
was minimal however, this was not directly assessed in this study, although
further experiments could use NK cell depleting antibodies to equalise the
depletion seen in DT-injected animals.
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8.1.2 Reconstitution of a pro-inflammatory DC subset after
transient depletion
As the enhanced T cell accumulation occurred in the absence of endogenous T
cell depletion, we investigated whether the DC that return after depletion were
capable of promoting this response. Isolated CD11c+ cells from the tumours of
transiently depleted mice did seem to show an enhanced ability to cross-present
tumour antigen ex vivo, although this was not clear. This would be in line with
data that shows the tumour produces immunosuppressive cytokines such as
VEGF, M-CSF, IL-10 and IL-6 which prevent DC maturation (Gabrilovich 2004).
In this setting the reconstituted DC would have been exposed to this
immunosuppressive milieu for a shorter time than tumour-resident DC. Although
PD-L1 expression was similar between tumour-resident and reconstituted DC,
further analysis of other functional markers such as CD80/86 could prove
informative. In addition, isolation of DC at different time points after
reconstitution and therefore after varying exposure to the tumour may reveal
phenotypic differences.
However the importance of these reconstituted DC in this tumour response is
questionable as the enhanced accumulation of transferred T cells was prevalent
when DC were depleted throughout the experiment. This suggests that DC
depletion at the time of T cell transfer, rather than later reconstitution is the
driving factor behind the enhanced accumulation of transferred T cells. However
this continuous DC depletion also seemed to improve the transferred T cell
response, more-so than transient depletion. This suggests that in this model, the
DC have an inhibitory effect on the transferred T cells and by depleting these
DC, the transferred T cells are de-regulated. However although DC depletion at
the time of T cell transfer appeared to be important, DC were not depleted at
different times during the transferred T cell response to test this. This could have
an important impact on the subsequent effect as DC have been shown to have
variable functions depending on the stage of tumour growth. For example in an
inducible ovarian cancer model, during the earlier phases of tumour
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development, DC promoted anti-tumour T cell responses and prevented rapid
tumour growth. However later the phenotype of these tumour-infiltrating DC
changed due to the immunosuppressive tumour environment, and this switch
correlated with enhanced tumour growth (Scarlett et al. 2012). In the melanoma
model described here it appears that DC are at this suppressive phase by the
time of T cell transfer, although DC depletion at different time points after tumour
inoculation could reveal different roles.
8.1.3 Depletion of a ‘regulatory DC’ subset
These data therefore suggested that the depletion of DC itself was responsible for
the enhanced accumulation of transferred T cells. A regulatory function of DC is in
line with the evidence that tumour-resident DC are often dysfunctional. This is as
a result of tumours inhibiting the proper differentiation or maturation of DC in the
tumour (Pinzon-Charry et al. 2005). This would explain why depletion of these
regulatory DC would promote T cell responses in the tumour. However this is
difficult to test directly because, as of yet, a specific regulatory DC population has
not been identified. Nonetheless to gain a better understanding of the efficiency of
DC depletion in the tumour we had identified various DC subsets before and after
DC depletion. Although DT injection in these mice should deplete cDC equally
we found that CD103+ were preferentially depleted in the tumour following DC
depletion. These cells are important for cross-presenting antigen to T cells in
lymphoid organs as well as controlling T cell effector function in the tissue (Broz
et al. 2014; Salmon et al. 2016). However this role is at odds with the regulatory
role predicted of the DC in our model. This suggests either that their role in
tumour control can vary or that a true ‘regulatory DC’ subset is depleted as well
as these CD103+ DC, which has been missed in this analysis. However this
seems unlikely as ‘regulatory DC’ is instead thought to describe DC of various
subsets that are tolerogenic because they are phenotypically immature, rather
than a separate population of specialised regulatory DC (Reis E Sousa 2006).
Therefore to investigate whether a regulatory DC population is depleted in the
tumour, a more informative question may be to assess the maturation state of
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those DC which are depleted, rather than their specific subtype. This could be
assessed by staining for inhibitory receptors such as PD-L1, or co-stimulation
molecules such as CD80/86, as well as measuring functional ability to promote T
cell expansion ex vivo.
Depletion of regulatory DC could enhance the accumulation of transferred T
cells by enhancing the proliferation. DC depletion did seem to enhance Ki67
expression on transferred T cells in the spleen, however Ki67 expression was
saturated in the tumour. To gain a better understanding of cell proliferation these
experiments could be repeated by transferring CFSE labelled T cells and
measuring dilution. Interestingly despite DC depletion transferred T cells were
still able to proliferate considerably. This proliferation was centred on the
TCR-transduced population that infiltrated the tumour, strongly suggesting that it
was dependant on tumour-antigen. It is unclear what population of APC is
presenting this antigen however as the cDC should be depleted. Either a
population of non-depleteable APC remain after DC depletion, or alternatively
DC depletion is incomplete and remaining DC are able to present antigen.
Certainly whilst depletion of CD24+ DC reached >90% by day 19, depletion at
the day of T cell transfer was only ~50%. Repeated DT injections before T cell
transfer may enhance the DC depletion at this time and influence the
proliferation of transferred T cells differently, although this has not been tested.
However although transferred T cells may have an enhanced proliferation, they
may alternatively be accumulating through improved survival.
8.1.4 Improved survival of transferred T cells
As the effect of DC depletion on T cell proliferation was inconclusive, an
alternative explanation may be that transferred T cells undergo less cell death
and so appear in higher frequencies. DC have been shown to enforce peripheral
tolerance by presenting self-antigen and inducing either deletion or anergy of
self-reactive T cell clones (Steinman and Nussenzweig 2002; Xing and Hogquist
2012). This mechanism can also be subverted by the tumour; DC dysfunction,
rather than a specific loss of tumour immunogenicity, can be the primary cause
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of tumour immune escape (Scarlett et al. 2012). Depletion of DC could result in
reduced antigen presentation and therefore a reduction in activation induced cell
death (AICD). This has been shown to limit T cell responses in tumours by
inducing apoptosis either by Fas/FasL interactions (Zaks et al. 1999) or through
a Bcl-2 regulated pathway (Strasser and Pellegrini 2004). In line with this
hypothesis is that the population of transferred T cells that accumulate in the
tumour and spleen after DC depletion have an enhanced effector phenotype. It
is therefore possible that in this setting, reduced exposure to antigen after DC
depletion leads to reduced AICD. These effector cells can therefore accumulate
without being deleted.
Although this would seem to fit with the data presented here, whether T cells are
deleted or anergised is determined by a combination of the level of antigen
available (Redmond et al. 2005) and the avidity of the TCR to that antigen (Smith
et al. 2014). CD8 T cells that receive a higher level of TCR signalling are more
prone to anergy than deletion. Therefore in this model, after DC depletion there
would be fewer DC to present self antigen to the transferred T cells, which would
therefore receive less TCR signalling. However this should induce anergy rather
than deletion in those transferred T cells. Nonetheless, the question remains
over the mechanism of transferred T cell accumulation. In the absence of
convincing data suggesting enhanced proliferation, the effect of DC depletion on
T cell survival could be addressed. Analysis of factors such as Annexin V
expression, PI incorporation, expression of FasL and activation of caspases can
all be measured in the transferred T cells.
8.1.5 Radio-resistant DC promoting T cell expansion
As mentioned earlier, tumour-resident T cells were still able to proliferate in
response to antigen, suggesting that some antigen-presenting function remained
after DC depletion. Whilst this could be due to incomplete depletion of DTR
expressing DC, alternatively a population of non-DTR expressing DC could be
present. A population of radio-resistant DC in the dermis have been identified
that are maintained after bone marrow transplantation (Bogunovic et al. 2006).
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Unlike other DC populations, these have been shown to proliferate in situ. These
cells could contribute to the enhanced T cell response seen in chimeric mice as
they would be of WT origin and hence resistant to DC depletion. After
DTR-sensitive cells are depleted these dermal DC could expand and
compensate for the depleted DC. Dermal DC are an important cell for cutaneous
immunity as they can acquire antigen and migrate to LN (Kissenpfennig et al.
2005). They are also able to initiate contact hypersensitivity in the absence of
epidermal Langerhans cells (Bennett et al. 2005; Kaplan et al. 2005). However
the impact of these DC on tumour immunity is unclear. Of note however is that a
previous study using the CD11c.DTR model had found that whilst DC depletion
abrogated lymphopenia driven expansion of T cells in CD11c.DTR mice, this
was not true of CD11c.DTR BM chimeras (Zaft et al. 2005). This suggests that
the effect of DC depletion in chimeras can be limited compared to non-chimeric
mice.
To investigate whether these radio-resistant dermal DC of WT origin infiltrate the
tumour, bone marrow chimeras could be made where host and transplant DC
express separate congenic markers. Alternatively, unlike WT DC,
DTR-expressing DC should also be GFP positive. However this expression may
be more variable than a congenic marker. In this study we attempted to address
whether the perseverance of WT DC after DT depletion was driving T cell
expansion by utilising the CD11c.DOG model, in which similar experiments
could be performed without making chimeras. However regardless of whether
they were chimeric or not, experiments in these mice failed to repeat the T cell
accumulation shown in the CD11c.DTR model. This suggests that the
chimerism was not a driving factor, although this is not conclusive as other
differences between these models could have affected the results. It would be
interesting to assess whether a single injection of DT before T cell transfer is
sufficient to increase T cell accumulation. If so then comparison between
chimeric and non-chimeric mice could be performed in CD11c.DTR mice, using
a single dose of DT to avoid toxicity. This would ensure the DTR model used is
the same and remove the confounding factor of the different DTR models. The
experiments that were performed in the CD11c.DOG models were informative
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however and are discussed in more detail in the next section.
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8.2 CD11c.DOG model discussion
Whereas DC depletion in the CD11c.DTR model was responsible for promoting
transferred T cell accumulation, this was not the case in the CD11c.DOG model.
DC depletion in these mice provided no such benefit. Indeed collectively the data
suggested that fewer transduced T cells infiltrated the tumour after depletion in
the CD11c.DOG mice.
To investigate whether this impaired expansion of transferred T cells would
impact on their ability to control tumour growth in this depletion model we had to
change the tumour model. This was because in the absence of pre-conditioning
irradiation, TRP2 transduced T cells were incapable of controlling the tumour.
The adoptive transfer of T cells into a lymphopenic environment has been shown
to cause T cell proliferation and is important for tumour control (De Witte et al.
2008a). However T cell proliferation in these conditions requires CD11chigh DC
(Zaft et al. 2005). Therefore depletion of DC would need to be separated from
irradiation to ensure the effect of DC depletion on homeostatic expansion is
minimised. We therefore made use of F5 TCR transduced T cells which are able
to mediate tumour regression with minimal pre-conditioning irradiation. The
added benefit with this model was that the previous B16.F10 tumour model
could be transduced with the NP antigen, and be recognised by F5 T cells. This
therefore allowed these experiments to be performed using essentially the same
basic tumour cells.
Unfortunately in these experiments, the high dose DT injection in the
CD11c.DOG animals led to toxicity after the 3rd injection, presumably due to a
build up in DT. When the dose of DT was reduced in the subsequent experiment,
animals showed little toxicity. Data from the high-dose DT however showed that
tumour antigen specific, introduced T cells expanded less well after DC
depletion. However even after DC depletion, a large number of tumour-specific T
cell still infiltrated the tumour. In line with this data, the subsequent experiment
showed that these T cells that infiltrate the tumour after DC depletion are still
able to mediate reliable tumour control. As in the CD11c.DTR model, this either
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suggests that DC depletion is incomplete or that transduced T cells don’t require
interaction with DC to expand and infiltrate the tumour. Mice in these
experiments received a high number of transduced T cells so the reduction in
expansion seen previously may be irrelevant on this scale. It would therefore be
interesting to titrate the number of T cells transferred down, to assess whether
DC depletion has a noticeable effect on tumour control when the T cell response
is more limited.
8.2.1 Comparison between transduced and transgenic T
cells
Of note in these experiments however was that the B16 NP GFP tumour model
allowed the comparison between F5 transduced and F5 transgenic T cells. This
allowed us to investigate whether the activation of transduced cells in vitro
diminished their need for DC interaction in vivo. As expected the requirement for
priming in vivo was much greater for the unactivated, naive, transgenic T cells
than for transduced T cells. However as for the F5 transduced T cells, a small
amount of these cells did infiltrate the tumour, but this was much reduced when
compared to DC replete mice. Interestingly, these cells seemed able to induce
tumour control, even after DC depletion. However the results from this
experiment would need to be repeated especially as so few mice were used.
Taken together these data suggest that naive F5 transgenic cells and to a lesser
extent, activated F5 transduced T cells, require DC interaction in vivo for optimal
T cell expansion. However even with sub-optimal expansion, F5 transduced and
possibly F5 transgenic T cells can mediate substantial tumour control after DC
depletion.
Although F5 transgenic T cells were less expanded after DC depletion, their
differentiation profiles were similar. This suggests that the DC that remain after
depletion are able to induce differentiation of naive T cells into effector T cells in
vivo. In contrast pre-activated F5 transduced T cells displayed a more memory,
less effector phenotype after DC depletion. This might suggests that the
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requirement for DC interaction in regards to controlling differentiation might vary
between naive and activated T cells. Effector T cells are often thought of as
terminally differentiated and therefore acquisition of this phenotype reduced
proliferative capacity. Adoptive transfer of less differentiated cells is associated
with improved anti-tumour efficacy (Hinrichs et al. 2009; Klebanoff et al. 2005). It
is possible therefore that the reduced exposure to antigen after DC depletion
limits the differentiation of adoptively transferred T cells. These therefore are
more likely to form a memory population, as is seen in the data for the F5
transduced T cells.
The impact of this enhanced memory formation of transferred T cells may also
be shown in the better long-term efficacy of tumour control after initial DC
depletion. Although 3/4 tumours regrew after the tumours escaped immune
control in the PBS treated mice, 0/2 of the DT treated mice that survived DT
injection had tumours that escaped. The enhanced ability of these memory cells
to proliferate and differentiate into effector cells may have prolonged immune
control. Of note is that we had previously shown that the loss of immune control
in this model was not through a specific loss of tumour immunogenicity such as a
down-regulation of NP expression, as has been described in similar B16 tumour
models (De Witte et al. 2006). It is therefore likely that tumour escape was either
driven by a lack of persistence of the transferred T cells in vivo or by a shift in the
tumour-resident DC phenotype as has been described during the development
of a separate tumour model (Scarlett et al. 2012). Although this occurred after
DC had reconstituted, the previous depletion of these cells may affect the ability
of the tumour to induce later dysfunction. As in the CD11c.DTR model, depletion
of DT at different time points may be revealing. It is possible that in this model
DC depletion at the time of transfer limits T cell expansion, although there were
sufficient T cells to mediate tumour control nonetheless. However as the tumour
subverts the DC response and escapes immune control, DC depletion at this
point may aid the continued control of tumour growth by transferred T cells.
Alternatively the infiltration of transferred T cells in the tumour and their presence
in the lymphoid organs would show whether tumour escape was instead driven
by a failure of these cells to persist long-term in vivo.
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8.3 Differences between the CD11c.DTR and
CD11c.DOG models
Although ostensibly both the CD11c.DTR and CD11c.DOG models deplete
CD11c+/high DC, there are clear differences in the response of the transferred T
cells to DC depletion. The likely reason behind this is that DT injection in these
mice have different patterns of depletion. In this study as with previous results
using these mice, both models induce significant and similar depletion of
CD11c+ cDC in the spleen. However depletion in the tumour in either of these
models had not been well documented. We have shown that in the CD11c.DTR
model, DT injection induces the specific depletion of the CD24+ DC in the
tumour, particularly the CD103+ population. It is unclear why CD103+ DC1 are
favourably depleted over CD11b+ DC2, as both populations express similar
levels of CD11c. However analysis of GFP expression suggested that whilst
CD11c expression was closely related to GFP (and therefore DTR) expression in
the homogenous CD103+ DC, CD11c was often expressed on CD11b+ DC
without GFP expression. This suggests that these heterogenous DC2 are able
to express their endogenous CD11c without expressing the DTR transgene. This
should normally be controlled by the CD11c promotor, however in the
CD11c.DTR mice, transgene expression is not additionally regulated by the
CD11c associated enhancers and silencers (Jung et al. 2002). This suggests, as
also suggested by the data from CD11b+ DC, that DTR expression in
CD11c.DTR mice is not as tightly regulated by CD11c expression as first
thought. Of note is also that in these mice, aberrant DTR expression on
non-haematopoetic tissue leads to lethality in mice after multiple DT injections
(Zaft et al. 2005).
In contrast the CD11c.DOG mice made use of BAC transfer to transfer a larger
amount of DNA containing the DTR transgene inserted into the whole CD11c
gene. DTR expression in these mice is therefore controlled by expression of the
CD11c promotor as well as the related control regions. Whereas these mice still
have a separate CD11c gene that could be expressed differently from the DTR,
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this is much less likely, due to this tighter restriction of DTR expression to
CD11c+ cells. Possibly due to this different control of DTR expression, DC
depletion in the tumour of CD11c.DOG mice is different from in the CD11c.DTR
model. Seemingly at odds with this more regulated DTR expression, depletion in
the CD11c.DOG mice favours depletion of the broad CD11c+ cells in the tumour,
rather than specifically depleting CD24+ DC. The reason why depletion in the
CD11.DTR and CD11c.DOG mice differs is ultimately unclear, however it is
reasonable to suggest that the differences in response to depletion from
transferred T cells in these models stem from this difference in depletion.
However there are other factors that separate these models which have not been
addressed. Whilst we have carefully evaluated the effect of DT injection of other
CD11c+ cells such as T cells and NK cells in the CD11c.DTR mice, this has not
yet been characterised in the CD11c.DOG mice. Although depletion of these
other cells seemed to have a minimal effect on the transferred T cell response,
this effect may vary in the CD11c.DOG mice. Properly accounting for these
various accessory effects after DT injection is of vital importance to generating
reliable data using these depletion models. It will therefore be a useful exercise
to properly document how other CD11c+ cells are affected by DT injection in the
CD11c.DOG model.
Lastly, regardless of DT injection, the LN of CD11c.DTR, but not CD11c.DOG
mice show reduced accumulation of DC and an overall hypocellularity (Blijswijk
et al. 2015). This was not directly measured in these experiments, however it
could have had an impact on transferred T cells in these models. It is unclear
how this would explain the difference in T cell response after depletion between
these two models, however it does provide further evidence that the CD11c.DTR
and CD11c.DOG models are not necessarily interchangeable.
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8.4 Further work
Taken together these data show that DC do have a role in interacting with
transduced T cells in vivo however this role is varied and is likely to encompass
both stimulatory and regulatory effects. Identifying the mechanism behind the
enhanced T cell accumulation after depletion in the CD11c.DTR model would be
vital to determining more about the role of DC in this setting. The experiments
mentioned previously, such as identifying whether T cells proliferate more or
survive better would be important. Likewise identifying either the subtype of DC,
or what state of maturation the DC that are depleted are would be essential to
identifying which DC are responsible for this regulatory function in the tumour. In
addition although this project has suggested that DC do interact with transferred
T cells, the nature of this interaction is unclear. The enhancement of this
accumulation in TCR-expressing T cells suggests that this interaction is
dependant on antigen presentation. However the importance of this can be
judged by transferring T cells into MHCI-/- mice. Alternatively, if co-stimulation
(signal 2) or cytokine production (signal 3) is important then the use of inhibitors
of these interactions could be informative. This could be achieved through
specific gene deletions such as mice that lack CD80/86 expression, or by
transferring transduced T cells that can’t respond to these signals, such as those
that lack expression of IL-12R. These experiments could shed some light of the
mechanisms behind the DC-transferred T cell interaction.
Likewise although these experiments have been performed in models that
deplete broad cDC populations, other models exist in which specific DC subsets
are depleted. These could be used to assess whether the effect of DC depletion
in the CD11c.DTR/DOG models is similar to when certain subtypes are
depleted. For example the importance of depleting the CD103+ DC1 in the
CD11c.DTR model could be assessed through use of either the zDC.DTR model
which has been shown to deplete tumour resident DC1 (Broz et al. 2014) or
through use of Batf3-/- mice, which constitutively lack CD8/CD103+ DC.
As the use of TCR transduced T cells for cancer immunotherapy becomes more
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widespread the need to understand why this approach is effective in some
patients but not in others becomes more important. A solid understanding
therefore of the ways in which these in vitro transduced T cells interact with the
host immune system is vital. DC are therefore of obvious interest due to their
ability to activate, control and regulate T cell immunity. In line with these various
functions, the interactions of transduced T cells with DC in vivo appears to
display a similar level of diversity. However this study has suggested that these
cells do interact in vivo, further work however will be needed to determine the
exact nature of these interactions and how they can be best exploited to improve
the anti-tumour response of transferred T cells.
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Appendix
pMP71 TRP2 IRES CD19 retroviral construct
HpaI(7950)		
BsaBI*(7839)		
BglII(7834)		
SpeI(7819)		
SspI(6488)		
AhdI(5684)		
lac	operator
BmtI(3867)		
NotI		(105)
SexAI*		(197)
NsiI		(238)
BclI*		(305)
AleI		(589)
BtgZI		(1662)
SalI		(1906)
AccI		(1907)
MluI		(1912)
BsiWI		(1915)
NruI		(1923)
BsrGI		(1936)
AccIII*		(3541)
EcoRI		(3632)
BamHI		(3638)
Eco47III		(3765)
NheI		(3863)
pMP71-TRP2-IRES-CD19
8102	bp
261
TRP2 TCR
1 ATGGCCCCGC GGCTGCTGTG CTACACCGTG CTGTGCCTGC TGGGCGCCAG AATCCTGAAC
61 AGCAAGGTGA TCCAGACCCC CAGATACCTG GTGAAGGGCC AGGGCCAGAA AGCCAAGATG
121 AGATGCATCC CCGAGAAGGG CCACCCCGTG GTGTTCTGGT ATCAGCAGAA CAAGAACAAC
181 GAGTTCAAGT TCCTGATCAA CTTCCAGAAC CAGGAAGTGC TGCAGCAGAT CGACATGACC
241 GAGAAGAGGT TCAGCGCCGA GTGCCCCAGC AACAGCCCCT GCAGCCTGGA AATCCAGAGC
301 AGCGAGGCCG GCGACAGCGC CCTGTACCTG TGCGCCAGCA GCCTGACAGG CGGCGAGCAG
361 TACTTCGGCC CTGGCACCAG GCTGACCGTG CTCGAGGACC TGAGGAACGT GACCCCCCCC
421 AAGGTGTCCC TGTTCGAGCC CAGCAAGGCC GAGATCGCCA ACAAGCAGAA GGCCACCCTG
481 GTGTGCCTGG CCAGGGGCTT CTTCCCCGAC CACGTGGAGC TGTCTTGGTG GGTGAACGGC
541 AAGGAGGTGC ACAGCGGCGT GTGCACCGAC CCCCAGGCCT ACAAGGAGAG CAACTACAGC
601 TACTGCCTGA GCAGCAGGCT GAGAGTGAGC GCCACCTTCT GGCACAACCC CAGGAACCAC
661 TTCCGCTGTC AGGTGCAGTT CCACGGCCTG AGCGAGGAGG ACAAGTGGCC CGAGGGCAGC
721 CCCAAGCCCG TGACCCAGAA CATCAGCGCC GAGGCCTGGG GCAGAGCCGA CTGCGGCATC
781 ACCAGCGCCA GCTACCACCA GGGCGTGCTG TCCGCCACCA TCCTGTACGA GATCCTGCTG
841 GGCAAGGCCA CACTGTACGC CGTGCTGGTG TCCGGCCTGG TGCTGATGGC CATGGTGAAG
901 AAGAAGAACA GCAGCGGCAG CGGCGCCACC AACTTCAGCC TGCTGAAGCA GGCCGGCGAC
961 GTGGAGGAAA ACCCTGGGCC CATGAGGCCC GTGACCTGCA GCGTGCTGGT GCTGCTGCTG
1021 ATGCTGCGGA GAAGCAACGG CGACGGCGAC AGCGTGACCC AGACCGAGGG CCTGGTGACC
1081 CTGACAGAGG GACTGCCCGT GATGCTGAAC TGCACCTACC AGACCATCTA CAGCAACCCC
1141 TTTCTGTTTT GGTACGTGCA GCACCTGAAC GAGAGCCCCA GACTGCTGCT GAAGAGCTTC
1201 ACCGACAACA AGAGGACCGA GCACCAGGGC TTCCACGCCA CCCTGCACAA GAGCAGCAGC
1261 AGCTTCCACC TGCAAAAGTC CAGCGCCCAG CTGTCCGACA GCGCCCTGTA CTACTGCGCC
1321 CTGAGGGGCA GCAACAACAG GATCTTCTTC GGCGACGGCA CCCAGCTGGT CGTGAAGCCC
1381 GACATCCAGA ACCCCGAGCC CGCCGTGTAC CAGCTGAAGG ACCCCAGAAG CCAGGACAGC
1441 ACCCTGTGCC TGTTCACCGA CTTCGACAGC CAGATCAACG TGCCCAAGAC CATGGAGAGC
1501 GGCACCTTCA TCACCGACAA GTGCGTGCTG GACATGAAGG CCATGGACAG CAAGAGCAAC
1561 GGCGCCATCG CCTGGTCCAA CCAGACCAGC TTCACATGCC AGGACATCTT CAAGGAGACC
1621 AACGCCACCT ACCCCAGCAG CGACGTGCCC TGCGACGCCA CCCTGACCGA GAAGAGCTTC
1681 GAGACCGACA TGAACCTGAA CTTCCAGAAC CTGAGCGTGA TGGGCCTGAG AATCCTGCTG
1741 CTGAAGGTGG CCGGCTTCAA CCTGCTGATG ACCCTGAGGC TGTGGAGCAG CTGA
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pMP71 Pmel-1 IRES CD19 retroviral construct
SfiI(7930)		
BsaBI*(7851)		
BglII(7846)		
SpeI(7831)		
SspI(6500)		
AhdI(5696)		
CAP	binding	site
lac	operator
BmtI(3879)		
HpaI		(7962)
NotI		(105)
BtgZI		(672)
AleI		(1480)
EcoNI		(1693)
SalI		(1918)
AccI		(1919)
MluI		(1924)
BsiWI		(1927)
NruI		(1935)
BsrGI		(1948)
PspXI		(1957)
AarI		(2304)
BstEII		(2707)
AccIII*		(3553)
EcoRI		(3644)
BamHI		(3650)
Eco47III		(3777)
NheI		(3875)
pMP71	Pmel-1	IRES	CD19
8114	bp
263
Pmel-1 TCR
1 ATGAAGAGCC TGAGCGTGAG CCTGGTGGTG CTGTGGCTGC AGTTCAACTG GGTGCGGAGC
61 CAGCAGAAGG TGCAGCAGAG CCCCGAGAGC CTGACCGTGT CCGAGGGCGC CATGGCCAGC
121 CTGAACTGCA CCTTCAGCGA CAGAAGCAGC GACAACTTCA GGTGGTACAG GCAGCACAGC
181 GGCAAGGGCC TGGAGGTGCT GGTGTCCATC TTCAGCGACG GCGAGAAGGA GGAGGGCAGC
241 TTCACCGCCC ACCTGAACAG GGCCAGCCTG CACGTGTTTC TGCACATCAG AGAGCCCCAG
301 CCCAGCGACA GCGCCCTGTA CCTGTGCGCC GTGAACACCG GCAACTACAA GTACGTGTTC
361 GGCGCTGGCA CCAGGCTGAA GGTGATCGCC GACATCCAGA ACCCCGAGCC CGCCGTGTAC
421 CAGCTGAAGG ACCCCAGAAG CCAGGACAGC ACCCTGTGCC TGTTCACCGA CTTCGACAGC
481 CAGATCAACG TGCCCAAGAC CATGGAGAGC GGCACCTTCA TCACCGACAA GACCGTGCTG
541 GACATGAAGG CCATGGACAG CAAGAGCAAC GGCGCCATCG CCTGGTCCAA CCAGACCAGC
601 TTCACATGCC AGGACATCTT CAAGGAGACC AACGCCACCT ACCCCAGCAG CGACGTGCCC
661 TGCGACGCCA CCCTGACCGA GAAGAGCTTC GAGACCGACA TGAACCTGAA CTTCCAGAAC
721 CTGAGCGTGA TGGGCCTGAG AATCCTGCTG CTGAAGGTGG CCGGCTTCAA CCTGCTGATG
781 ACCCTGAGGC TGTGGAGCAG CAGCGGCAGC GGCGCCACCA ACTTCAGCCT GCTGAAGCAG
841 GCCGGCGACG TGGAGGAAAA CCCTGGGCCC ATGGCCACAA CCATGGCCCC GCGGCTGCTG
901 GGCTGGGCCG TGTTCTGCCT GCTGGACACC GTGCTGTCCG AGGCCGGCGT GACCCAGAGC
961 CCCAGATACG CCGTGCTGCA GGAGGGCCAG GCCGTCAGCT TTTGGTGCGA CCCCATCAGC
1021 GGCCACGACA CCCTGTACTG GTATCAGCAG CCCAGGGACC AGGGCCCCCA GCTGCTGGTG
1081 TACTTCAGGG ACGAGGCCGT GATCGACAAC AGCCAGCTGC CCAGCGACAG GTTCAGCGCC
1141 GTGAGGCCCA AGGGCACCAA CAGCACCCTG AAGATCCAGA GCGCCAAGCA GGGCGACACC
1201 GCCACCTACC TGTGCGCCAG CAGCTTCCAC AGGGACTACA ACAGCCCCCT GTACTTCGCC
1261 GCTGGCACCA GGCTGACCGT GACCGAGGAC CTGAGGAACG TGACCCCCCC CAAGGTGTCC
1321 CTGTTCGAGC CCAGCAAGGC CGAGATCGCC AACAAGCAGA AGGCCACCCT GGTGTGCCTG
1381 GCCAGGGGCT TCTTCCCCGA CCACGTGGAG CTGTCTTGGT GGGTGAACGG CAAGGAGGTG
1441 CACAGCGGCG TGAGCACCGA CCCCCAGGCC TACAAGGAGA GCAACTACAG CTACTGCCTG
1501 AGCAGCAGGC TGAGAGTGAG CGCCACCTTC TGGCACAACC CCAGGAACCA CTTCCGCTGT
1561 CAGGTGCAGT TCCACGGCCT GAGCGAGGAG GACAAGTGGC CCGAGGGCAG CCCCAAGCCC
1621 GTGACCCAGA ACATCAGCGC CGAGGCCTGG GGCAGAGCCG ACTGCGGCAT CACCAGCGCC
1681 AGCTACCACC AGGGCGTGCT GTCCGCCACC ATCCTGTACG AGATCCTGCT GGGCAAGGCC
1741 ACACTGTACG CCGTGCTGGT GTCCGGCCTG GTGCTGATGG CCATGGTGAA GAAGAAGAAC
1801 AGCTGA
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pMP71 TRP1 IRES CD19 retroviral construct
HpaI(7949)		
SfiI(7917)		
BsaBI*(7838)		
SpeI(7818)		
SspI(6487)		
BspQI	-	SapI(4674)		
lac	operator
NotI		(105)
Kozak
EcoNI		(411)
PshAI		(920)
AleI		(1467)
SalI		(1905)
MluI		(1911)
BsiWI		(1914)
NruI		(1922)
BsrGI		(1935)
PspXI		(1944)
AarI		(2291)
BstEII		(2694)
AccIII*		(3540)
EcoRI		(3631)
BamHI		(3637)
pMP71	TRP1	CD19
8101	bp
265
TRP1 TCR
1 ATGGTGCTGG CTCTGCTGCC TGTGCTGGGC ATCCACTTTC TGCTGAGAGA TGCCCAGGCC
61 CAGAGCGTGA CACAGCCTGA TGCTAGAGTG ACCGTGTCCG AGGGCGCCAG CCTGCAGCTG
121 AGATGCAAGT ACAGCAGCAG CGTGACCCCC TACCTGTTTT GGTACGTGCA GTACCCCAGA
181 CAGGGACTGC AGCTGCTGCT GAAGTACTAC AGCGGCGACC CTGTGGTGCA GGGCGTGAAC
241 GGATTCGAGG CCGAGTTCAG CAAGAGCAAC AGCAGCTTCC ACCTGAGAAA GGCCTCCGTG
301 CATTGGAGCG ACAGCGCCGT GTACTTCTGC GCCGTGTCCA GCAACAACAA CAGAATCTTC
361 TTCGGCGACG GCACCCAGCT GGTCGTGAAG CCCAACATCC AGAACCCCGA GCCTGCCGTG
421 TACCAGCTGA AGGACCCTAG AAGCCAGGAC AGCACCCTGT GCCTGTTCAC CGACTTCGAC
481 AGCCAGATCA ACGTGCCCAA GACCATGGAA AGCGGCACCT TCATCACCGA TAAGTGCGTG
541 CTGGACATGA AGGCCATGGA CAGCAAGTCC AACGGCGCTA TCGCCTGGTC CAACCAGACC
601 AGCTTCACAT GCCAGGACAT CTTCAAAGAG ACAAACGCCA CCTACCCCAG CAGCGACGTG
661 CCATGTGACG CCACCCTGAC CGAGAAGTCC TTCGAGACAG ACATGAACCT GAACTTCCAG
721 AACCTGAGCG TGATGGGCCT GAGAATCCTG CTGCTGAAAG TGGCCGGCTT CAACCTGCTG
781 ATGACCCTGA GACTGTGGTC CAGCGGCTCT GGCGCCACGA ACTTCTCTCT GTTAAAGCAA
841 GCAGGAGACG TGCAAGAAAA CCCCGGTCCC ATGCTGTACT CCCTGCTGGC TTTCCTGCTG
901 GGAATGTTCC TGGGCGTGTC CGCCCAGACC ATCCACCAGT GGCCTGTGGC CGAGATCAAG
961 GCTGTGGGCA GCCCTCTGTC TCTGGGCTGC ACCATCAAGG GCAAGAGCAG CCCCAACCTG
1021 TACTGGTACT GGCAGGCTAC CGGCGGCACA CTGCAGCAGC TGTTCTACAG CATCACCGTG
1081 GGCCAGGTGG AAAGCGTGGT GCAGCTGAAC CTGTCCGCCA GCAGACCCAA GGACGACCAG
1141 TTCATCCTGA GCACCGAGAA ACTGCTGCTG AGCCACAGCG GCTTCTACCT GTGTGCTTGG
1201 AGCCCTGGCC ACCAGGACAC CCAGTACTTT GGCCCTGGCA CAAGACTGCT GGTGCTGGAA
1261 GATCTGAGAA ACGTGACCCC TCCCAAGGTG TCCCTGTTCG AGCCTAGCAA GGCTGAGATC
1321 GCCAACAAGC AGAAAGCCAC CCTCGTGTGC CTGGCCAGAG GCTTCTTCCC CGACCACGTG
1381 GAACTGTCTT GGTGGGTCAA CGGCAAAGAG GTGCACTCCG GCGTGTGCAC AGACCCCCAG
1441 GCCTACAAAG AGAGCAACTA CAGCTACTGC CTGAGCAGCA GACTGAGAGT GTCCGCCACC
1501 TTCTGGCACA ACCCCAGAAA CCACTTCAGG TGCCAGGTGC AGTTTCACGG CCTGAGCGAA
1561 GAGGACAAGT GGCCTGAGGG CAGCCCAAAG CCCGTGACCC AGAACATCTC TGCCGAGGCT
1621 TGGGGCAGAG CCGACTGCGG CATTACAAGC GCTAGCTACC AGCAGGGGGT GCTGAGCGCC
1681 ACCATCCTGT ACGAGATTCT GCTGGGCAAG GCCACCCTGT ACGCCGTGCT GGTGTCTACC
1741 CTGGTCGTGA TGGCCATGGT CAAGAGAAAG AACTCCTGA
266
pMP71 F5 CD19 IRES retroviral construct
HpaI(7962)		
SfiI(7930)		
BsaBI*(7851)		
BglII(7846)		
SpeI(7831)		
SspI(6500)		
CAP	binding	site
lac	operator
BmtI(3879)		
PstI		(1)
NotI		(105)
PsiI		(235)
EcoNI		(296)
Csp45I		(1194)
BbuI	-	SphI		(1351)
AbsI		(1390)
SalI		(1918)
AccI		(1919)
MluI		(1924)
BsiWI		(1927)
NruI		(1935)
BsrGI		(1948)
AarI		(2304)
BstEII		(2707)
AccIII*		(3553)
EcoRI		(3644)
BamHI		(3650)
Eco47III		(3777)
NheI		(3875)
pMP71-F5-IRES-CD19
8114	bp
267
F5 TCR
1 ATGAACTATT CTCCAGCTTT AGTGACTGTG ATGCTGTTTG TGTTTGGGAG GACCCATGGA
61 GACTCAGTAA CCCAGATGCA AGGTCAAGTG ACCCTCTCAG AAGACGACTT CCTATTTATA
121 AACTGTACTT ATTCAACCAC ATGGTACCCG ACTCTTTTCT GGTATGTCCA ATATCCTGGA
181 GAAGGTCCAC AGCTCCTTTT GAAAGTCACA ACAGCCAACA ACAAGGGAAT CAGCAGAGGT
241 TTTGAAGCTA CATATGATAA AGGAACAACG TCCTTCCACT TGCAGAAAGC CTCAGTGCAG
301 GAGTCAGACT CTGCTGTGTA CTACTGTGTT CTGGGTGATC GACAGGGAGG CAGAGCTCTG
361 ATATTTGGAA CAGGAACCAC GGTATCAGTC AGCCCCAACA TCCAGAACCC AGAACCCGCG
421 GTGTACCAGC TGAAGGACCC CAGAAGCCAG GACAGCACCC TGTGCCTGTT CACCGACTTC
481 GACAGCCAGA TCAACGTGCC CAAGACAATG GAAAGCGGCA CCTTCATCAC CGACAAGTGC
541 GTGCTGGACA TGAAGGCTAT GGACAGCAAG AGCAACGGCG CCATCGCCTG GTCCAACCAG
601 ACCTCCTTCA CATGCCAAGA CATCTTCAAA GAGACCAACG CCACCTACCC CAGCAGCGAC
661 GTGCCCTGCG ATGCCACTCT CACCGAGAAG AGCTTCGAGA CCGACATGAA CCTGAACTTC
721 CAGAACCTGA GCGTGATGGG CCTGAGAATC CTGCTCCTGA AAGTGGCCGG CTTCAACCTG
781 CTGATGACCC TGCGGCTCTG GAGTTCTGGC AGCGGCGCTA CCAACTTCAG CCTGCTGAAG
841 CAGGCCGGCG ACGTGGAGGA AAACCCTGGG CCCATGGCCC CCCGGCTCCT TTTCTGTCTG
901 GTTCTTTGCT TCTTGAGAGC AGAACCAACA AATGCTGGTG TCATCCAAAC ACCTAGGCAC
961 AAGGTGACAG GGAAGGGACA AGAAGCAACT CTGTGGTGTG AGCCAATTTC AGGACATAGT
1021 GCTGTTTTCT GGTACAGACA GACCATTGTG CAGGGCCTGG AGTTCCTGAC TTACTTTCGA
1081 AATCAAGCTC CTATAGATGA TTCAGGGATG CCCAAGGAAC GATTCTCAGC TCAGATGCCC
1141 AATCAGTCGC ACTCAACTCT GAAGATCCAG AGCACGCAAC CCCAGGACTC AGCGGTGTAT
1201 CTTTGTGCAA GCAGCTCCCG GACTGGGGGG CATGCTGAGC AGTTCTTCGG ACCAGGGACA
1261 CGACTCACCG TCCTCGAGGA CCTGCGGAAC GTGACCCCCC CCAAGGTGTC CCTGTTCGAG
1321 CCCAGCAAGG CCGAGATCGC CAACAAGCAG AAAGCCACAC TGGTCTGTCT GGCTAGGGGC
1381 TTCTTCCCCG ACCACGTGGA GCTGTCTTGG TGGGTCAACG GCAAAGAAGT CCATAGCGGC
1441 GTCTGCACCG ACCCTCAGGC TTACAAAGAG AGCAACTACT CCTACTGCCT GAGCAGCCGG
1501 CTGAGAGTGA GCGCCACCTT CTGGCACAAC CCCCGGAACC ACTTCCGGTG CCAGGTGCAG
1561 TTCCACGGCC TGAGCGAAGA GGACAAGTGG CCTGAGGGCT CCCCCAAGCC CGTGACCCAG
1621 AACATCAGCG CCGAGGCCTG GGGCAGAGCC GACTGCGGCA TCACCAGCGC CAGCTACCAC
1681 CAGGGCGTGC TGTCCGCCAC CATCCTGTAC GAGATCCTGC TGGGCAAGGC CACACTGTAC
1741 GCCGTGCTGG TGTCCGGCCT GGTCCTGATG GCTATGGTGA AGAAGAAGAA CAGCTGA
268
